<SEC-DOCUMENT>0001171843-19-003295.txt : 20190513
<SEC-HEADER>0001171843-19-003295.hdr.sgml : 20190513
<ACCEPTANCE-DATETIME>20190513120222
ACCESSION NUMBER:		0001171843-19-003295
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		35
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190513
DATE AS OF CHANGE:		20190513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Capstone Therapeutics Corp.
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21214
		FILM NUMBER:		19817477

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6022865520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		STREET 2:		SUITE 101
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOLOGIC CORP
		DATE OF NAME CHANGE:	19940211
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_051019.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 11pt">UNITED STATES</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 11pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 11pt"><B>Washington, DC 20549</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>FORM 10-Q</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">(Mark One)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">[ &nbsp;X &nbsp;]</TD><TD>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 29%; font-size: 10pt"><FONT STYLE="font-size: 10pt">For the quarterly period ended</FONT></TD>
    <TD STYLE="width: 71%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;March 31, 2019</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> or</P>



<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</B></TD><TD STYLE="text-align: justify"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934</B></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; width: 25%">For the transition period from</TD>
    <TD STYLE="font-size: 10pt; width: 25%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%; text-align: center">to</TD>
    <TD STYLE="font-size: 10pt; width: 25%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 20%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><B></B></P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">Commission File Number: 0-21214</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-left: 0.5in; font-size: 10pt; text-align: center; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">CAPSTONE THERAPEUTICS CORP.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-size: 10pt; text-align: center; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">86-0585310</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(IRS Employer Identification
No.)</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1275 W. Washington Street,&nbsp;&nbsp;Suite 104, Tempe, Arizona</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">85281</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(602) 286-5520</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Registrant's telephone number, including area code)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Former name, former address and former fiscal year, if changed since
last report)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days (See https://www.sec.gov or Capstonethx.com). </FONT><BR>
&#9746;&nbsp;<FONT STYLE="font-size: 10pt">Yes</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;<FONT STYLE="font-size: 10pt">No</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule
405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). &#9746;&nbsp;<FONT STYLE="font-size: 10pt">Yes&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&#9744;&nbsp;<FONT STYLE="font-size: 10pt">No</FONT><BR> <BR> <FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller
reporting company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo;
&ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule
12b-2 of the Exchange Act. (Check one):</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 26%"><FONT STYLE="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="width: 43%"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 26%"><FONT STYLE="font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&#9746;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9746;</FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;&#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&#9746; No</FONT><BR></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">APPLICABLE ONLY TO CORPORATE ISSUERS:</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Indicate the number of shares outstanding of each of the issuer's classes of common stock,
as of the latest practicable date.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">54,385,411 shares of common stock outstanding as of May 1, 2019</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">Common Stock</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">CAPS</P>


</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">OTCQB</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #2F5496; font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="color: black"><B>TABLE OF CONTENTS</B></FONT></P>

<P STYLE="color: #2F5496; font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="color: black"><B>&nbsp;</B></FONT><BR></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="3"><A HREF="#a_001">Forward Looking Statements</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_001">4</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; width: 78%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="3"><A HREF="#a_002">Part I &ndash; Financial Information</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_002">5</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_003">Item 1.</A></TD>
    <TD><A HREF="#a_003">Financial Statements </A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_003">5</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_004"><FONT STYLE="text-transform: uppercase">Condensed Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_004">5</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD><A HREF="#a_005"><FONT STYLE="text-transform: uppercase">Condensed Consolidated Statements of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_005">6</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></TD>
    <TD><A HREF="#a_006"><FONT STYLE="text-transform: uppercase">Condensed Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_006">7</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="3"><A HREF="#a_007"><FONT STYLE="text-transform: uppercase">Notes to Unaudited Condensed Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_007">8</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_008">Item 2.</A></TD>
    <TD><A HREF="#a_008">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_008">19</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_009">Item 4.</A></TD>
    <TD><A HREF="#a_009">Controls and Procedures</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_009">23</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: middle">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><A HREF="#a_013">Disclosure Controls and Procedures </A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_013">23</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="3"><A HREF="#a_010">Part II &ndash; Other Information</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_010">23</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_011">Item 1.</A></TD>
    <TD><A HREF="#a_011">Legal Proceedings</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_011">23</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_012">Item 6.</A></TD>
    <TD><A HREF="#a_012">Exhibits</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_012">23</A></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001827/0001171843-19-001827-index.htm">EXHIBIT 10.1</A>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001877/0001171843-19-001877-index.htm">EXHIBIT 10.2</A><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001876/0001171843-19-001876-index.htm">EXHIBIT 10.3</A><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001875/0001171843-19-001875-index.htm">EXHIBIT 10.4</A><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001874/0001171843-19-001874-index.htm">EXHIBIT 10.5</A>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<A HREF="exh_311.htm">EXHIBIT 31.1</A><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<A HREF="exh_312.htm">EXHIBIT 31.2</A><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<A HREF="exh_32.htm">EXHIBIT 32</A><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>
<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">EXHIBIT 101</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_001"></A>Forward Looking Statements</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">We may from time to time make written or oral forward-looking statements, including statements
contained in our filings with the Securities and Exchange Commission and our reports to stockholders. The safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995 protects companies from liability for their forward
looking statements if they comply with the requirements of that Act. This Quarterly Report on Form 10-Q should be read in conjunction
with our Annual Report on Form 10-K for the year ended December 31, 2018, and contains forward-looking statements made pursuant
to that safe harbor. These forward-looking statements relate to future events or to our future financial performance, and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or
achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as &ldquo;may,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; or the negative
of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve
known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could materially
affect actual results, levels of activity, performance or achievements. Factors that may cause actual results to differ materially
from current expectations, which we describe in more detail in this section titled &ldquo;Risks,&rdquo; include, but are not limited
to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="margin: 0pt 0; font-size: 10pt">failure of the Company, or its joint venture, LipimetiX Development, Inc., to obtain
additional funds to continue operations;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">the impact of the terms or conditions of agreements associated with funds obtained to
fund operations;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">failure to obtain additional funds required to complete clinical trials and supporting
research and production efforts necessary to obtain FDA or comparable foreign agencies approval for product candidates or secure
development agreements with pharmaceutical manufacturers;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">the impact of using a virtual operating model;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">unfavorable results of product candidate development efforts;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">unfavorable results of pre-clinical or clinical testing;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">delays in obtaining, or failure to obtain FDA or comparable foreign agencies approvals;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">increased regulation by the FDA or comparable foreign agencies;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">the introduction of competitive products;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">impairment of license, patent or other proprietary rights;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">the impact of present and future joint venture, collaborative or partnering agreements
or the lack thereof;</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">failure of the Company&rsquo;s common stock to continue to be listed at the OTCQB stock
market; and</LI>

<LI STYLE="margin: 0pt 0; font-size: 10pt">failure to successfully implement our drug development strategy for AEM-28 and its analogs.</LI>
</ul>





<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">If one or more of these or other risks or uncertainties materialize,
or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking
statement you read in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject
to these and other risks, uncertainties and assumptions relating to our operations, results of operations, business strategy and
liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the
reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information
becomes available in the future.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_002"></A>PART I &ndash; Financial Information</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_003"></A>Item 1. Financial Statements</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CAPSTONE THERAPEUTICS CORP.</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><A NAME="a_004"></A>CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>(in thousands, except share and per share data)</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; text-align: center">(Unaudited)</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,092</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,341</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">129</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,438</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Patent license rights, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,221</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,477</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">102</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">732</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Secured debt and accrued interest, net of unamortized issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capstone Therapeutics Corp. Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; text-indent: -10pt">Common Stock$.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,483</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(192,609</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(191,754</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total Capstone Therapeutics Corp. stockholders' equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,095</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,244</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,095</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,244</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,221</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,477</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>
</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><I>See notes to unaudited condensed consolidated financial statements</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>CAPSTONE THERAPEUTICS
Corp.</B></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><A NAME="a_005"></A>CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>(in thousands, except per share data)</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>(Unaudited)</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">SUBLICENSE REVENUE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Sublicense transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">188</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">601</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">301</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">789</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">530</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Income (loss) after operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(789</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(530</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest and other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(63</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(60</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Income(loss) from operations before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(852</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(590</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax benefit (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 20pt">NET INCOME (LOSS)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(587</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; text-indent: -10pt">Less: Net Income (Loss) attributable to the noncontrolling interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Income (Loss) attributable to Capstone</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Therapeutics Corp. stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(855</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(587</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Per Share Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Net Income (Loss), basic and diluted, attributable to</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Capstone Therapeutic Corp. stockholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.02</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.01</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,385</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,385</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><I>See notes to unaudited condensed consolidated
financial statements</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>CAPSTONE THERAPEUTICS
Corp.</B></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><A NAME="a_006"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>(in thousands)</I></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Unaudited)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(855</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(587</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non cash items:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Non-cash interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Non-cash stock based interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in other operating items:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Cash flows used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(299</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(470</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Cash flows provided by investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Secured Debt funding</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Cash flows provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-&nbsp;&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">NET DECREASE IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(249</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(470</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">CASH, BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,341</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,275</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">CASH, END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,092</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">805</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><I>See notes to unaudited condensed consolidated financial statements</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CAPSTONE THERAPEUTICS CORP. </B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><A NAME="a_007"></A>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>March 31, 2019</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><B>Note A. OVERVIEW OF BUSINESS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 2.25pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B><FONT STYLE="font-size: 10pt">Description of the Business</FONT></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Capstone Therapeutics Corp. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;,
&ldquo;our&rdquo; or &ldquo;us&rdquo;) is a biotechnology company committed to developing a pipeline of novel peptides and other
molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization
of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic
indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights
to or interest in Chrysalin or AZX100.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 3, 2012, we entered into a joint venture, LipimetiX Development,
LLC, (now LipimetiX Development, Inc.), (the &ldquo;JV&rdquo;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs.
The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia,
other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended
through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary
endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In early 2014, the JV received allowance from regulatory authorities
in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia
in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized,
double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating
single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from
Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass
Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials
were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed
a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing
pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker
endpoints.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Concurrent with the clinical development activities of AEM-28, the
JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of
increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the
U.S. Patent and Trademark Office in 2014).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The JV and the Company are exploring fundraising, partnering or licensing,
to obtain additional funding to continue development activities and operations.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The JV and the Company do not have sufficient funding at this time
to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other
regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company, funding permitting, intends to continue limiting
its internal operations to a virtual operating model while monitoring and participating in the management of JV&rsquo;s development
activities.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Description of Current Peptide Drug Candidates.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><U>Apo E Mimetic Peptide Molecule &ndash; AEM-28 and its analogs</U></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Apolipoprotein E is a 299 amino acid protein that plays an important
role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential
for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged
in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors
in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for
atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo
E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain
a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance
through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics,
have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse
cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and
its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease,
and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development
of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral
artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation
for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Company History</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Prior to November 2003, we developed, manufactured and marketed proprietary,
technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular
emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation
devices, are referred to as our &ldquo;Bone Device Business.&rdquo; In November 2003, we sold our Bone Device Business.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In August 2004, we purchased substantially all of the assets and
intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for
all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing
our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer
have any interest in, or rights to, Chrysalin.)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In February 2006, we purchased certain assets and assumed certain
liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property
relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual
property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 3, 2012, we entered into a joint venture (As described
in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our development activities represent a single operating segment as
they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate
to reflect our operations as one reportable segment.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">OrthoLogic Corp. commenced doing business under the trade name of
Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp.
on May 21, 2010.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In these notes, references to &ldquo;we&rdquo;, &ldquo;our&rdquo;,
&ldquo;us&rdquo;, the &ldquo;Company&rdquo;, &ldquo;Capstone Therapeutics&rdquo;, &ldquo;Capstone&rdquo;, and &ldquo;OrthoLogic&rdquo;
refer to Capstone Therapeutics Corp. References to our joint venture or &ldquo;JV&rdquo;, refer to LipimetiX Development, Inc.
(formerly LipimetiX Development, LLC).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Basis of presentation, Going Concern, and Management&rsquo;s Plans.
</B>The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates
the realization of assets and satisfaction of liabilities in the normal course of business.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Management has determined that the Company will require additional
capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations.
Accordingly, the Company has significantly reduced its development activities. The Company&rsquo;s corporate strategy is to raise
funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities
for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately
$2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below,
in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.&rsquo;s
Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as
needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form
8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second
Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations
up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity&rsquo;s ability to continue as a going concern.
However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue
its planned operations.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In the opinion of management, the unaudited condensed interim financial
statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash
flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily
indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results
of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions
have been eliminated.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant
to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make
the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the
financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information
presented as of December 31, 2018 is derived from audited financial statements.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>Use of estimates.</B>
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America
requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and
expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various
other assumptions believed to be reasonable. Although these estimates are based on management&rsquo;s assumptions regarding current
events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our significant estimates include accounting for stock-based compensation.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Legal and Other Contingencies. </B>The Company is subject to
legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise
in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount
is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an
exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the
Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and
claims brought against the Company are subject to significant uncertainty.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Legal costs related to contingencies are expensed as incurred and
were not material in either 2019 or 2018.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Joint Venture Accounting. </B>The Company entered into a joint
venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights.
As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&rsquo;s Series
B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional
funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance
or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated
basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint
venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0.
Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture
losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series
B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership
interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving
loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December
31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment
required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in
excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Cash. </B>Cash consists of balances held in commercial bank accounts.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Accounts Payable. </B>Accounts payable includes officer
compensation of <B>$</B>158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier
of July 15, 2020, occurrence of certain transaction or approval by the Company&rsquo;s Board of Directors. Accounts payable at
March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>Stockholders&rsquo; Equity.</B> During the 1<SUP>st</SUP>
quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the
cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note
D in these Consolidated Financial Statements. During the 1<SUP>st</SUP> quarter of 2019 and 2018 Accumulated deficit increased
by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Revenue Recognition</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In May 2014, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
issued Accounting Standards Update (&ldquo;ASU 606&rdquo;) No. 2014-09 &ldquo;Revenue from Contracts from Customers&rdquo;. Pursuant
to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue
that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company
applies the following five-step model in order to determine this amount: (i)&nbsp;identification of the promised goods or services
in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they
are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration;
(iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company
satisfies each performance obligation.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Upfront License Fees</I>: If a license to the Company&rsquo;s intellectual property
is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues
from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the
arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use
and benefit from the license.&nbsp;&nbsp;For licenses that are not distinct from other obligations identified in the arrangement,
the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance
obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company
applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.&nbsp;&nbsp;The
Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related
revenue recognition.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Leases.</I> In February 2016 the FASB issued ASU 2016-02
<I>Leases (Topic 842) </I>and subsequently amended the guidance relating largely to transition considerations under the standard
in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations
by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.
This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods
and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1<SUP>st</SUP>
quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at
March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other
Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the
new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Cooperation Agreement.</I>&nbsp;In May 2018 the Company&rsquo;s
joint venture (&ldquo;JV&rdquo;) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (&ldquo;ANJI&rdquo;) (see
Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs.
The JV entered into a License Agreement (the &ldquo;Sub-License&rdquo;) with ANJI to sublicense, under its Exclusive License Agreement
with the UAB Research Foundation, the use of the JV&rsquo;s AEM-28 and analogs intellectual property in the Territory of the People&rsquo;s
Republic of China, Taiwan and Hong Kong (the &ldquo;Territory&rdquo;). As both parties intend to develop AEM-28 and its analogs,
conducting independent development activities would result in both parties performing the same or similar pre-clinical work and
clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work
at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV
has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development
will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net
the reimbursements against the clinical trial drug development costs in Operating Expenses &ndash; Research &amp; Development in
the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities &ndash; Net Loss in
the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and
reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $52,000,
respectively, and has been shown net. In the 1<SUP>st</SUP> quarter of 2019 the Company charged costs totaling $401,000 to research
and development expense related to its activities under the Cooperation Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In May 2014, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction
between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim
periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of
the ASU did not have a material effect on the Company&rsquo;s financial statements at March 31, 2019 or December 31, 2018.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><BR>
Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 3, 2012, we entered into a Contribution Agreement with
LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (&ldquo;JV&rdquo;), to develop Apo E mimetic molecules, including
AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development,
Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock),
representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now Series A Preferred
Stock), which have preferential distribution rights. On March 31, 2016, the Company converted 1,500,000 shares of its preferred
stock into 120,000 shares of common stock, increasing its common stock ownership from 60% to 64%. On August 11, 2017, the remaining
$3,500,000 (3,500,000 shares) of Series A preferred stock became convertible, at the Company&rsquo;s option, into common stock,
at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next
LipimetiX Development, Inc. financing, exceeding $1,000,000 on independently set valuation and terms. On August 11, 2017, the Company
purchased 93,458 shares of LipimetiX Development, Inc.&rsquo;s Series B-2 Preferred Stock for $1,000,000 (LipimetiX Development,
Inc. incurred $15,000 in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown as a reduction
of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities
in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock
issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company&rsquo;s
ownership in the JV to 62.2%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting
its Series A Preferred Stock to common stock, the Company&rsquo;s ownership would change to 69.75%. The JV 2016 Equity Incentive
Plan has 83,480 shares of the JV&rsquo;s common stock available to grant, of which, at December 31, 2018, options to purchase JV
common stock shares totaling 81,479 have been granted and are fully vested. All options were granted with an exercise price of
$1.07, vested 50% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable
for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised,
and the Series B-1 Preferred Stock Warrants were exercised, the Company&rsquo;s fully diluted ownership (on an as-converted basis)
would be approximately 65.11%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase 14,126 shares of the LipimetiX
Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $10.70 per share, subject to adjustment
and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date
of grant. If exercised, this option would reduce the Company&rsquo;s fully diluted ownership (on an as-converted basis including
assumed exercise of other options and warrants) to approximately 64.31%.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc.
(&ldquo;Benu&rdquo;) and UABRF to commercialize UABRF&rsquo;s intellectual property related to Apo E mimetic molecules, including
AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed
all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The
University of Alabama at Birmingham Research Foundation (&ldquo;UABRF&rdquo;) and LipimetiX, LLC, for the UABRF intellectual property
related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common
stock), representing a 40% ownership interest in the JV at formation, and $378,000 in cash (for certain initial patent-related
costs and legal expenses).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1
Preferred Stock offering, raising funds of $1,012,000 ($946,000 net of issuance costs of approximately $66,000). Individual accredited
investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted
in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV&rsquo;s common stock at the election
of the holders and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with
a ten-year term.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As disclosed above, on August 11, 2017, the Company purchased 93,458
shares of LipimetiX Development, Inc.&rsquo;s Series B-2 Preferred Stock for $1,000,000.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Series B (B-1 and B-2) Preferred Stock is a participating preferred
stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in
liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive
their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in
future distributions on an equal &ldquo;as-converted&rdquo; share basis with common stock holders. The Series B Preferred Stock
has &ldquo;as-converted&rdquo; voting rights and other terms standard to a security of this nature.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Exclusive License Agreement assigned by LipimetiX, LLC to the
JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as
a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration
of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement,
as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum
royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which
the First Commercial Sale occurs. UABRF will also be paid 5% of Non-Royalty Income received.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Concurrent with entering into the Contribution Agreement and the
First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company
and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (&ldquo;JDC&rdquo;)
to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered
into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed
of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member
appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence
of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of
annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an &ldquo;as -converted&rdquo;
basis) stockholders.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The JV, on August 3, 2012, entered into a Management Agreement with
Benu to manage JV development activities and an Accounting Services Agreement with the Company to manage JV accounting and administrative
functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were
entered into effective June 1, 2016. However, no Management or Accounting Services fees are due or payable except to the extent
funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating
budget in effect at that time. In August 2017 the Accounting Services Agreement monthly fee was increased to $20,000 and will thereafter
be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31,
2019, accounting fees of $400,000 were earned but unpaid. In August 2017, a Management Fee of $300,000 was approved by the joint
venture&rsquo;s Board of Directors with $150,000 paid and charged to expense in the third quarter of 2017 and $150,000 paid and
expensed in the first quarter of 2018. In the 1<SUP>st</SUP> quarter of 2019 a Management Fee of $50,000 was charged to expense
and paid in the second quarter of 2019..</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The joint venture formation was as follows ($000&rsquo;s):</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 79%; text-align: left">Patent license rights</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">1,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(667</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid at formation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">378</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Patent license rights were recorded at their estimated fair value
and were amortized on a straight-line basis over the key patent life of eighty months.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The financial position and results of operations of the joint venture
are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions
have been eliminated. In the Company&rsquo;s consolidated financial statements, joint venture losses were recorded on the basis
of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were being
allocated to the Series A preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses had
been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($946,000 net of issuance costs) in a Series B-1 Preferred
Stock and Warrant offering and in 2016, $946,000 of losses were allocated to the Series B-1 Preferred Stock ownership interests.
As of December 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement
with the joint venture, with the loan due December 31, 2016. The due date of the revolving loan was extended to July 15, 2020,
with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June
30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture
by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company&rsquo;s
option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the
capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance.
At March 31, 2019, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $140,000, was
$1,740,000.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The joint venture incurred net operating income (expenses), prior
to the elimination of intercompany transactions, of ($684,000) in 2019 and ($10,282,000) for the period from August 3, 2012 (inception)
to March 31, 2019, of which ($684,000), and ($8,670,000), respectively, have been recorded by the Company. The joint venture operating
expenses are included in research and development expenses in the condensed consolidated statements of operations.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Neither the Company nor the noncontrolling interests have an obligation
to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either
joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent
an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets
to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses
associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2019, losses totaling
$667,000 have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain
additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would
the joint venture&rsquo;s ability to continue operations. If the joint venture does not continue as a going concern, at March
31, 2019, the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the common stock noncontrolling
interests.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;<BR></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Note C <FONT STYLE="text-transform: uppercase">Australian Refundable Research &amp;
Development Credit</FONT></B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In March 2014, LipimetiX Development LLC, (Now LipimetiX Development,
Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a
clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit
equal to 43.5% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits
claims for a refundable research and development tax credit. At December 31, 2018, expected refundable research and development
tax credit of AUD$4,000, is included in Other current assets in the Condensed Consolidated Balance Sheets. &nbsp;The expected
refundable research and development tax credits for the three-month periods ended March 31, 2019 and 2018 were AUD$0 and AUD$4,000,
respectively.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;<BR></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Note D <FONT STYLE="text-transform: uppercase">SALE OF COMMON STOCK AND ISSUANCE OFSECURED
debT</FONT><BR>
<BR>
</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As described in our Current Report on Form 8-K filed with the Securities
and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement
(the &ldquo;Agreement&rdquo;) with BP Peptides, LLC (&ldquo;Brookstone&quot;). The net proceeds have been used to fund our operations,
infuse new capital into our joint venture, LipimetiX Development, Inc. (&quot;JV&quot;) (As described in Note B above, in August
2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.&rsquo;s Series B-2
Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes totaling $1,000,000, plus
$79,000 in accrued interest.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">Pursuant to the Agreement, Brookstone funded
an aggregate of $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes and
transaction costs, of which $1,012,500 was for the purchase of 13,500,000 newly issued shares of our Common Stock, and $2,427,500
was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased 5,041,197 shares of the Company&rsquo;s
Common Stock directly from Biotechnology Value Fund affiliated entities, resulting in ownership of 18,541,197 shares of the Company&rsquo;s
Common Stock, representing approximately 34.1% of outstanding shares of the Company&rsquo;s Common Stock at March 31, 2019.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">As described in our Current Report on Form
8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First
Amendment to Securities Purchase, Loan and Security Agreement (the &ldquo;Amendment&rdquo;) with Brookstone. Interest on the Secured
Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt&rsquo;s maturity, October 15, 2020.
In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to 6,321,930 shares of the Company&rsquo;s
Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting
of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement,
converted into shares at $0.75. At March 31, 2019, 2,926,302 shares are fully vested and exercisable.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The fair value of the Warrants was determined
to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020,
on the straight-line basis, as additional interest expense. Amortization expenses totaled $4,000 and $2,000 in 1<SUP>st</SUP> quarter
of 2019 and 2018, respectively, and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of
Operations.<BR>
<BR>
</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">As described in our Current Report on Form 8-K filed with the Securities
and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase,
Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000.
Any additional amounts advanced will be added to the current Loan and subject to the same terms and conditions. At Brookstone&rsquo;s
sole discretion, the Maximum Amount may be increased to an amount not to exceed $700,000. The Company borrowed $50,000 in March
2019 against the Maximum Amount of $500,000.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Transaction costs of $287,000 have been deferred and will be written
off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. Additional
transaction costs of $12,000 were incurred with the Amendment and will be written off over the period of the date of the Amendment,
January 30, 2018, to October 15, 2020. At March 31, 2019 transaction costs of $157,000 has been amortized, and $23,000 in the 1<SUP>st</SUP>
quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.
At March 31, 2019 and December 31, 2018, unamortized transaction costs of $142,000 and $165,000, respectively, have been netted
against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. Interest payable on the Secured Debt
is now due at loan maturity, October 15, 2020, and, at March 31, 2019 and December 31, 2018, accrued interest of $249,000 and $213,000,
respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured
debt of $36,000 in 1<SUP>st</SUP> quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations
in Interest and Other Expenses.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">A summary of the Secured Debt activity is as follows (000&rsquo;s):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: left">Secured Debt</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">2,477</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">2,427</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Transaction costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(299</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(299</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,128</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">157</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">134</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,262</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">249</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">213</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,584</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,475</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The secured loan bears interest at 6% per annum, with interest payable
quarterly (now due at loan maturity) and is secured by a security interest in all of our assets. As part of the Agreement, the
Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration
rights. <FONT STYLE="background-color: white">A provision in the Agreement entered into with Brookstone also requires the Company
to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially
owns over 20% of the Company&rsquo;s outstanding common stock and to nominate one candidate for a director position that has been
recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company&rsquo;s outstanding
common stock.</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">On April 18, 2017, the Company and Computershare
Trust Company, N.A., as Rights Agent (the &ldquo;Rights Agent&rdquo;) entered into Tax Benefit Preservation Plan Agreement (the
&ldquo;Plan&rdquo;), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company&rsquo;s
Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017.&nbsp; The Plan is intended to
act as a deterrent to any person (together with all affiliates and associates of such person) acquiring &ldquo;beneficial ownership&rdquo;
(as defined in the Plan) of 4.99% or more of the outstanding shares of Common Stock without the approval of the Board (an &ldquo;Acquiring
Person&rdquo;), in an effort to protect against a possible limitation on the Company&rsquo;s ability to use its net operating
loss carryforwards.&nbsp; The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share
acquisition described above, and Brookstone&rsquo;s acquisition of 5,041,197 shares of the Company&rsquo;s Common Stock from Biotechnology
Value Fund affiliated entities, making Brookstone an Exempt Person in respect of such transactions.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>Note E LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As described in our Current Report on Form 8-K filed with the Securities
and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the
&ldquo;Sub-License&rdquo;) with Anji Pharmaceuticals Inc. (&ldquo;ANJI&quot;) to sublicense, under its Exclusive License Agreement
with the UAB Research Foundation, the use of the JV&rsquo;s AEM-28 and analogs intellectual property in the Territory of the People&rsquo;s
Republic of China, Taiwan and Hong Kong (the &ldquo;Territory&rdquo;). The Sub-License calls for an initial payment of $2,000,000,
payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events.
ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. The JV
recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction costs related to the revenue
totaled $254,000 and consisted of a $100,000 payment to the UAB Research Foundation, as required by the UAB Research Foundation
Exclusive License Agreement, a $100,000 advisory fee and $54,000 in legal fees. As described in Note B above, at March 31, 2019,
JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue recorded for the $2,000,000
payment reduced the amount of JV net losses previously allocated to the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A copy of the UAB Research Foundation Exclusive License Agreement
was attached as Exhibit 10.7 to the Company&rsquo;s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with
Securities and Exchange Commission (&lsquo;SEC&rdquo;) on August 10, 2012. A copy of the First Amendment and Consent to Assignment
of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company&rsquo;s Quarterly Report on Form 10-Q for the period
ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached
as Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 30, 2015.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_008"></A>Item 2. Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 35.3pt; margin: 0pt 0">The following is management&rsquo;s discussion of significant events
in the three-month period ended March 31, 2019 and factors that affected our interim financial condition and results of operations.
This should be read in conjunction with our &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; and &ldquo;Risk Factors&rdquo; included in our Annual Report on Form 10-K for the year ended December 31,
2018.</P>

<P STYLE="font-size: 10pt; text-indent: 35.3pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Description of the Business</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Capstone Therapeutics Corp. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;,
&ldquo;our&rdquo; or &ldquo;us&rdquo;) is a biotechnology company committed to developing a pipeline of novel peptides and other
molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization
of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic
indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights
to or interest in Chrysalin or AZX100.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 3, 2012, we entered into a joint venture, LipimetiX Development,
LLC, (now LipimetiX Development, Inc.), (the &ldquo;JV&rdquo;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs.
The JV has a development plan to pursue regulatory approval of AEM-28 or an analog, as treatment for Homozygous Familial Hypercholesterolemia,
other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended
through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary
endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">In early 2014, the JV received allowance from regulatory authorities
in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia
in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized,
double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating
single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from
Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass
Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials
were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed
a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing
pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker
endpoints.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Concurrent with the clinical development activities of AEM-28, the
JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of
increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the
U.S. Patent and Trademark Office in 2014).</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The JV and the Company are exploring fundraising, partnering or licensing,
to obtain additional funding to continue development activities and operations.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The JV and the Company do not have sufficient funding at this time
to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other
regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company, funding permitting, intends to continue limiting its
internal operations to a virtual operating model while monitoring and participating in the management of JV&rsquo;s development
activities.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;<BR>
<B>Description of Current Peptide Drug Candidates.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><U>Apo E Mimetic Peptide Molecule &ndash; AEM-28 and its analogs</U></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Apolipoprotein E is a 299 amino acid protein that plays an important
role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential
for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged
in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors
in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for
atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo
E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain
a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance
through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics,
have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse
cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and
its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease,
and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development
of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral
artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation
for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our critical accounting policies are those that affect or could affect our financial statements materially and involve a significant
level of judgment by management. The accounting policies and related risks described in our Annual Report on Form 10-K, filed
with the Securities and Exchange Commission on March 22, 2019, for the year ended December 31, 2018 are those that depend most
heavily on these judgments and estimates. As of March 31, 2019, there have been no material changes to any of the critical accounting
policies contained in our Annual Report for the year ended December 31, 2018.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Results of Operations Comparing Three-Month Period Ended March 31, 2018 to the Corresponding
Period in 2017.</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Sublicense Revenue:</I> As described in Note 12 to the Financial
Statements included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2019, the
JV entered into a License Agreement (the &ldquo;Sub-License&rdquo;) with Anji Pharmaceuticals Inc. (&ldquo;ANJI&quot;) to sublicense,
under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&rsquo;s AEM-28 and analogs intellectual
property in the Territory of the People&rsquo;s Republic of China, Taiwan and Hong Kong (the &ldquo;Territory&rdquo;). The Sub-License
calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments
based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory
at its sole cost and expense. The JV recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction
costs related to the sublicense totaled $254,000 and were separately stated on the Consolidated Statement of Operations included
in the Financial Statements included in the Annual Report on Form 10-K. There was no sublicense activity in the first quarter of
2019 or 2018.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>General and Administrative (&ldquo;G&amp;A&rdquo;) Expenses:</I>
G&amp;A expenses related to our ongoing operations were $188,000 in the first quarter of 2019 compared to $229,000 in the first
quarter of 2018. Administration expenses were higher in the 1<SUP>st</SUP> quarter of 2018 than 2019 primarily due higher JV patent
legal fees in 2018.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Research and Development Expenses:</I> Research and development
expenses were $601,000 for the first quarter of 2019 compared to $301,000 for the first quarter of 2018. Our research and development
expenses increased due to the availability of funds from the ANJI sublicense income received in 2018, discussed above, but continues
to reflect reduced spending as our development activities of AEM-28 and its analogs were limited, as we attempt to obtain additional
funding.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Interest and other income (expense), net:</I> Interest and other
income (expense), net was ($63,000) for 2019 compared to ($60,000) for 2018. The expense is interest recorded on the Secured Debt
and on the issuance of Warrants.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>Net Loss attributable to Capstone Therapeutics stockholders:
</I>We incurred a net loss in the first quarter of 2019 of $.9 million compared to a net loss of $.6 million in the first quarter
of 2018. Net losses were comparable between periods after considering the above comments. Our operations and the development activities
of AEM-28 and its analogs were limited, as we attempt to obtain additional funding.</P>


<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="color: #272727; font-size: 10pt; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">With the sale of our Bone Device Business in November 2003, we sold
all of our revenue producing operations. Since that time, we have primarily relied on our cash and investments to finance all our
operations, the focus of which has been research and development of our product candidates.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">On August 3, 2012, we entered into a joint venture, to develop Apo
E mimetic peptide AEM-28 and its analogs. We contributed $6.0 million and through December 31, 2018 we have loaned an additional
$1,740,000 (including deferred interest of $140,000) to the JV. The JV raised $1,012,000 ($946,000 net of issuance costs) in the
JV&rsquo;s Series B-1 Preferred Stock and Warrant offering in August 2016. As described in Note D to the Financial Statements included
in this Quarterly Report on Form 10-Q, the Company on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000,
after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As disclosed in Note E to the Financial Statements
included in Quarterly Report on Form 10-Q, on May 2, 2018, our JV entered into a License Agreement which resulted in the receipt
of a $2,000,000 nonrefundable payment ($1,746,000 net of transaction costs). At March 31, 2019, we had cash of $1,092,000, of which
$940,000 is held by our JV.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As described in our Current Report on Form 8-K filed with the Securities
and Exchange Commission on March 19, 2019, on March 15, 2019, the Company entered into the Second Amendment to Securities Purchase,
Loan and Security Agreement with Brookstone. The 2<SUP>nd</SUP> Amendment provides for additional advances to the Company up to
a Maximum Amount of $500,000 to be used for Company operations. Advances made will be added to the secured debt and be subject
to the terms and conditions of the Securities Purchase, Loan and Security Agreement. At Brookstone&rsquo;s sole discretion, the
Maximum Amount of the advances may be increased to an amount not exceeding $700,000. The Company borrowed $50,000 in March 2019
against the Maximum Amount of $500,000.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We intend to continue limiting our internal operations to a virtual
operating model in 2019; however, without additional funding, we will also limit the development activities of AEM-28 and its analogs.
Lack of additional funding for development activities of AEM-28 and its analogs could would impair our ability to continue our
current operations as planned.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Funding permitting, our planned operations in 2019 consist of continuing
monitoring and participating in the management of the JV&rsquo;s development activities.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Our future research and development and other expenses will vary
significantly from prior periods and depend on the Company&rsquo;s decisions on future JV operations and obtaining additional funding.</P>

<P STYLE="font-size: 10pt; text-indent: -0.5in; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">We will require additional funds if we choose to extend the development
of AEM-28 and its analogs. We cannot currently predict the amount of funds that will be required if we choose to extend the development
activities of AEM-28 and its analogs and to continue operations. In any event, to complete the clinical trials and supporting research
and production efforts necessary to obtain FDA or comparable foreign agencies&rsquo; approval for product candidates would require
us to obtain additional capital. New sources of funds, including raising capital through the sales of our debt or equity securities,
joint venture or other forms of joint development arrangements, sales of development rights, or licensing agreements, may not be
available or may only be available on terms that would have a material adverse impact on our existing stockholders&rsquo; interests.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The Company has a secured loan of $2,477,500,
due October 15, 2020, from BP Peptides, LLC, an entity that at March 31, 2019 owns approximately 34.1% of the Company&rsquo;s common
stock. Interest on the secured loan, at a rate of 6% per annum, is payable on the maturity date of the secured loan.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_009"></A>Item 4. Controls and Procedures</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-weight: normal"><A NAME="a_013"></A>Disclosure Controls and Procedures</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Our management, with the participation
of our principal executive officer and principal financial and accounting officer, has reviewed and evaluated our disclosure controls
and procedures (as defined in the Securities Exchange Act Rule&nbsp;13a-15(e)) as of the end of the period covered by this Form
10-Q. Based on that evaluation, our management, including our principal executive officer and principal financial and accounting
officer, has concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form
10-Q in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange
Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&rsquo;s
rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial
and accounting officer, as appropriate, to allow timely decisions regarding required disclosure. </FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">Internal Control Over Financial Reporting</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">There were no changes in our internal control over financial reporting
during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.<BR>
</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_010"></A>Part II &ndash; Other Information</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_011"></A>Item 1. Legal Proceedings</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><B>None</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><A NAME="a_012"></A>Item 6. Exhibits</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">See the Exhibit Index following this report.<BR STYLE="clear: both"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><U>SIGNATURES</U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 2.7pt 0pt 9pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 2.7pt 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font-size: 10pt; margin: 0pt 2.7pt 0pt 9pt"></P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 2.7pt 0pt 9pt"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-decoration: underline; text-align: left">CAPSTONE THERAPEUTICS CORP.</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; width: 31%">(Registrant)</TD>
    <TD STYLE="text-align: left; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 39%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-decoration: underline; text-align: left">Signature</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: left">Title</TD>
    <TD STYLE="text-decoration: underline; text-align: left">Date</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">/s/ John M. Holliman, III</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Chairman and Chief Executive Officer</TD>
    <TD STYLE="text-align: left">May 13, 2019</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">John M. Holliman, III</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(Principal Executive Officer)</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">/s/ Les M. Taeger</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Senior Vice President and Chief</TD>
    <TD STYLE="text-align: left">May 13, 2019</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">Les M. Taeger</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Financial Officer</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">(Principal Financial and Accounting Officer)</TD>
    <TD STYLE="vertical-align: middle; text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Capstone Therapeutics Corp. </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Exhibit Index to Quarterly Report on Form 10-Q</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">For the Quarterly Period Ended March 31, 2019</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid"><FONT STYLE="font-size: 10pt">No.</FONT></TD>
    <TD STYLE="width: 42%; text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Description</FONT></TD>
    <TD STYLE="width: 40%; text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Incorporated by Reference To:</FONT></TD>
    <TD STYLE="width: 10%; text-align: center; font-weight: bold; border: Black 1pt solid"><FONT STYLE="font-size: 10pt">Filed Herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001827/0001171843-19-001827-index.htm">10.1</A></FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Second Amendment to Securities Purchase, Loan and Security Agreement dated March 15, 2019</FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on March 15, 2019</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001877/0001171843-19-001877-index.htm">10.2</A></FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-205160 for Capstone Therapeutics Corp. 2015 Equity Incentive Plan.</FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Form S-8 POS filed with the SEC on March 21, 2019</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001876/0001171843-19-001876-index.htm">10.3</A></FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-196828 for Capstone Therapeutics Corp. 2005 Equity Incentive Plan.</FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Form S-8 POS filed with the SEC on March 21, 2019</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001875/0001171843-19-001875-index.htm">10.4</A></FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-159238 for Capstone Therapeutics Corp. 2005 Equity Incentive Plan.</FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Form S-8 POS filed with the SEC on March 21, 2019</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="http://www.sec.gov/Archives/edgar/data/887151/000117184319001874/0001171843-19-001874-index.htm">10.5</A></FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-134980 for Capstone Therapeutics Corp. 2005 Equity Incentive Plan.</FONT></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt; font-weight: normal">Form S-8 POS filed with the SEC on March 21, 2019</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="exh_311.htm">31.1</A></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0pt; text-align: left"><FONT STYLE="font-weight: normal">Certification of Principal Executive
        Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.</FONT></P>
        <P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0 0pt 20pt"></P></TD>
    <TD STYLE="text-align: left; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="exh_312.htm">31.2</A></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0pt; text-align: left"><FONT STYLE="font-weight: normal">Certification of Principal Financial
        and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.</FONT></P>
        <P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0 0pt 20pt"></P></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal"><A HREF="exh_32.htm">32</A></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0pt">Certification of Principal Executive Officer and Principal Financial and Accounting Officer
        Pursuant to 18 U.S.C. Section 1350.*</P>
        <P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0 0pt 20pt"></P></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">101</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; padding-left: 10pt">
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0pt">The following financial information from our Quarterly Report on Form 10-Q for the first
        quarter of fiscal year 2019, filed with the SEC on May 13, 2019 formatted in Extensible Business Reporting Language (XBRL): (i)
        the Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018, (ii) the Condensed Consolidated Statements
        of Operations for the three months ended March 31, 2019 and 2018 (iii) the Condensed Consolidated Statements of Cash Flows for
        the three months ended March 31, 2019 and 2018, and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt"></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0 0pt 20pt; text-align: left"><FONT STYLE="font-weight: normal"></FONT></P></TD>
    <TD STYLE="text-align: center; font-weight: bold; border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 10pt; font-weight: normal">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">* Furnished herewith</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">25</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">I, John M. Holliman, III certify that:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -348.8pt; margin: 0pt 0 0pt 348.8pt">Date: May 13, 2019</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">By: <U>/s/ John M. Holliman, III</U>&#9;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">John M. Holliman, III<BR>
Chairman and Chief Executive Officer</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">(Principal Executive Officer)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">26</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 6.25in; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Les M. Taeger, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -348.8pt; margin: 0pt 0 0pt 348.8pt">Date: May 13, 2019</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -348.8pt; margin: 0pt 0 0pt 348.8pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -348.8pt; margin: 0pt 0 0pt 348.8pt">By: <U>/s/ Les M. Taeger&#9;</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Les M. Taeger<BR>
Senior Vice President and Chief Financial Officer</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">(Principal Financial and Accounting Officer)</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">27</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>exh_32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 32</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO </B><BR>
<B>18 U.S.C. SECTION 1350, </B><BR>
<B>AS ADOPTED PURSUANT TO </B><BR>
<B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">In connection with the Quarterly Report of Capstone Therapeutics
Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2019 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), each of John M. Holliman, III, Executive Chairman and Principal Executive Officer
of the Company, and Les M. Taeger, Senior Vice President and Chief Financial Officer, and Principal Financial and Accounting Officer
of the Company, certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002,
that to the best of his knowledge:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(1) The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Date: May 13, 2019</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>/s/ John M. Holliman, III</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">John M. Holliman, III</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Chairman and Chief Executive Officer</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">(Principal Executive Officer)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>/s/ Les M. Taeger</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Les M. Taeger</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Senior Vice President and Chief Financial Officer</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">(Principal Financial and Accounting Officer)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">28</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>caps-20190331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 11-May-2019 [12:09:07] {AM}-->
<xbrli:xbrl xmlns:caps="http://www.capstonethx.com/20190331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2018-01-31">
<link:schemaRef xlink:type="simple" xlink:href="caps-20190331.xsd" />
<xbrli:context id="P01_01_2019To03_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn05_01_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-05-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P12_01_2015To12_11_2015">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-12-01</xbrli:startDate>
<xbrli:endDate>2015-12-11</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_03_2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2012-08-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2012To08_03_2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-01</xbrli:startDate>
<xbrli:endDate>2012-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_02_2012To12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-02</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2017To08_11_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-08-01</xbrli:startDate>
<xbrli:endDate>2017-08-11</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2016To03_31_2016">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-03-01</xbrli:startDate>
<xbrli:endDate>2016-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_25_2016">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-08-25</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_31_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-08-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2017To10_27_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-10-01</xbrli:startDate>
<xbrli:endDate>2017-10-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To12_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2018To06_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2019To03_15_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-03-01</xbrli:startDate>
<xbrli:endDate>2019-03-15</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_LipimetixMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:LipimetixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_LipimetixAustraliaPtyLtdMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:LipimetixAustraliaPtyLtdMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_InterestAndOtherExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">caps:InterestAndOtherExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_LicenseMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_RoyaltyMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2019To03_31_2019_OtherAssetsMemberusgaapBalanceSheetLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_SecuredDebtMemberusgaapCreditFacilityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_JointVentureMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:JointVentureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_LipimetixMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:LipimetixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_SecuredDebtMemberusgaapCreditFacilityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2018_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_LipimetixAustraliaPtyLtdMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:LipimetixAustraliaPtyLtdMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_InterestAndOtherExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">caps:InterestAndOtherExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-07-14</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To07_14_2017_BrookstoneMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-07-14</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To07_14_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-07-14</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2017To08_31_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-08-01</xbrli:startDate>
<xbrli:endDate>2017-08-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2017To08_31_2017_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-08-01</xbrli:startDate>
<xbrli:endDate>2017-08-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2012To08_03_2012_LipimetixMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:LipimetixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-01</xbrli:startDate>
<xbrli:endDate>2012-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2012To08_03_2012_ExclusiveLicenseAgreementMembercapsAgreementAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="caps:AgreementAxis">caps:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-01</xbrli:startDate>
<xbrli:endDate>2012-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2012To08_03_2012_ExclusiveLicenseAgreementMembercapsAgreementAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="caps:AgreementAxis">caps:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-01</xbrli:startDate>
<xbrli:endDate>2012-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2012To08_03_2012_SeriesB1AndB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1AndB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-01</xbrli:startDate>
<xbrli:endDate>2012-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2012To08_03_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-01</xbrli:startDate>
<xbrli:endDate>2012-08-03</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_03_2012_VotingCommonOwnershipUnitsMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:VotingCommonOwnershipUnitsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2012-08-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_03_2012_NonVotingPreferredOwnershipUnitsMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:NonVotingPreferredOwnershipUnitsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2012-08-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2016To03_31_2016_PreferredStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-03-01</xbrli:startDate>
<xbrli:endDate>2016-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2016To03_31_2016_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-03-01</xbrli:startDate>
<xbrli:endDate>2016-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2016To03_31_2016_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-03-01</xbrli:startDate>
<xbrli:endDate>2016-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2017To08_11_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-08-01</xbrli:startDate>
<xbrli:endDate>2017-08-11</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2017To10_27_2017_OwnershipAsConvertedIncludingOptionsAndWarrantsMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:OwnershipAsConvertedIncludingOptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-10-01</xbrli:startDate>
<xbrli:endDate>2017-10-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To12_31_2018_OwnershipAsConvertedMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:OwnershipAsConvertedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To12_31_2018_LipimetixMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">caps:LipimetixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2016To08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-01</xbrli:startDate>
<xbrli:endDate>2016-08-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="caps:AgreementAxis">caps:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-01</xbrli:startDate>
<xbrli:endDate>2016-08-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="caps:AgreementAxis">caps:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-01</xbrli:startDate>
<xbrli:endDate>2016-08-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="caps:AgreementAxis">caps:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-01</xbrli:startDate>
<xbrli:endDate>2016-08-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_01_2016To08_25_2016_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-08-01</xbrli:startDate>
<xbrli:endDate>2016-08-25</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_25_2016_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB2PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-08-25</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:SeriesB1PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-08-25</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P08_02_2012To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2012-08-02</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P03_01_2014To03_31_2014_LipimetixAustraliaPtyLtdMemberusgaapStatementClassOfStockAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caps:LipimetixAustraliaPtyLtdMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2014-03-01</xbrli:startDate>
<xbrli:endDate>2014-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_14_2017_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-14</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_14_2017_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-14</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P04_01_2017To04_18_2017_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-04-01</xbrli:startDate>
<xbrli:endDate>2017-04-18</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn04_18_2017_BrookstoneMembersrtOwnershipAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-04-18</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_15_2019_SecuredDebtMemberusgaapCreditFacilityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-15</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn03_15_2019_BrookstoneMembersrtOwnershipAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000887151</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:OwnershipAxis">caps:BrookstoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-15</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:OtherAssetsCurrent id="Factid_5369695" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">129000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_5369696" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">97000</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_5369697" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1221000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_5369698" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1438000</us-gaap:AssetsCurrent>
<us-gaap:FiniteLivedIntangibleAssetsNet id="Factid_5369699" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet id="Factid_5369700" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">39000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AccountsPayableCurrent id="Factid_5369701" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">630000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent id="Factid_5369702" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">245000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_5369703" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">102000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent id="Factid_5369704" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:Assets id="Factid_5369705" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1221000</us-gaap:Assets>
<us-gaap:Assets id="Factid_5369706" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1477000</us-gaap:Assets>
<us-gaap:LiabilitiesCurrent id="Factid_5369707" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">732000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_5369708" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">246000</us-gaap:LiabilitiesCurrent>
<us-gaap:SecuredLongTermDebt id="Factid_5369709" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">2584000</us-gaap:SecuredLongTermDebt>
<us-gaap:SecuredLongTermDebt id="Factid_5369710" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">2475000</us-gaap:SecuredLongTermDebt>
<us-gaap:CommonStockValue id="Factid_5369711" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">27000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue id="Factid_5369712" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">27000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_5369713" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">190487000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_5369714" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">190483000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_5369715" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">-192609000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_5369716" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">-191754000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity id="Factid_5369717" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">-2095000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_5369718" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">-1244000</us-gaap:StockholdersEquity>
<us-gaap:MinorityInterest id="Factid_5369719" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest id="Factid_5369720" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:MinorityInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="Factid_5369721" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">-2095000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="Factid_5369722" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">-1244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_5369723" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1221000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_5369724" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1477000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_5369725" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">188000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_5369726" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">229000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Factid_5369727" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">601000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Factid_5369728" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">301000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:OperatingExpenses id="Factid_5369729" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">789000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_5369730" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">530000</us-gaap:OperatingExpenses>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_5369731" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-63000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_5369732" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-60000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Factid_5369733" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-852000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Factid_5369734" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-590000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit id="Factid_5369735" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">3000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit id="Factid_5369736" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-3000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:ProfitLoss id="Factid_5369737" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-855000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss id="Factid_5369738" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-587000</us-gaap:ProfitLoss>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="Factid_5369739" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="Factid_5369740" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLoss id="Factid_5369741" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-855000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5369742" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-587000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_5369743" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_5369744" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD_per_Share" decimals="2">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_5369745" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="0">54385</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_5369746" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_shares" decimals="0">54385</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:ProceedsFromRelatedPartyDebt id="Factid_5369747" contextRef="P07_01_2017To07_14_2017_BrookstoneMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0">3440000</us-gaap:ProceedsFromRelatedPartyDebt>
<caps:ProceedsFromRelatedPartyDebtNet id="Factid_5369748" contextRef="P07_01_2017To07_14_2017_BrookstoneMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0">2074000</caps:ProceedsFromRelatedPartyDebtNet>
<us-gaap:PaymentsOfStockIssuanceCosts id="Factid_5369749" contextRef="P07_01_2017To07_14_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">287000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions id="Factid_5369750" contextRef="P08_01_2017To08_31_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Factid_5369752" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="0">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 id="Factid_5369753" contextRef="P01_01_2019To03_31_2019_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3">1045000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="Factid_5369754" contextRef="P03_01_2014To03_31_2014_LipimetixAustraliaPtyLtdMemberusgaapStatementClassOfStockAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_5369755" contextRef="P01_01_2018To03_31_2018_LipimetixAustraliaPtyLtdMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">4000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:TaxCreditCarryforwardAmount id="Factid_5369756" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="0">4000</us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures id="Factid_5369757" contextRef="PAsOn08_03_2012" unitRef="Unit_USD" decimals="-6">6000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
<us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures id="Factid_5369758" contextRef="PAsOn08_03_2012_VotingCommonOwnershipUnitsMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6">1000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
<us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures id="Factid_5369759" contextRef="PAsOn08_03_2012_NonVotingPreferredOwnershipUnitsMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6">5000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
<caps:JointVentureInvestmentsInVotingCommonOwnershipUnits id="Factid_5369760" contextRef="P08_01_2012To08_03_2012" unitRef="Unit_shares" decimals="0">600000</caps:JointVentureInvestmentsInVotingCommonOwnershipUnits>
<caps:JointVentureInvestmentsInNonVotingPreferredOwnershipUnits id="Factid_5369761" contextRef="P08_01_2012To08_03_2012" unitRef="Unit_shares" decimals="0">5000000</caps:JointVentureInvestmentsInNonVotingPreferredOwnershipUnits>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369762" contextRef="P08_01_2012To08_03_2012" unitRef="Unit_pure" decimals="2">0.60</caps:JointVentureMethodInvestmentOwnershipPercentage>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369763" contextRef="P03_01_2016To03_31_2016_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.60</caps:JointVentureMethodInvestmentOwnershipPercentage>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369764" contextRef="P03_01_2016To03_31_2016_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.64</caps:JointVentureMethodInvestmentOwnershipPercentage>
<us-gaap:ConversionOfStockSharesConverted1 id="Factid_5369765" contextRef="P03_01_2016To03_31_2016_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">-1500000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesIssued1 id="Factid_5369766" contextRef="P03_01_2016To03_31_2016" unitRef="Unit_shares" decimals="0">120000</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ConversionOfStockAmountConverted1 id="Factid_5369767" contextRef="P08_01_2017To08_11_2017" unitRef="Unit_USD" decimals="0">3500000</us-gaap:ConversionOfStockAmountConverted1>
<us-gaap:ConversionOfStockSharesConverted1 id="Factid_5369768" contextRef="P08_01_2017To08_11_2017" unitRef="Unit_shares" decimals="0">3500000</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockAmountIssued1 id="Factid_5369769" contextRef="P08_01_2017To08_11_2017" unitRef="Unit_USD" decimals="0">1000000</us-gaap:ConversionOfStockAmountIssued1>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="Factid_5369770" contextRef="P08_01_2017To08_11_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">15000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369771" contextRef="P08_01_2012To08_03_2012_SeriesB1AndB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="3">0.622</caps:JointVentureMethodInvestmentOwnershipPercentage>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369772" contextRef="P08_01_2012To08_03_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="4">0.6975</caps:JointVentureMethodInvestmentOwnershipPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Factid_5369773" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="0">83480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_5369774" contextRef="P01_01_2018To12_31_2018_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0">81479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_5369775" contextRef="P01_01_2018To12_31_2018_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2">1.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="Factid_5369776" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369777" contextRef="P01_01_2018To12_31_2018_OwnershipAsConvertedMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4">0.6511</caps:JointVentureMethodInvestmentOwnershipPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_5369778" contextRef="P10_01_2017To10_27_2017" unitRef="Unit_shares" decimals="0">14126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_5369779" contextRef="P10_01_2017To10_27_2017" unitRef="Unit_USD_per_Share" decimals="2">10.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<caps:JointVentureMethodInvestmentOwnershipPercentage id="Factid_5369780" contextRef="P10_01_2017To10_27_2017_OwnershipAsConvertedIncludingOptionsAndWarrantsMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="4">0.6431</caps:JointVentureMethodInvestmentOwnershipPercentage>
<caps:JointVentureInvestmentsCommonOwnershipUnitsCoventure id="Factid_5369781" contextRef="P08_01_2012To08_03_2012_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0">400000</caps:JointVentureInvestmentsCommonOwnershipUnitsCoventure>
<caps:OwnershipPercentageCoventure id="Factid_5369782" contextRef="P08_01_2012To08_03_2012_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2">0.40</caps:OwnershipPercentageCoventure>
<us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 id="Factid_5369783" contextRef="P08_01_2012To08_03_2012_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0">378000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
<us-gaap:PaymentsOfStockIssuanceCosts id="Factid_5369785" contextRef="P08_01_2016To08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">66000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_5369786" contextRef="P08_01_2016To08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0">94537</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Factid_5369787" contextRef="PAsOn08_25_2016" unitRef="Unit_shares" decimals="0">33088</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_5369788" contextRef="PAsOn08_25_2016" unitRef="Unit_USD_per_Share" decimals="2">10.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<caps:PercentageOfRoyaltyPayment id="Factid_5369792" contextRef="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis" unitRef="Unit_pure" decimals="2">0.03</caps:PercentageOfRoyaltyPayment>
<caps:AnnualMaintenancePayments id="Factid_5369793" contextRef="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis" unitRef="Unit_USD" decimals="0">25000</caps:AnnualMaintenancePayments>
<caps:MilestonePayments id="Factid_5369794" contextRef="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0">50000</caps:MilestonePayments>
<us-gaap:RoyaltyExpense id="Factid_5369795" contextRef="P08_01_2012To08_03_2012_ExclusiveLicenseAgreementMembercapsAgreementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0">500000</us-gaap:RoyaltyExpense>
<caps:MilestonePayments id="Factid_5369796" contextRef="P08_01_2016To08_25_2016_ExclusiveLicenseAgreementMembercapsAgreementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0">500000</caps:MilestonePayments>
<us-gaap:RoyaltyExpense id="Factid_5369797" contextRef="P08_01_2012To08_03_2012_ExclusiveLicenseAgreementMembercapsAgreementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0">1000000</us-gaap:RoyaltyExpense>
<caps:PercentageOfNonRoyaltyIncome id="Factid_5369798" contextRef="P08_01_2012To08_03_2012" unitRef="Unit_pure" decimals="2">0.05</caps:PercentageOfNonRoyaltyIncome>
<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent id="Factid_5369799" contextRef="PAsOn08_31_2017" unitRef="Unit_USD" decimals="0">20000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
<us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent id="Factid_5369800" contextRef="PAsOn03_31_2019_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">400000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
<caps:ManagementFees id="Factid_5369801" contextRef="P08_01_2017To08_31_2017_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">300000</caps:ManagementFees>
<caps:ManagementFees id="Factid_5369802" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">50000</caps:ManagementFees>
<us-gaap:ManagementFeeExpense id="Factid_5369803" contextRef="P01_01_2019To03_31_2019_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">150000</us-gaap:ManagementFeeExpense>
<us-gaap:ManagementFeeExpense id="Factid_5369804" contextRef="P01_01_2018To03_31_2018_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">150000</us-gaap:ManagementFeeExpense>
<us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 id="Factid_5369805" contextRef="P01_01_2019To03_31_2019_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3">667000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
<us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 id="Factid_5369806" contextRef="P01_01_2019To03_31_2019_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3">378000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
<us-gaap:LineOfCredit id="Factid_5369807" contextRef="PAsOn03_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0">1740000</us-gaap:LineOfCredit>
<us-gaap:InterestPayableCurrentAndNoncurrent id="Factid_5369808" contextRef="PAsOn03_31_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0">140000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="Factid_5369809" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="Factid_5369810" contextRef="P01_01_2019To03_31_2019_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">946000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<caps:JointVentureOperatingExpensesInterCompanyTransactions id="Factid_5369811" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">-684000</caps:JointVentureOperatingExpensesInterCompanyTransactions>
<caps:JointVentureOperatingExpensesInterCompanyTransactions id="Factid_5369812" contextRef="P08_02_2012To12_31_2018" unitRef="Unit_USD" decimals="0">-10282000</caps:JointVentureOperatingExpensesInterCompanyTransactions>
<caps:JointVentureOperatingExpensesAllocatedToCompany id="Factid_5369813" contextRef="P08_02_2012To12_31_2018" unitRef="Unit_USD" decimals="0">-8670000</caps:JointVentureOperatingExpensesAllocatedToCompany>
<caps:OperatingExpensesNetOfEliminationOfIntercompanyTransactions id="Factid_5369814" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">684000</caps:OperatingExpensesNetOfEliminationOfIntercompanyTransactions>
<us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 id="Factid_5369815" contextRef="P08_02_2012To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0">667000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
<us-gaap:DebtInstrumentFaceAmount id="Factid_5369817" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">2477000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount id="Factid_5369818" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">2427000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DeferredFinanceCostsNoncurrentNet id="Factid_5369819" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">299000</us-gaap:DeferredFinanceCostsNoncurrentNet>
<us-gaap:DeferredFinanceCostsNoncurrentNet id="Factid_5369820" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">299000</us-gaap:DeferredFinanceCostsNoncurrentNet>
<us-gaap:Revenues id="Factid_5369821" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5369822" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:Revenues>
<caps:SublicenseTransactionCosts id="Factid_5369823" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">0</caps:SublicenseTransactionCosts>
<caps:SublicenseTransactionCosts id="Factid_5369824" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">0</caps:SublicenseTransactionCosts>
<us-gaap:OperatingIncomeLoss id="Factid_5369825" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-789000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_5369826" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-530000</us-gaap:OperatingIncomeLoss>
<us-gaap:ProfitLoss id="Factid_5369827" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-855000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss id="Factid_5369828" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-587000</us-gaap:ProfitLoss>
<us-gaap:AdjustmentForAmortization id="Factid_5369829" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">39000</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization id="Factid_5369830" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">39000</us-gaap:AdjustmentForAmortization>
<us-gaap:OtherNoncashExpense id="Factid_5369831" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">59000</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNoncashExpense id="Factid_5369832" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">59000</us-gaap:OtherNoncashExpense>
<us-gaap:ShareBasedCompensation id="Factid_5369833" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">4000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_5369834" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">2000</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets id="Factid_5369835" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">5000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets id="Factid_5369836" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-10000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable id="Factid_5369837" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">385000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable id="Factid_5369838" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">6000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="Factid_5369839" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">74000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="Factid_5369840" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">1000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_5369841" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-299000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_5369842" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-470000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_5369843" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_5369844" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_5369845" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">50000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_5369846" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_5369847" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">-249000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_5369848" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">-470000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5369849" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1341000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5369850" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">1275000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5369851" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1092000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5369852" contextRef="PAsOn03_31_2018" unitRef="Unit_USD" decimals="-3">805000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsPayableCurrentAndNoncurrent id="Factid_5369853" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="0">158000</us-gaap:AccountsPayableCurrentAndNoncurrent>
<us-gaap:AccountsPayableCurrentAndNoncurrent id="Factid_5369854" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="0">135000</us-gaap:AccountsPayableCurrentAndNoncurrent>
<caps:ReimbursementOfRevenue id="Factid_5369855" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">114000</caps:ReimbursementOfRevenue>
<us-gaap:DebtInstrumentCarryingAmount id="Factid_5369856" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">2178000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentCarryingAmount id="Factid_5369857" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">2128000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:AccumulatedAmortizationDeferredFinanceCosts id="Factid_5369858" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">157000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
<us-gaap:AccumulatedAmortizationDeferredFinanceCosts id="Factid_5369859" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">134000</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
<caps:SecuredLongTermDebtGross id="Factid_5369860" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">2335000</caps:SecuredLongTermDebtGross>
<caps:SecuredLongTermDebtGross id="Factid_5369861" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">2262000</caps:SecuredLongTermDebtGross>
<us-gaap:InterestPayableCurrentAndNoncurrent id="Factid_5369862" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">249000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:InterestPayableCurrentAndNoncurrent id="Factid_5369863" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">213000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:SecuredLongTermDebt id="Factid_5369864" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">2584000</us-gaap:SecuredLongTermDebt>
<us-gaap:SecuredLongTermDebt id="Factid_5369865" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">2475000</us-gaap:SecuredLongTermDebt>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="Factid_5369866" contextRef="P08_01_2017To08_11_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0">93458</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<us-gaap:ConvertibleLongTermNotesPayable id="Factid_5369867" contextRef="PAsOn07_14_2017_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="0">1000000</us-gaap:ConvertibleLongTermNotesPayable>
<us-gaap:InterestPayableCurrentAndNoncurrent id="Factid_5369868" contextRef="PAsOn07_14_2017_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="0">79000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:ProceedsFromRelatedPartyDebt id="Factid_5369869" contextRef="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">3440000</us-gaap:ProceedsFromRelatedPartyDebt>
<caps:ProceedsFromRelatedPartyDebtNet id="Factid_5369870" contextRef="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">2074000</caps:ProceedsFromRelatedPartyDebtNet>
<us-gaap:StockRepurchasedDuringPeriodValue id="Factid_5369871" contextRef="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">1012500</us-gaap:StockRepurchasedDuringPeriodValue>
<us-gaap:StockRepurchasedDuringPeriodShares id="Factid_5369872" contextRef="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0">13500000</us-gaap:StockRepurchasedDuringPeriodShares>
<us-gaap:SecuredLongTermDebt id="Factid_5369873" contextRef="PAsOn07_14_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">2427500</us-gaap:SecuredLongTermDebt>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_5369874" contextRef="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0">5041197</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_5369875" contextRef="P01_01_2019To03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0">18541197</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<caps:BeneficialOwnershipPercentage id="Factid_5369876" contextRef="PAsOn04_18_2017_BrookstoneMembersrtOwnershipAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4">0.0499</caps:BeneficialOwnershipPercentage>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_5369877" contextRef="P04_01_2017To04_18_2017_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0">5041197</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<caps:UABResearchFoundationExpense id="Factid_5369878" contextRef="P01_01_2019To03_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0">100000</caps:UABResearchFoundationExpense>
<caps:AdvisoryFees id="Factid_5369879" contextRef="P01_01_2019To03_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0">100000</caps:AdvisoryFees>
<us-gaap:LegalFees id="Factid_5369880" contextRef="P01_01_2019To03_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0">54000</us-gaap:LegalFees>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_5369881" contextRef="P01_01_2019To03_31_2019_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="0">2000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5369921" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3">1092000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_5369922" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3">1341000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock id="Factid_5370072" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-left: 0.5in; text-indent: -0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note A. OVERVIEW OF BUSINESS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.03in; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of the Business&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capstone Therapeutics Corp. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221; or &amp;#8220;us&amp;#8221;) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the &amp;#8220;JV&amp;#8221;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV&amp;#8217;s development activities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of Current Peptide Drug Candidates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Apo E Mimetic Peptide Molecule &amp;#8211; AEM-28 and its analogs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Company History&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our &amp;#8220;Bone Device Business.&amp;#8221; In November 2003, we sold our Bone Device Business.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In these notes, references to &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221;, &amp;#8220;us&amp;#8221;, the &amp;#8220;Company&amp;#8221;, &amp;#8220;Capstone Therapeutics&amp;#8221;, &amp;#8220;Capstone&amp;#8221;, and &amp;#8220;OrthoLogic&amp;#8221; refer to Capstone Therapeutics Corp. References to our joint venture or &amp;#8220;JV&amp;#8221;, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation, Going Concern, and Management&amp;#8217;s Plans. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company&amp;#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity&amp;#8217;s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information presented as of December 31, 2018 is derived from audited financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management&amp;#8217;s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our significant estimates include accounting for stock-based compensation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and Other Contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Joint Venture Accounting. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash consists of balances held in commercial bank accounts.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Payable. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable includes officer compensation of &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company&amp;#8217;s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&amp;#8217; Equity.&lt;/div&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;During the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU 606&amp;#8221;) No. 2014-09 &amp;#8220;Revenue from Contracts from Customers&amp;#8221;. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i)&amp;#160;identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Upfront License Fees&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;: If a license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.&amp;#160;&amp;#160;For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.&amp;#160;&amp;#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;In February 2016 the FASB issued ASU 2016-02 &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases (Topic 842) &lt;/div&gt; and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cooperation Agreement.&lt;/div&gt; &amp;#160;In May 2018 the Company&amp;#8217;s joint venture (&amp;#8220;JV&amp;#8221;) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (&amp;#8220;ANJI&amp;#8221;) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the &amp;#8220;Sub-License&amp;#8221;) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&amp;#8217;s AEM-28 and analogs intellectual property in the Territory of the People&amp;#8217;s Republic of China, Taiwan and Hong Kong (the &amp;#8220;Territory&amp;#8221;). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses &amp;#8211; Research &amp;amp; Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities &amp;#8211; Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $52,000, respectively, and has been shown net. In the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 the Company charged costs totaling $401,000 to research and development expense related to its activities under the Cooperation Agreement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company&amp;#8217;s financial statements at March 31, 2019 or December 31, 2018.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_5370193" contextRef="PAsOn03_31_2019_LipimetixMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures id="Factid_5370956" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="0">6000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="Factid_5371027" contextRef="P08_01_2017To08_31_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0">93458</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<caps:JointVentureLossesRecognitionCriteriaCommonOwnershipEquity id="Factid_5371078" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0">0</caps:JointVentureLossesRecognitionCriteriaCommonOwnershipEquity>
<caps:ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts id="Factid_5371099" contextRef="P08_01_2016To08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">1012000</caps:ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts>
<caps:JointVentureLossesRecognitionCriteriaCommonOwnershipEquity id="Factid_5371114" contextRef="PAsOn08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">946000</caps:JointVentureLossesRecognitionCriteriaCommonOwnershipEquity>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="Factid_5371115" contextRef="P08_01_2016To08_25_2016_SeriesB1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">946000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<caps:ReimbursementOfRevenue id="Factid_5371218" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="0">52000</caps:ReimbursementOfRevenue>
<us-gaap:ProceedsFromIssuanceOfSecuredDebt id="Factid_5371549" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3">50000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
<us-gaap:ProceedsFromIssuanceOfSecuredDebt id="Factid_5371550" contextRef="P01_01_2018To03_31_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_5371553" contextRef="PAsOn03_31_2019" unitRef="Unit_USD_per_Share" decimals="4">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_5371555" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="4">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_5371556" contextRef="PAsOn03_31_2019" unitRef="Unit_shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized id="Factid_5371557" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesOutstanding id="Factid_5371558" contextRef="PAsOn03_31_2019" unitRef="Unit_shares" decimals="0">54385411</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding id="Factid_5371559" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="0">54385411</us-gaap:CommonStockSharesOutstanding>
<us-gaap:BusinessCombinationDisclosureTextBlock id="Factid_5371561" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (&amp;#8220;JV&amp;#8221;), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now Series A Preferred Stock), which have preferential distribution rights. On March 31, 2016, the Company converted 1,500,000 shares of its preferred stock into 120,000 shares of common stock, increasing its common stock ownership from 60% to 64%. On August 11, 2017, the remaining $3,500,000 (3,500,000 shares) of Series A preferred stock became convertible, at the Company&amp;#8217;s option, into common stock, at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next LipimetiX Development, Inc. financing, exceeding $1,000,000 on independently set valuation and terms. On August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock for $1,000,000 (LipimetiX Development, Inc. incurred $15,000 in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown as a reduction of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company&amp;#8217;s ownership in the JV to 62.2%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting its Series A Preferred Stock to common stock, the Company&amp;#8217;s ownership would change to 69.75%. The JV 2016 Equity Incentive Plan has 83,480 shares of the JV&amp;#8217;s common stock available to grant, of which, at December 31, 2018, options to purchase JV common stock shares totaling 81,479 have been granted and are fully vested. All options were granted with an exercise price of $1.07, vested 50% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised, and the Series B-1 Preferred Stock Warrants were exercised, the Company&amp;#8217;s fully diluted ownership (on an as-converted basis) would be approximately 65.11%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase 14,126 shares of the LipimetiX Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $10.70 per share, subject to adjustment and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date of grant. If exercised, this option would reduce the Company&amp;#8217;s fully diluted ownership (on an as-converted basis including assumed exercise of other options and warrants) to approximately 64.31%.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (&amp;#8220;Benu&amp;#8221;) and UABRF to commercialize UABRF&amp;#8217;s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (&amp;#8220;UABRF&amp;#8221;) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock), representing a 40% ownership interest in the JV at formation, and $378,000 in cash (for certain initial patent-related costs and legal expenses).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1 Preferred Stock offering, raising funds of $1,012,000 ($946,000 net of issuance costs of approximately $66,000). Individual accredited investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV&amp;#8217;s common stock at the election of the holders and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with a ten-year term.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock for $1,000,000.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Series B (B-1 and B-2) Preferred Stock is a participating preferred stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in future distributions on an equal &amp;#8220;as-converted&amp;#8221; share basis with common stock holders. The Series B Preferred Stock has &amp;#8220;as-converted&amp;#8221; voting rights and other terms standard to a security of this nature.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Exclusive License Agreement assigned by LipimetiX, LLC to the JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non-Royalty Income received.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (&amp;#8220;JDC&amp;#8221;) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an &amp;#8220;as -converted&amp;#8221; basis) stockholders.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were entered into effective June 1, 2016. However, no Management or Accounting Services fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time. In August 2017 the Accounting Services Agreement monthly fee was increased to $20,000 and will thereafter be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31, 2019, accounting fees of $400,000 were earned but unpaid. In August 2017, a Management Fee of $300,000 was approved by the joint venture&amp;#8217;s Board of Directors with $150,000 paid and charged to expense in the third quarter of 2017 and $150,000 paid and expensed in the first quarter of 2018. In the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 a Management Fee of $50,000 was charged to expense and paid in the second quarter of 2019..&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The joint venture formation was as follows ($000&amp;#8217;s):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.50in;width: 50%;"&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 77.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent license rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 20.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,045&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Noncontrolling interests&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(667&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid at formation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;378&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent license rights were recorded at their estimated fair value and were amortized on a straight-line basis over the key patent life of eighty months.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. In the Company&amp;#8217;s consolidated financial statements, joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were being allocated to the Series A preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 of losses were allocated to the Series B-1 Preferred Stock ownership interests. As of December 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture, with the loan due December 31, 2016. The due date of the revolving loan was extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June 30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company&amp;#8217;s option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance. At March 31, 2019, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $140,000, was $1,740,000.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The joint venture incurred net operating income (expenses), prior to the elimination of intercompany transactions, of ($684,000) in 2019 and ($10,282,000) for the period from August 3, 2012 (inception) to March 31, 2019, of which ($684,000), and ($8,670,000), respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2019, losses totaling $667,000 have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would the joint venture&amp;#8217;s ability to continue operations. If the joint venture does not continue as a going concern, at March 31, 2019, the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the common stock noncontrolling interests.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
<caps:ScheduleOfJointVenturePaymentsTableTextBlock id="Factid_5371564" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The joint venture formation was as follows ($000&amp;#8217;s):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.50in;width: 50%;"&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 77.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent license rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 20.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,045&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Noncontrolling interests&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(667&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid at formation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;378&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:ScheduleOfJointVenturePaymentsTableTextBlock>
<caps:PercentageOfNonRoyaltyIncome id="Factid_5371575" contextRef="P08_01_2017To08_11_2017" unitRef="Unit_pure" decimals="2">0.05</caps:PercentageOfNonRoyaltyIncome>
<us-gaap:MinorityInterestOwnershipPercentageByParent id="Factid_5371594" contextRef="PAsOn03_31_2019_JointVentureMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:MinorityInterestOwnershipPercentageByParent>
<caps:ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts id="Factid_5371616" contextRef="P08_01_2016To08_25_2016_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">1012000</caps:ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts>
<caps:JointVentureLossesRecognitionCriteriaCommonOwnershipEquity id="Factid_5371661" contextRef="PAsOn08_25_2016_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">946000</caps:JointVentureLossesRecognitionCriteriaCommonOwnershipEquity>
<caps:RefundableResearchAndDevelopmentCreditTextBlock id="Factid_5371662" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note C &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-transform: uppercase; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Australian Refundable Research &amp;amp; Development Credit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2014, LipimetiX Development LLC, (Now LipimetiX Development, Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits claims for a refundable research and development tax credit. At December 31, 2018, expected refundable research and development tax credit of AUD$4,000, is included in Other current assets in the Condensed Consolidated Balance Sheets. &amp;#160;The expected refundable research and development tax credits for the three-month periods ended March 31, 2019 and 2018 were AUD$0 and AUD$4,000, respectively.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:RefundableResearchAndDevelopmentCreditTextBlock>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners id="Factid_5371689" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3">0.341</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:DeferredFinanceCostsNet id="Factid_5371697" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">287000</us-gaap:DeferredFinanceCostsNet>
<us-gaap:PaymentOfFinancingAndStockIssuanceCosts id="Factid_5371702" contextRef="P01_01_2019To03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">12000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
<us-gaap:AmortizationOfFinancingCosts id="Factid_5371729" contextRef="P01_01_2019To03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">157000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts id="Factid_5371733" contextRef="P01_01_2018To03_31_2018_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">23000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:UnamortizedDebtIssuanceExpense id="Factid_5371736" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">142000</us-gaap:UnamortizedDebtIssuanceExpense>
<us-gaap:UnamortizedDebtIssuanceExpense id="Factid_5371737" contextRef="PAsOn12_31_2018_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">165000</us-gaap:UnamortizedDebtIssuanceExpense>
<us-gaap:InterestPayableCurrentAndNoncurrent id="Factid_5371742" contextRef="PAsOn03_31_2019_SecuredDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0">249000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:InterestPayableCurrentAndNoncurrent id="Factid_5371758" contextRef="PAsOn12_31_2018_SecuredDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0">213000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:InterestExpenseDebt id="Factid_5371760" contextRef="P01_01_2019To03_31_2019_InterestAndOtherExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0">36000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt id="Factid_5371761" contextRef="P01_01_2018To03_31_2018_InterestAndOtherExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0">36000</us-gaap:InterestExpenseDebt>
<us-gaap:DebtInstrumentMaturityDate id="Factid_5371783" contextRef="P12_01_2015To12_11_2015">2017-04-30</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities id="Factid_5371786" contextRef="P07_01_2017To07_14_2017_BrookstoneMembersrtOwnershipAxis">Brookstone beneficially owns over 20% of the Company&amp;#8217;s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company&amp;#8217;s outstanding common stock.</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions id="Factid_5371789" contextRef="P08_01_2017To08_11_2017_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<dei:DocumentType id="Factid_5371847" contextRef="P01_01_2019To03_31_2019">10-Q</dei:DocumentType>
<dei:AmendmentFlag id="Factid_5371848" contextRef="P01_01_2019To03_31_2019">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate id="Factid_5371849" contextRef="P01_01_2019To03_31_2019">2019-03-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_5371850" contextRef="P01_01_2019To03_31_2019">2019</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_5371851" contextRef="P01_01_2019To03_31_2019">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_5371852" contextRef="P01_01_2019To03_31_2019">Capstone Therapeutics Corp.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_5371853" contextRef="P01_01_2019To03_31_2019">0000887151</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_5371854" contextRef="P01_01_2019To03_31_2019">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory id="Factid_5371855" contextRef="P01_01_2019To03_31_2019">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:TradingSymbol id="Factid_5371856" contextRef="P01_01_2019To03_31_2019">CAPS</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding id="Factid_5371857" contextRef="PAsOn05_01_2019" unitRef="Unit_shares" decimals="0">54385411</dei:EntityCommonStockSharesOutstanding>
<dei:EntityEmergingGrowthCompany id="Factid_5371858" contextRef="P01_01_2019To03_31_2019">false</dei:EntityEmergingGrowthCompany>
<dei:EntitySmallBusiness id="Factid_5371859" contextRef="P01_01_2019To03_31_2019">true</dei:EntitySmallBusiness>
<us-gaap:SubsequentEventsTextBlock id="Factid_5372074" contextRef="P01_01_2019To03_31_2019">&lt;div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note E LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the &amp;#8220;Sub-License&amp;#8221;) with Anji Pharmaceuticals Inc. (&amp;#8220;ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&amp;#8217;s AEM-28 and analogs intellectual property in the Territory of the People&amp;#8217;s Republic of China, Taiwan and Hong Kong (the &amp;#8220;Territory&amp;#8221;). The Sub-License calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. The JV recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction costs related to the revenue totaled $254,000 and consisted of a $100,000 payment to the UAB Research Foundation, as required by the UAB Research Foundation Exclusive License Agreement, a $100,000 advisory fee and $54,000 in legal fees. As described in Note B above, at March 31, 2019, JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue recorded for the $2,000,000 payment reduced the amount of JV net losses previously allocated to the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A copy of the UAB Research Foundation Exclusive License Agreement was attached as Exhibit 10.7 to the Company&amp;#8217;s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with Securities and Exchange Commission (&amp;#8216;SEC&amp;#8221;) on August 10, 2012. A copy of the First Amendment and Consent to Assignment of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company&amp;#8217;s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached as Exhibit 10.1 to the Company&amp;#8217;s Current Report on Form 8-K filed with the SEC on January 30, 2015.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
<caps:IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock id="Factid_5372076" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 12pt;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note D &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-transform: uppercase; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement (the &amp;#8220;Agreement&amp;#8221;) with BP Peptides, LLC (&amp;#8220;Brookstone"). The net proceeds have been used to fund our operations, infuse new capital into our joint venture, LipimetiX Development, Inc. ("JV") (As described in Note B above, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes totaling $1,000,000, plus $79,000 in accrued interest.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Agreement, Brookstone funded an aggregate of $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes and transaction costs, of which $1,012,500 was for the purchase of 13,500,000 newly issued shares of our Common Stock, and $2,427,500 was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased 5,041,197 shares of the Company&amp;#8217;s Common Stock directly from Biotechnology Value Fund affiliated entities, resulting in ownership of 18,541,197 shares of the Company&amp;#8217;s Common Stock, representing approximately 34.1% of outstanding shares of the Company&amp;#8217;s Common Stock at March 31, 2019.&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First Amendment to Securities Purchase, Loan and Security Agreement (the &amp;#8220;Amendment&amp;#8221;) with Brookstone. Interest on the Secured Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt&amp;#8217;s maturity, October 15, 2020. In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to 6,321,930 shares of the Company&amp;#8217;s Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement, converted into shares at $0.75. At March 31, 2019, 2,926,302 shares are fully vested and exercisable.&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 12pt;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Warrants was determined to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $4,000 and $2,000 in 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018, respectively, and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000. Any additional amounts advanced will be added to the current Loan and subject to the same terms and conditions. At Brookstone&amp;#8217;s sole discretion, the Maximum Amount may be increased to an amount not to exceed $700,000. The Company borrowed $50,000 in March 2019 against the Maximum Amount of $500,000.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs of $287,000 have been deferred and will be written off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. Additional transaction costs of $12,000 were incurred with the Amendment and will be written off over the period of the date of the Amendment, January 30, 2018, to October 15, 2020. At March 31, 2019 transaction costs of $157,000 has been amortized, and $23,000 in the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2019 and December 31, 2018, unamortized transaction costs of $142,000 and $165,000, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. Interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2019 and December 31, 2018, accrued interest of $249,000 and $213,000, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt of $36,000 in 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the Secured Debt activity is as follows (000&amp;#8217;s):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 70%;margin-left: auto;margin-right: auto;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Secured Debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,477&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,427&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,178&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,128&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;134&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,262&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;249&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;213&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,584&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,475&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The secured loan bears interest at 6% per annum, with interest payable quarterly (now due at loan maturity) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. &lt;/div&gt;&lt;div style="background: rgb(255, 255, 255); font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially owns over 20% of the Company&amp;#8217;s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company&amp;#8217;s outstanding common stock.&lt;/div&gt;&lt;/div&gt;&lt;div style="background: none; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April 18, 2017, the Company and Computershare Trust Company, N.A., as Rights Agent (the &amp;#8220;Rights Agent&amp;#8221;) entered into Tax Benefit Preservation Plan Agreement (the &amp;#8220;Plan&amp;#8221;), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company&amp;#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017.&amp;#160;&amp;#160;The Plan is intended to act as a deterrent to any person (together with all affiliates and associates of such person) acquiring &amp;#8220;beneficial ownership&amp;#8221; (as defined in the Plan) of 4.99% or more of the outstanding shares of Common Stock without the approval of the Board (an &amp;#8220;Acquiring Person&amp;#8221;), in an effort to protect against a possible limitation on the Company&amp;#8217;s ability to use its net operating loss carryforwards.&amp;#160;&amp;#160;The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share acquisition described above, and Brookstone&amp;#8217;s acquisition of 5,041,197 shares of the Company&amp;#8217;s Common Stock from Biotechnology Value Fund affiliated entities, making Brookstone an Exempt Person in respect of such transactions.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock>
<us-gaap:ScheduleOfDebtTableTextBlock id="Factid_5372077" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the Secured Debt activity is as follows (000&amp;#8217;s):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 70%;margin-left: auto;margin-right: auto;"&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Secured Debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,477&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,427&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(299&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,178&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,128&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;157&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;134&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,262&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;249&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;213&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,584&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,475&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_5372180" contextRef="P01_01_2019To03_31_2019_LipimetixAustraliaPtyLtdMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_5372245" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="0">401000</us-gaap:ResearchAndDevelopmentExpense>
<caps:CompanyHistoryPolicyTextBlock id="Factid_5372384" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Company History&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our &amp;#8220;Bone Device Business.&amp;#8221; In November 2003, we sold our Bone Device Business.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In these notes, references to &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221;, &amp;#8220;us&amp;#8221;, the &amp;#8220;Company&amp;#8221;, &amp;#8220;Capstone Therapeutics&amp;#8221;, &amp;#8220;Capstone&amp;#8221;, and &amp;#8220;OrthoLogic&amp;#8221; refer to Capstone Therapeutics Corp. References to our joint venture or &amp;#8220;JV&amp;#8221;, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:CompanyHistoryPolicyTextBlock>
<caps:BasisOfPresentationAndManagementPlanPolicyTextBlock id="Factid_5372385" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation, Going Concern, and Management&amp;#8217;s Plans. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company&amp;#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase &lt;div style="display:inline;"&gt;93,458&lt;/div&gt; shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity&amp;#8217;s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information presented as of December 31, 2018 is derived from audited financial statements.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:BasisOfPresentationAndManagementPlanPolicyTextBlock>
<us-gaap:UseOfEstimates id="Factid_5372386" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management&amp;#8217;s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our significant estimates include accounting for stock-based compensation.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
<us-gaap:CommitmentsAndContingenciesPolicyTextBlock id="Factid_5372389" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and Other Contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_5372392" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU 606&amp;#8221;) No. 2014-09 &amp;#8220;Revenue from Contracts from Customers&amp;#8221;. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i)&amp;#160;identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Upfront License Fees&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;: If a license to the Company&amp;#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.&amp;#160;&amp;#160;For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.&amp;#160;&amp;#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_5372394" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;In February 2016 the FASB issued ASU 2016-02 &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases (Topic 842) &lt;/div&gt; and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cooperation Agreement.&lt;/div&gt; &amp;#160;In May 2018 the Company&amp;#8217;s joint venture (&amp;#8220;JV&amp;#8221;) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (&amp;#8220;ANJI&amp;#8221;) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the &amp;#8220;Sub-License&amp;#8221;) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&amp;#8217;s AEM-28 and analogs intellectual property in the Territory of the People&amp;#8217;s Republic of China, Taiwan and Hong Kong (the &amp;#8220;Territory&amp;#8221;). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses &amp;#8211; Research &amp;amp; Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities &amp;#8211; Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $&lt;div style="display:inline;"&gt;52,000&lt;/div&gt;, respectively, and has been shown net. In the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 the Company charged costs totaling $&lt;div style="display:inline;"&gt;401,000&lt;/div&gt;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203;&amp;#8203; to research and development expense related to its activities under the Cooperation Agreement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company&amp;#8217;s financial statements at March 31, 2019 or December 31, 2018.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:StockholdersEquityPolicyTextBlock id="Factid_5372489" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&amp;#8217; Equity.&lt;/div&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160;During the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;st&lt;/div&gt; quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Factid_5372490" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash consists of balances held in commercial bank accounts.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<caps:AmortisationOfFinancingCostOfWarrants id="Factid_5406124" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0">4000</caps:AmortisationOfFinancingCostOfWarrants>
<caps:AmortisationOfFinancingCostOfWarrants id="Factid_5406125" contextRef="P01_01_2018To03_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0">2000</caps:AmortisationOfFinancingCostOfWarrants>
<us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability id="Factid_5406183" contextRef="P01_01_2019To03_31_2019_OtherAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="0">28000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_5406184" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="0">28000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_5411067" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_shares" decimals="0">6321930</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:AdjustmentForAmortization id="Factid_5411068" contextRef="P01_01_2019To03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">4000</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization id="Factid_5411069" contextRef="P01_01_2018To03_31_2018_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">2000</us-gaap:AdjustmentForAmortization>
<us-gaap:WarrantsAndRightsOutstanding id="Factid_5411070" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">43000</us-gaap:WarrantsAndRightsOutstanding>
<caps:AdditionalFundForOperations id="Factid_5411105" contextRef="PAsOn03_15_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">500000</caps:AdditionalFundForOperations>
<caps:AdditionalFundForOperations id="Factid_5411383" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="0">50000</caps:AdditionalFundForOperations>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_5411463" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_shares" decimals="0">2926302</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:CommonStockValue id="Factid_5411465" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="2">0.75</us-gaap:CommonStockValue>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_5411940" contextRef="PAsOn03_31_2019" unitRef="Unit_pure" decimals="2">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_5412009" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DerivativeFixedInterestRate id="Factid_5412842" contextRef="PAsOn03_31_2019" unitRef="Unit_pure" decimals="2">0.06</us-gaap:DerivativeFixedInterestRate>
<us-gaap:WarrantsAndRightsOutstandingMaturityDate id="Factid_5412853" contextRef="PAsOn03_31_2019">2025-10-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
<caps:SublicenseTransactionCosts id="Factid_5417529" contextRef="P01_01_2019To03_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">254000</caps:SublicenseTransactionCosts>
<caps:AccountsPayableCorporationAgreement id="Factid_5417697" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="0">416000</caps:AccountsPayableCorporationAgreement>
<caps:AdditionalFundForOperations id="Factid_5417698" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="0">500000</caps:AdditionalFundForOperations>
<caps:DescriptionOfBusinessPolicyTextBlock id="Factid_5418175" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of the Business&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capstone Therapeutics Corp. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;our&amp;#8221; or &amp;#8220;us&amp;#8221;) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the &amp;#8220;JV&amp;#8221;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV&amp;#8217;s development activities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of Current Peptide Drug Candidates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Apo E Mimetic Peptide Molecule &amp;#8211; AEM-28 and its analogs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:DescriptionOfBusinessPolicyTextBlock>
<us-gaap:InterestInUnincorporatedJointVenturesOrPartnershipsPolicy id="Factid_5418177" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Joint Venture Accounting. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&amp;#8217;s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestInUnincorporatedJointVenturesOrPartnershipsPolicy>
<caps:AccountsPayablePolicyPolicyTextBlock id="Factid_5418179" contextRef="P01_01_2019To03_31_2019">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Payable. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable includes officer compensation of &lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company&amp;#8217;s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</caps:AccountsPayablePolicyPolicyTextBlock>
<us-gaap:Revenues id="Factid_5418244" contextRef="P04_01_2018To06_30_2018" unitRef="Unit_USD" decimals="-6">2000000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_5418254" contextRef="P01_01_2019To03_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6">2000000</us-gaap:Revenues>
<us-gaap:NetIncomeLoss id="Factid_5418352" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">855000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_5418353" contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">587000</us-gaap:NetIncomeLoss>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions id="Factid_5418725" contextRef="P08_01_2016To08_25_2016_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="Factid_5418731" contextRef="P08_01_2016To08_25_2016_SeriesB2PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0">93458</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<us-gaap:CommonStockValue id="Factid_5421122" contextRef="PAsOn03_31_2019_BrookstoneMembersrtOwnershipAxis" unitRef="Unit_USD" decimals="2">0.75</us-gaap:CommonStockValue>
<us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet id="Factid_5421189" contextRef="P03_01_2019To03_15_2019" unitRef="Unit_USD" decimals="0">700000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
<us-gaap:SecuredDebtCurrent id="Factid_5421193" contextRef="PAsOn03_15_2019_SecuredDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0">500000</us-gaap:SecuredDebtCurrent>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>caps-20190331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 11-May-2019 [12:09:07] {AM}-->
<schema targetNamespace="http://www.capstonethx.com/20190331" elementFormDefault="qualified" xmlns:caps="http://www.capstonethx.com/20190331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2018-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.capstonethx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>1001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations" id="CondensedConsolidatedStatementOfOperations">
<link:definition>1004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/OverviewOfBusiness" id="OverviewOfBusiness">
<link:definition>1006 - Disclosure - OVERVIEW OF BUSINESS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs" id="JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs">
<link:definition>1007 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit" id="AustralianRefundableResearchDevelopmentCredit">
<link:definition>1008 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt" id="SaleOfCommonStockAndIssuanceOfsecuredDebt">
<link:definition>1009 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement" id="LipimetixDevelopmentIncLicenseAgreement">
<link:definition>1010 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/OverviewOfBusinessPolicies" id="OverviewOfBusinessPolicies">
<link:definition>1011 - Disclosure - OVERVIEW OF BUSINESS (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables" id="JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables">
<link:definition>1012 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables" id="SaleOfCommonStockAndIssuanceOfsecuredDebtTables">
<link:definition>1013 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual" id="OverviewOfBusinessDetailsTextual">
<link:definition>1014 - Disclosure - OVERVIEW OF BUSINESS (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" id="JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails">
<link:definition>1015 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual" id="JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual">
<link:definition>1016 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual" id="AustralianRefundableResearchDevelopmentCreditDetailsTextual">
<link:definition>1017 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails" id="SaleOfCommonStockAndIssuanceOfsecuredDebtDetails">
<link:definition>1018 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual" id="SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual">
<link:definition>1019 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual" id="LipimetixDevelopmentIncLicenseAgreementDetailsTextual">
<link:definition>1020 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="caps-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="caps-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="caps-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="caps-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
<import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
<element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_DocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_BalanceSheetParentheticalAbstract" substitutionGroup="xbrli:item" />
<element name="SublicenseTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_SublicenseTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RefundableResearchAndDevelopmentCreditTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_RefundableResearchAndDevelopmentCreditTextBlock" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfBusinessPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_DescriptionOfBusinessPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CompanyHistoryPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_CompanyHistoryPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndManagementPlanPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountsPayablePolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_AccountsPayablePolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfJointVenturePaymentsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_ScheduleOfJointVenturePaymentsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_AccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BrookstoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_BrookstoneMember" substitutionGroup="xbrli:item" />
<element name="LipimetixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_LipimetixMember" substitutionGroup="xbrli:item" />
<element name="SeriesB2PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_SeriesB2PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesB1PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_SeriesB1PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromRelatedPartyDebtNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_ProceedsFromRelatedPartyDebtNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReimbursementOfRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_ReimbursementOfRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortisationOfFinancingCostOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_AmortisationOfFinancingCostOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccountsPayableCorporationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="caps_AccountsPayableCorporationAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdditionalFundForOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="caps_AdditionalFundForOperations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="ExclusiveLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_ExclusiveLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="VotingCommonOwnershipUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_VotingCommonOwnershipUnitsMember" substitutionGroup="xbrli:item" />
<element name="NonVotingPreferredOwnershipUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_NonVotingPreferredOwnershipUnitsMember" substitutionGroup="xbrli:item" />
<element name="SeriesB1AndB2PreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_SeriesB1AndB2PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfNonRoyaltyIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_PercentageOfNonRoyaltyIncome" substitutionGroup="xbrli:item" />
<element name="JointVentureInvestmentsInVotingCommonOwnershipUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" substitutionGroup="xbrli:item" />
<element name="JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" substitutionGroup="xbrli:item" />
<element name="JointVentureInvestmentsCommonOwnershipUnitsCoventure" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" substitutionGroup="xbrli:item" />
<element name="OwnershipPercentageCoventure" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_OwnershipPercentageCoventure" substitutionGroup="xbrli:item" />
<element name="PercentageOfRoyaltyPayment" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_PercentageOfRoyaltyPayment" substitutionGroup="xbrli:item" />
<element name="JointVentureOperatingExpensesInterCompanyTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_JointVentureOperatingExpensesInterCompanyTransactions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="JointVentureOperatingExpensesAllocatedToCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_JointVentureOperatingExpensesAllocatedToCompany" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualMaintenancePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_AnnualMaintenancePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_MilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_ManagementFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="JointVentureMethodInvestmentOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_JointVentureMethodInvestmentOwnershipPercentage" substitutionGroup="xbrli:item" />
<element name="OperatingExpensesNetOfEliminationOfIntercompanyTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OwnershipAsConvertedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_OwnershipAsConvertedMember" substitutionGroup="xbrli:item" />
<element name="OwnershipAsConvertedIncludingOptionsAndWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" substitutionGroup="xbrli:item" />
<element name="JointVentureMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_JointVentureMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfResearchAndDevelopmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_ScheduleOfResearchAndDevelopmentTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ResearchAndDevelopmentDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_ResearchAndDevelopmentDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="LipimetixAustraliaPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_LipimetixAustraliaPtyLtdMember" substitutionGroup="xbrli:item" />
<element name="SecuredLongTermDebtGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="caps_SecuredLongTermDebtGross" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InterestAndOtherExpensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="caps_InterestAndOtherExpensesMember" substitutionGroup="xbrli:item" />
<element name="BeneficialOwnershipPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="caps_BeneficialOwnershipPercentage" substitutionGroup="xbrli:item" />
<element name="UABResearchFoundationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_UABResearchFoundationExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdvisoryFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="caps_AdvisoryFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>caps-20190331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 11-May-2019 [12:09:07] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedStatementOfOperations" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="100" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="90" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="70" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="80" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="170" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="150" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="160" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="290" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="270" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="240" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="250" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="260" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="280" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_SecuredLongTermDebt" use="optional" order="200" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="150" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="120" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="110" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="100" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3616680" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="70" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SublicenseTransactionCosts" xlink:label="loc_CAPS_SublicenseTransactionCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_CAPS_SublicenseTransactionCosts" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="130" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="190" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="100" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" use="optional" order="120" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashExpense" use="optional" order="130" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" use="optional" order="160" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="170" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" use="optional" order="180" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="4203910" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" use="optional" order="230" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" order="70" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>caps-20190331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 11-May-2019 [12:09:07] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedStatementOfOperations" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#OverviewOfBusinessDetailsTextual" roleURI="http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#AustralianRefundableResearchDevelopmentCreditDetailsTextual" roleURI="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#SaleOfCommonStockAndIssuanceOfsecuredDebtDetails" roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual" roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#LipimetixDevelopmentIncLicenseAgreementDetailsTextual" roleURI="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_AssetsAbstract_36" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_AssetsCurrentAbstract_37" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_420335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_420335" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_OtherAssetsCurrent_45" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_AssetsCurrent_46" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_Assets_49" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_StatementTable_33" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34" xlink:to="loc_us-gaap_ClassOfStockDomain_43" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_43_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34" xlink:to="loc_us-gaap_ClassOfStockDomain_43_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_AccountsPayableCurrent_50" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_51" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_LiabilitiesCurrent_52" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_SecuredLongTermDebt_54" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" xlink:to="loc_us-gaap_StockholdersEquityAbstract_42" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_CommonStockValue_56" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_StockholdersEquity_59" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" xlink:to="loc_us-gaap_MinorityInterest_60" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_62" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_162" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_StatementTable_160" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_160" xlink:to="loc_us-gaap_StatementClassOfStockAxis_161" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161" xlink:to="loc_us-gaap_ClassOfStockDomain_163" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_163_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161" xlink:to="loc_us-gaap_ClassOfStockDomain_163_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_164" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_165" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_166" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_321" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_StatementTable_319" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_320" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_320" xlink:to="loc_us-gaap_ClassOfStockDomain_324" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_320" xlink:to="loc_us-gaap_ClassOfStockDomain_324_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_OperatingExpensesAbstract_322" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_325" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_326" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_us-gaap_OperatingExpenses_327" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SublicenseTransactionCosts" xlink:label="loc_caps_SublicenseTransactionCosts_361668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_caps_SublicenseTransactionCosts_361668" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_335" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_NetIncomeLoss_333" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_323" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_323" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_334" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_328" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_329" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_330" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_ProfitLoss_331" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_332" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_361674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_OperatingIncomeLoss_361674" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_361657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_Revenues_361657" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_573" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_StatementTable_569" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_569" xlink:to="loc_dei_LegalEntityAxis_570" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_570" xlink:to="loc_dei_EntityDomain_579" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_570" xlink:to="loc_dei_EntityDomain_579_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_569" xlink:to="loc_us-gaap_StatementClassOfStockAxis_571" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_571" xlink:to="loc_us-gaap_ClassOfStockDomain_572" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_571" xlink:to="loc_us-gaap_ClassOfStockDomain_572_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_ProfitLoss_582" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" xlink:to="loc_us-gaap_AdjustmentForAmortization_583" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" xlink:to="loc_us-gaap_OtherNoncashExpense_584" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" xlink:to="loc_us-gaap_ShareBasedCompensation_585" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_586" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_587" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_588" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_589" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_577" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_577" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_590" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_420391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_420391" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_596" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_597" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual">
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountingPoliciesLineItems" xlink:label="loc_caps_AccountingPoliciesLineItems_116" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountingPoliciesTable" xlink:label="loc_caps_AccountingPoliciesTable_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AccountingPoliciesTable_101" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_srt_RangeAxis_102" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_102" xlink:to="loc_srt_RangeMember_103" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_102" xlink:to="loc_srt_RangeMember_103_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_105" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_105_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_105_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_106" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_106" xlink:to="loc_us-gaap_EquityComponentDomain_107" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_106" xlink:to="loc_us-gaap_EquityComponentDomain_107_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_107" xlink:to="loc_us-gaap_CommonStockMember_120" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_423157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_107" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_423157" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_423164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_107" xlink:to="loc_us-gaap_RetainedEarningsMember_423164" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_dei_LegalEntityAxis_108" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_108" xlink:to="loc_dei_EntityDomain_109" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_109_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_108" xlink:to="loc_dei_EntityDomain_109_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BrookstoneMember" xlink:label="loc_caps_BrookstoneMember_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_109" xlink:to="loc_caps_BrookstoneMember_121" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember_420341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_109" xlink:to="loc_caps_LipimetixMember_420341" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_CreditFacilityAxis_110" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_110" xlink:to="loc_us-gaap_CreditFacilityDomain_111" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_111_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_110" xlink:to="loc_us-gaap_CreditFacilityDomain_111_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_112" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_112" xlink:to="loc_us-gaap_ClassOfStockDomain_113" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_113_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_112" xlink:to="loc_us-gaap_ClassOfStockDomain_113_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_caps_SeriesB2PreferredStockMember_124" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1PreferredStockMember" xlink:label="loc_caps_SeriesB1PreferredStockMember_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_caps_SeriesB1PreferredStockMember_123" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_363062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_srt_ProductOrServiceAxis_363062" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_363065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_363062" xlink:to="loc_srt_ProductsAndServicesDomain_363065" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_363065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_363062" xlink:to="loc_srt_ProductsAndServicesDomain_363065_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_420429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_420429" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_420431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_420429" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_420431" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_420431_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_420429" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_420431_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_423239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" xlink:to="loc_us-gaap_TypeOfAdoptionMember_423239" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_423239_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" xlink:to="loc_us-gaap_TypeOfAdoptionMember_423239_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_423267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_423267" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_423268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_423267" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_423268" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_423268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_423267" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_423268_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_423270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_423268" xlink:to="loc_us-gaap_OtherAssetsMember_423270" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_128" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_137" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xlink:label="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_138" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_139" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromRelatedPartyDebtNet" xlink:label="loc_caps_ProceedsFromRelatedPartyDebtNet_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_ProceedsFromRelatedPartyDebtNet_140" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_141" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_142" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xlink:label="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_420435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_420435" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_130" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_362814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_362814" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_362835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_362835" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ReimbursementOfRevenue" xlink:label="loc_caps_ReimbursementOfRevenue_362839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_ReimbursementOfRevenue_362839" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_420340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_420340" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AmortisationOfFinancingCostOfWarrants" xlink:label="loc_caps_AmortisationOfFinancingCostOfWarrants_423154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AmortisationOfFinancingCostOfWarrants_423154" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_423158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_NetIncomeLoss_423158" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_423232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_423232" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_423255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_423255" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountsPayableCorporationAgreement" xlink:label="loc_caps_AccountsPayableCorporationAgreement_424851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AccountsPayableCorporationAgreement_424851" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdditionalFundForOperations" xlink:label="loc_caps_AdditionalFundForOperations_424852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AdditionalFundForOperations_424852" use="optional" order="59" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_350" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" xlink:to="loc_dei_LegalEntityAxis_348" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_348" xlink:to="loc_dei_EntityDomain_349" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_349_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_348" xlink:to="loc_dei_EntityDomain_349_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_349" xlink:to="loc_caps_LipimetixMember_351" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_352" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_353" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_354" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_379" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementAxis" xlink:label="loc_caps_AgreementAxis_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_caps_AgreementAxis_360" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementDomain" xlink:label="loc_caps_AgreementDomain_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_caps_AgreementAxis_360" xlink:to="loc_caps_AgreementDomain_361" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementDomain" xlink:label="loc_caps_AgreementDomain_361_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_caps_AgreementAxis_360" xlink:to="loc_caps_AgreementDomain_361_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ExclusiveLicenseAgreementMember" xlink:label="loc_caps_ExclusiveLicenseAgreementMember_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_AgreementDomain_361" xlink:to="loc_caps_ExclusiveLicenseAgreementMember_383" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_srt_RangeAxis_362" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_362" xlink:to="loc_srt_RangeMember_363" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_362" xlink:to="loc_srt_RangeMember_363_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_363" xlink:to="loc_srt_MaximumMember_384" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_363" xlink:to="loc_srt_MinimumMember_385" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_364" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_364" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_386" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_386_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_364" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_386_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_365" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_365" xlink:to="loc_us-gaap_EquityComponentDomain_366" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_365" xlink:to="loc_us-gaap_EquityComponentDomain_366_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_366" xlink:to="loc_us-gaap_PreferredStockMember_388" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_366" xlink:to="loc_us-gaap_NoncontrollingInterestMember_389" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_dei_LegalEntityAxis_358" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_358" xlink:to="loc_dei_EntityDomain_359" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_358" xlink:to="loc_dei_EntityDomain_359_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_359" xlink:to="loc_caps_LipimetixMember_380" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_VotingCommonOwnershipUnitsMember" xlink:label="loc_caps_VotingCommonOwnershipUnitsMember_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_359" xlink:to="loc_caps_VotingCommonOwnershipUnitsMember_381" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_NonVotingPreferredOwnershipUnitsMember" xlink:label="loc_caps_NonVotingPreferredOwnershipUnitsMember_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_359" xlink:to="loc_caps_NonVotingPreferredOwnershipUnitsMember_382" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_TypeOfArrangementAxis_371" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_371" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_372" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_372_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_371" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_372_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_CreditFacilityAxis_367" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_367" xlink:to="loc_us-gaap_CreditFacilityDomain_368" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_368_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_367" xlink:to="loc_us-gaap_CreditFacilityDomain_368_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_368" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_390" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_StatementClassOfStockAxis_369" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_369" xlink:to="loc_us-gaap_ClassOfStockDomain_370" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_370_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_369" xlink:to="loc_us-gaap_ClassOfStockDomain_370_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1PreferredStockMember" xlink:label="loc_caps_SeriesB1PreferredStockMember_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_caps_SeriesB1PreferredStockMember_391" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_caps_SeriesB2PreferredStockMember_392" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1AndB2PreferredStockMember" xlink:label="loc_caps_SeriesB1AndB2PreferredStockMember_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_caps_SeriesB1AndB2PreferredStockMember_394" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_395" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_373" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_373" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_397" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_397_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_373" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_397_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_StatementScenarioAxis_374" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_374" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_398" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_398_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_374" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_398_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_srt_OwnershipAxis_375" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_375" xlink:to="loc_srt_OwnershipDomain_376" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_375" xlink:to="loc_srt_OwnershipDomain_376_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipAsConvertedMember" xlink:label="loc_caps_OwnershipAsConvertedMember_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_376" xlink:to="loc_caps_OwnershipAsConvertedMember_399" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" xlink:label="loc_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_376" xlink:to="loc_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember_400" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureMember" xlink:label="loc_caps_JointVentureMember_424779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_376" xlink:to="loc_caps_JointVentureMember_424779" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_TitleOfIndividualAxis_377" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_377" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_378" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_378_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_377" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_378_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_402" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_RoyaltyExpense_414" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_PercentageOfNonRoyaltyIncome" xlink:label="loc_caps_PercentageOfNonRoyaltyIncome_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_PercentageOfNonRoyaltyIncome_415" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xlink:label="loc_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits_403" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xlink:label="loc_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits_404" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xlink:label="loc_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure_405" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipPercentageCoventure" xlink:label="loc_caps_OwnershipPercentageCoventure_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_OwnershipPercentageCoventure_406" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_PercentageOfRoyaltyPayment" xlink:label="loc_caps_PercentageOfRoyaltyPayment_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_PercentageOfRoyaltyPayment_407" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xlink:label="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_409" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureOperatingExpensesInterCompanyTransactions" xlink:label="loc_caps_JointVentureOperatingExpensesInterCompanyTransactions_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureOperatingExpensesInterCompanyTransactions_410" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureOperatingExpensesAllocatedToCompany" xlink:label="loc_caps_JointVentureOperatingExpensesAllocatedToCompany_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureOperatingExpensesAllocatedToCompany_411" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AnnualMaintenancePayments" xlink:label="loc_caps_AnnualMaintenancePayments_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_AnnualMaintenancePayments_412" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_MilestonePayments" xlink:label="loc_caps_MilestonePayments_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_MilestonePayments_413" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_416" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_LineOfCredit_417" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_418" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_419" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_420" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_428" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ManagementFees" xlink:label="loc_caps_ManagementFees_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_ManagementFees_430" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_421" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureMethodInvestmentOwnershipPercentage" xlink:label="loc_caps_JointVentureMethodInvestmentOwnershipPercentage_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureMethodInvestmentOwnershipPercentage_422" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xlink:label="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_423" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_424" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_425" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_426" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_442" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_443" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_444" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_445" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_447" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_427" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" xlink:label="loc_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions_433" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_434" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_435" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_436" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ManagementFeeExpense_432" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_437" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_438" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_440" use="optional" order="93" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual">
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ResearchAndDevelopmentDisclosureLineItems" xlink:label="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_314" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ScheduleOfResearchAndDevelopmentTable" xlink:label="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_307" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_307" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_313" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_313_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_307" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_313_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_srt_RangeAxis_304" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_304" xlink:to="loc_srt_RangeMember_305" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_305_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_304" xlink:to="loc_srt_RangeMember_305_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_305" xlink:to="loc_srt_MinimumMember_311" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_us-gaap_StatementClassOfStockAxis_302" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_302" xlink:to="loc_us-gaap_ClassOfStockDomain_303" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_303_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_302" xlink:to="loc_us-gaap_ClassOfStockDomain_303_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixAustraliaPtyLtdMember" xlink:label="loc_caps_LipimetixAustraliaPtyLtdMember_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_303" xlink:to="loc_caps_LipimetixAustraliaPtyLtdMember_309" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_306" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_306" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_312" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_306" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_312_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_316" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_315" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_470" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_471" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_472" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_473" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SecuredLongTermDebtGross" xlink:label="loc_caps_SecuredLongTermDebtGross_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_caps_SecuredLongTermDebtGross_474" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_475" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_SecuredLongTermDebt_476" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_StatementTable_466" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_us-gaap_StatementClassOfStockAxis_467" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_467" xlink:to="loc_us-gaap_ClassOfStockDomain_469" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_467" xlink:to="loc_us-gaap_ClassOfStockDomain_469_default" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_494" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StatementTable_479" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_StatementClassOfStockAxis_480" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_480" xlink:to="loc_us-gaap_ClassOfStockDomain_481" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_481_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_480" xlink:to="loc_us-gaap_ClassOfStockDomain_481_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_481" xlink:to="loc_caps_SeriesB2PreferredStockMember_495" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_srt_OwnershipAxis_488" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_488" xlink:to="loc_srt_OwnershipDomain_489" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_489_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_488" xlink:to="loc_srt_OwnershipDomain_489_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BrookstoneMember" xlink:label="loc_caps_BrookstoneMember_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_489" xlink:to="loc_caps_BrookstoneMember_499" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_srt_RangeAxis_490" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_490" xlink:to="loc_srt_RangeMember_491" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_491_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_490" xlink:to="loc_srt_RangeMember_491_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_491" xlink:to="loc_srt_MinimumMember_500" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_482" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_482" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_483" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_482" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_483_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_CreditFacilityAxis_484" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_484" xlink:to="loc_us-gaap_CreditFacilityDomain_485" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_485_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_484" xlink:to="loc_us-gaap_CreditFacilityDomain_485_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_485" xlink:to="loc_us-gaap_SecuredDebtMember_497" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_486" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_486" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_487" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_486" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_487_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_InterestAndOtherExpensesMember" xlink:label="loc_caps_InterestAndOtherExpensesMember_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_487" xlink:to="loc_caps_InterestAndOtherExpensesMember_498" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_492" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_492" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_493" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_493_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_492" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_493_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_493" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_501" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_508" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromRelatedPartyDebtNet" xlink:label="loc_caps_ProceedsFromRelatedPartyDebtNet_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_caps_ProceedsFromRelatedPartyDebtNet_509" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_502" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_InterestExpenseDebt_503" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_504" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_505" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_506" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_507" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_510" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_511" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_SecuredLongTermDebt_512" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_513" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_514" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_516" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BeneficialOwnershipPercentage" xlink:label="loc_caps_BeneficialOwnershipPercentage_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_caps_BeneficialOwnershipPercentage_517" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_518" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_519" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_520" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_362456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_362456" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent_362959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_SecuredDebtCurrent_362959" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_362961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_362961" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_423843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_423843" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_423844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_AdjustmentForAmortization_423844" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_423846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_423846" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_423865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_CommonStockValue_423865" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdditionalFundForOperations" xlink:label="loc_caps_AdditionalFundForOperations_423886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_caps_AdditionalFundForOperations_423886" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424160" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_424259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_424259" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_424264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_424264" use="optional" order="57" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_361738" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_361740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_Revenues_361740" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SublicenseTransactionCosts" xlink:label="loc_caps_SublicenseTransactionCosts_361743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_caps_SublicenseTransactionCosts_361743" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_361746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_361746" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_361735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_StatementTable_361735" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_361736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_361735" xlink:to="loc_us-gaap_StatementClassOfStockAxis_361736" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_361737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_361736" xlink:to="loc_us-gaap_ClassOfStockDomain_361737" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_361737_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_361736" xlink:to="loc_us-gaap_ClassOfStockDomain_361737_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_361765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_361735" xlink:to="loc_srt_ProductOrServiceAxis_361765" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_361766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_361765" xlink:to="loc_srt_ProductsAndServicesDomain_361766" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_361766_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_361765" xlink:to="loc_srt_ProductsAndServicesDomain_361766_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_361767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_361766" xlink:to="loc_us-gaap_RoyaltyMember_361767" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_361768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_361766" xlink:to="loc_us-gaap_LicenseMember_361768" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_UABResearchFoundationExpense" xlink:label="loc_caps_UABResearchFoundationExpense_361750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_caps_UABResearchFoundationExpense_361750" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdvisoryFees" xlink:label="loc_caps_AdvisoryFees_361754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_caps_AdvisoryFees_361754" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_361757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_LegalFees_361757" use="optional" order="15" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>caps-20190331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 11-May-2019 [12:09:07] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_DocumentAndEntityInformationAbstract" xlink:label="loc_caps_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_DocumentAndEntityInformationAbstract" xlink:to="lab_caps_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patent license rights, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">CASH, BEGINNING OF PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">CASH, END OF PERIOD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredLongTermDebt" xml:lang="en-US">Secured Long-term Debt, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SecuredLongTermDebt" xml:lang="en-US">Secured debt and accrued interest, net of unamortized issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Capstone Therapeutics Corp. Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Capstone Therapeutics Corp. stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BalanceSheetParentheticalAbstract" xlink:label="loc_caps_BalanceSheetParentheticalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet [Parenthetical] [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_BalanceSheetParentheticalAbstract" xlink:to="lab_caps_BalanceSheetParentheticalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">OPERATING EXPENSES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SublicenseTransactionCosts" xlink:label="loc_caps_SublicenseTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_SublicenseTransactionCosts" xml:lang="en-US">Sublicense Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_SublicenseTransactionCosts" xml:lang="en-US">Sublicense transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_SublicenseTransactionCosts" xlink:to="lab_caps_SublicenseTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_SublicenseTransactionCosts" xml:lang="en-US">The amount of sublicense transaction costs recognized during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Per Share Information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Interest and other income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (loss) from operations before taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">NET INCOME (LOSS)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Less: Net Income (Loss) attributable to the noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income (loss) after operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">SUBLICENSE REVENUE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Non cash items:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashExpense" xml:lang="en-US">Other Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNoncashExpense" xml:lang="en-US">Non-cash interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Non-cash stock based interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in other operating items:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash flows used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">INVESTING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Cash flows provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Cash flows provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US">Secured Debt funding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET DECREASE IN CASH</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xml:lang="en-US">Research and Development Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_RefundableResearchAndDevelopmentCreditTextBlock" xlink:label="loc_caps_RefundableResearchAndDevelopmentCreditTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_RefundableResearchAndDevelopmentCreditTextBlock" xml:lang="en-US">Refundable Research And Development Credit [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_RefundableResearchAndDevelopmentCreditTextBlock" xlink:to="lab_caps_RefundableResearchAndDevelopmentCreditTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_RefundableResearchAndDevelopmentCreditTextBlock" xml:lang="en-US">The entire disclosure for Refundable Research &amp; Development Credit during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" xlink:label="loc_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" xml:lang="en-US">Issuance Of Common Stock And Secured Debt Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" xlink:to="lab_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_DescriptionOfBusinessPolicyTextBlock" xlink:label="loc_caps_DescriptionOfBusinessPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_DescriptionOfBusinessPolicyTextBlock" xml:lang="en-US">Description Of Business [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_DescriptionOfBusinessPolicyTextBlock" xml:lang="en-US">Description Of Business [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_DescriptionOfBusinessPolicyTextBlock" xlink:to="lab_caps_DescriptionOfBusinessPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_DescriptionOfBusinessPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for description of business.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_CompanyHistoryPolicyTextBlock" xlink:label="loc_caps_CompanyHistoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_CompanyHistoryPolicyTextBlock" xml:lang="en-US">Company History [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_CompanyHistoryPolicyTextBlock" xml:lang="en-US">Company History [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_CompanyHistoryPolicyTextBlock" xlink:to="lab_caps_CompanyHistoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_CompanyHistoryPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for company history.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" xlink:label="loc_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" xml:lang="en-US">Basis Of Presentation and Management Plan [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" xml:lang="en-US">Basis Of Presentation and Management Plan [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" xlink:to="lab_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for basis of presentation and management plan.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" xlink:label="loc_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" xml:lang="en-US">Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" xml:lang="en-US">Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" xlink:to="lab_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountsPayablePolicyPolicyTextBlock" xlink:label="loc_caps_AccountsPayablePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AccountsPayablePolicyPolicyTextBlock" xml:lang="en-US">Accounts Payable Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AccountsPayablePolicyPolicyTextBlock" xlink:to="lab_caps_AccountsPayablePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_AccountsPayablePolicyPolicyTextBlock" xml:lang="en-US">Accounting policy for payables</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ScheduleOfJointVenturePaymentsTableTextBlock" xlink:label="loc_caps_ScheduleOfJointVenturePaymentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ScheduleOfJointVenturePaymentsTableTextBlock" xml:lang="en-US">Schedule Of Joint Venture Payments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_ScheduleOfJointVenturePaymentsTableTextBlock" xml:lang="en-US">Schedule Of Joint Venture Payments [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ScheduleOfJointVenturePaymentsTableTextBlock" xlink:to="lab_caps_ScheduleOfJointVenturePaymentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_ScheduleOfJointVenturePaymentsTableTextBlock" xml:lang="en-US">Tabular disclosure of payments in formation of joint venture.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountingPoliciesTable" xlink:label="loc_caps_AccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AccountingPoliciesTable" xml:lang="en-US">Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AccountingPoliciesTable" xlink:to="lab_caps_AccountingPoliciesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BrookstoneMember" xlink:label="loc_caps_BrookstoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_BrookstoneMember" xml:lang="en-US">Brookstone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_BrookstoneMember" xlink:to="lab_caps_BrookstoneMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_LipimetixMember" xml:lang="en-US">Lipimetix [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_LipimetixMember" xlink:to="lab_caps_LipimetixMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_SeriesB2PreferredStockMember" xml:lang="en-US">Series B2 Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_SeriesB2PreferredStockMember" xlink:to="lab_caps_SeriesB2PreferredStockMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1PreferredStockMember" xlink:label="loc_caps_SeriesB1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_SeriesB1PreferredStockMember" xml:lang="en-US">Series B1 Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_SeriesB1PreferredStockMember" xml:lang="en-US">Series B-1 Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_SeriesB1PreferredStockMember" xlink:to="lab_caps_SeriesB1PreferredStockMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountingPoliciesLineItems" xlink:label="loc_caps_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AccountingPoliciesLineItems" xml:lang="en-US">Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AccountingPoliciesLineItems" xlink:to="lab_caps_AccountingPoliciesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xlink:label="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xml:lang="en-US">Proceeds From Issunance Of Preferred Stock Before Adjusted Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xml:lang="en-US">Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xlink:to="lab_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xml:lang="en-US">Represent that cash inflow for issuance of preferred stock before adjusted stock offering costs.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromRelatedPartyDebtNet" xlink:label="loc_caps_ProceedsFromRelatedPartyDebtNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ProceedsFromRelatedPartyDebtNet" xml:lang="en-US">Proceeds From Related Party Debt, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ProceedsFromRelatedPartyDebtNet" xlink:to="lab_caps_ProceedsFromRelatedPartyDebtNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_ProceedsFromRelatedPartyDebtNet" xml:lang="en-US">Net Proceeds from related party debt after adjustments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ReimbursementOfRevenue" xlink:label="loc_caps_ReimbursementOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ReimbursementOfRevenue" xml:lang="en-US">Reimbursement of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ReimbursementOfRevenue" xlink:to="lab_caps_ReimbursementOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_ReimbursementOfRevenue" xml:lang="en-US">Amount received for expenses incured.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xlink:label="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xml:lang="en-US">Joint Venture Losses Recognition Criteria Common Ownership Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xml:lang="en-US">Joint Venture Losses Recognition Criteria, Common Ownership Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xlink:to="lab_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xml:lang="en-US">Represents the common ownership equity value, upon which the company records joint venture losses.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AmortisationOfFinancingCostOfWarrants" xlink:label="loc_caps_AmortisationOfFinancingCostOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AmortisationOfFinancingCostOfWarrants" xml:lang="en-US">Amortisation Of Financing Cost Of Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AmortisationOfFinancingCostOfWarrants" xlink:to="lab_caps_AmortisationOfFinancingCostOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_AmortisationOfFinancingCostOfWarrants" xml:lang="en-US">Amortisation Of Financing Cost Of Warrants</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountsPayableCorporationAgreement" xlink:label="loc_caps_AccountsPayableCorporationAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AccountsPayableCorporationAgreement" xml:lang="en-US">Accounts Payable Corporation Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AccountsPayableCorporationAgreement" xlink:to="lab_caps_AccountsPayableCorporationAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_AccountsPayableCorporationAgreement" xml:lang="en-US">Accounts Payable with Corporation Agreement.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdditionalFundForOperations" xlink:label="loc_caps_AdditionalFundForOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AdditionalFundForOperations" xml:lang="en-US">Additional fund for operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AdditionalFundForOperations" xlink:to="lab_caps_AdditionalFundForOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_AdditionalFundForOperations" xml:lang="en-US">Additional Funding for Operations</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsMember" xml:lang="en-US">Other Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US">Patent license rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xml:lang="en-US">Noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xml:lang="en-US">Cash paid at formation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementAxis" xlink:label="loc_caps_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AgreementAxis" xlink:to="lab_caps_AgreementAxis" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementDomain" xlink:label="loc_caps_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AgreementDomain" xlink:to="lab_caps_AgreementDomain" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ExclusiveLicenseAgreementMember" xlink:label="loc_caps_ExclusiveLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ExclusiveLicenseAgreementMember" xml:lang="en-US">Exclusive License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ExclusiveLicenseAgreementMember" xlink:to="lab_caps_ExclusiveLicenseAgreementMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_VotingCommonOwnershipUnitsMember" xlink:label="loc_caps_VotingCommonOwnershipUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_VotingCommonOwnershipUnitsMember" xml:lang="en-US">Voting Common Ownership Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_VotingCommonOwnershipUnitsMember" xlink:to="lab_caps_VotingCommonOwnershipUnitsMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_NonVotingPreferredOwnershipUnitsMember" xlink:label="loc_caps_NonVotingPreferredOwnershipUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_NonVotingPreferredOwnershipUnitsMember" xml:lang="en-US">Non Voting Preferred Ownership Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_NonVotingPreferredOwnershipUnitsMember" xlink:to="lab_caps_NonVotingPreferredOwnershipUnitsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1AndB2PreferredStockMember" xlink:label="loc_caps_SeriesB1AndB2PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_SeriesB1AndB2PreferredStockMember" xml:lang="en-US">Series B1 And B2 Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_SeriesB1AndB2PreferredStockMember" xlink:to="lab_caps_SeriesB1AndB2PreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_PercentageOfNonRoyaltyIncome" xlink:label="loc_caps_PercentageOfNonRoyaltyIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_PercentageOfNonRoyaltyIncome" xml:lang="en-US">Percentage Of Non Royalty Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_PercentageOfNonRoyaltyIncome" xml:lang="en-US">Percentage Of Non Royalty Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_PercentageOfNonRoyaltyIncome" xlink:to="lab_caps_PercentageOfNonRoyaltyIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_PercentageOfNonRoyaltyIncome" xml:lang="en-US">It represents the percentage of non royalty income.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xlink:label="loc_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xml:lang="en-US">Joint Venture Investments In Voting Common Ownership Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xml:lang="en-US">Joint Venture Investments In Voting Common Ownership Units (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xlink:to="lab_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xml:lang="en-US">Share represents joint venture investments in voting common ownership units.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xlink:label="loc_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xml:lang="en-US">Joint Venture Investments In Non Voting Preferred Ownership Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xml:lang="en-US">Joint Venture Investments In Non Voting Preferred Ownership Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xlink:to="lab_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xml:lang="en-US">Share represents joint venture investments in non voting preferred ownership.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xlink:label="loc_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xml:lang="en-US">Joint Venture Investments Common Ownership Units Coventure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xml:lang="en-US">Joint Venture Investments Common Ownership Units, Co-venture (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xlink:to="lab_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xml:lang="en-US">Share represents joint venture investments common ownership units of co-venture.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipPercentageCoventure" xlink:label="loc_caps_OwnershipPercentageCoventure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_OwnershipPercentageCoventure" xml:lang="en-US">Ownership Percentage Coventure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_OwnershipPercentageCoventure" xml:lang="en-US">Ownership Percentage Co-venture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_OwnershipPercentageCoventure" xlink:to="lab_caps_OwnershipPercentageCoventure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_OwnershipPercentageCoventure" xml:lang="en-US">Ownership percentage of co- venture.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_PercentageOfRoyaltyPayment" xlink:label="loc_caps_PercentageOfRoyaltyPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_PercentageOfRoyaltyPayment" xml:lang="en-US">Percentage Of Royalty Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_PercentageOfRoyaltyPayment" xml:lang="en-US">Percentage Of Royalty Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_PercentageOfRoyaltyPayment" xlink:to="lab_caps_PercentageOfRoyaltyPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_PercentageOfRoyaltyPayment" xml:lang="en-US">Percentage of royalty payment.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureOperatingExpensesInterCompanyTransactions" xlink:label="loc_caps_JointVentureOperatingExpensesInterCompanyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureOperatingExpensesInterCompanyTransactions" xml:lang="en-US">Joint Venture Operating Expenses Inter Company Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_caps_JointVentureOperatingExpensesInterCompanyTransactions" xml:lang="en-US">Joint Venture, Operating Expenses, Inter Company Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureOperatingExpensesInterCompanyTransactions" xlink:to="lab_caps_JointVentureOperatingExpensesInterCompanyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureOperatingExpensesInterCompanyTransactions" xml:lang="en-US">Represents the operating expenses incurred by joint venture, in relation to inter company transactions.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureOperatingExpensesAllocatedToCompany" xlink:label="loc_caps_JointVentureOperatingExpensesAllocatedToCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureOperatingExpensesAllocatedToCompany" xml:lang="en-US">Joint Venture, Operating Expenses Allocated To Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_caps_JointVentureOperatingExpensesAllocatedToCompany" xml:lang="en-US">Joint Venture, Operating Expenses Allocated To Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureOperatingExpensesAllocatedToCompany" xlink:to="lab_caps_JointVentureOperatingExpensesAllocatedToCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureOperatingExpensesAllocatedToCompany" xml:lang="en-US">Represents the operating expenses incurred by joint venture allocated to the company.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AnnualMaintenancePayments" xlink:label="loc_caps_AnnualMaintenancePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AnnualMaintenancePayments" xml:lang="en-US">Annual Maintenance Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_AnnualMaintenancePayments" xml:lang="en-US">Annual Maintenance Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AnnualMaintenancePayments" xlink:to="lab_caps_AnnualMaintenancePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_AnnualMaintenancePayments" xml:lang="en-US">It represents the value of annual maintenance payments during the period.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_MilestonePayments" xlink:label="loc_caps_MilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_MilestonePayments" xml:lang="en-US">Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_caps_MilestonePayments" xml:lang="en-US">Milestone Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_MilestonePayments" xlink:to="lab_caps_MilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_MilestonePayments" xml:lang="en-US">It represents the value of milestone payments during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ManagementFees" xlink:label="loc_caps_ManagementFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ManagementFees" xml:lang="en-US">Management Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ManagementFees" xlink:to="lab_caps_ManagementFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_ManagementFees" xml:lang="en-US">Amount represents the monthly management fees for services rendered during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureMethodInvestmentOwnershipPercentage" xlink:label="loc_caps_JointVentureMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureMethodInvestmentOwnershipPercentage" xml:lang="en-US">Joint Venture Method Investment Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureMethodInvestmentOwnershipPercentage" xlink:to="lab_caps_JointVentureMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_JointVentureMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage represents joint venture method investment ownership.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" xlink:label="loc_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" xml:lang="en-US">Operating Expenses Net Of Elimination Of Intercompany Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" xlink:to="lab_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" xml:lang="en-US">It represents operating expenses net of elimination of intercompany transactions.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ManagementFeeExpense" xml:lang="en-US">Management Fee Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Interest Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipAsConvertedMember" xlink:label="loc_caps_OwnershipAsConvertedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_OwnershipAsConvertedMember" xml:lang="en-US">Ownership As Converted [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_OwnershipAsConvertedMember" xlink:to="lab_caps_OwnershipAsConvertedMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" xlink:label="loc_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" xml:lang="en-US">Ownership As Converted Including Options And Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" xlink:to="lab_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureMember" xlink:label="loc_caps_JointVentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_JointVentureMember" xml:lang="en-US">Joint Venture [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_caps_JointVentureMember" xml:lang="en-US">Joint Venture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_JointVentureMember" xlink:to="lab_caps_JointVentureMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ScheduleOfResearchAndDevelopmentTable" xlink:label="loc_caps_ScheduleOfResearchAndDevelopmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ScheduleOfResearchAndDevelopmentTable" xml:lang="en-US">Schedule Of Research And Development [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable" xlink:to="lab_caps_ScheduleOfResearchAndDevelopmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ResearchAndDevelopmentDisclosureLineItems" xlink:label="loc_caps_ResearchAndDevelopmentDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_ResearchAndDevelopmentDisclosureLineItems" xml:lang="en-US">Research And Development Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems" xlink:to="lab_caps_ResearchAndDevelopmentDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixAustraliaPtyLtdMember" xlink:label="loc_caps_LipimetixAustraliaPtyLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_LipimetixAustraliaPtyLtdMember" xml:lang="en-US">Lipimetix Australia Pty Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_LipimetixAustraliaPtyLtdMember" xlink:to="lab_caps_LipimetixAustraliaPtyLtdMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Secured Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Accumulated Amortization, Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SecuredLongTermDebtGross" xlink:label="loc_caps_SecuredLongTermDebtGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_SecuredLongTermDebtGross" xml:lang="en-US">Secured Long term Debt Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_SecuredLongTermDebtGross" xlink:to="lab_caps_SecuredLongTermDebtGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_SecuredLongTermDebtGross" xml:lang="en-US">The gross amount of secured long term debt before adjusting accrued interest.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredDebtMember" xml:lang="en-US">Secured Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_InterestAndOtherExpensesMember" xlink:label="loc_caps_InterestAndOtherExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_InterestAndOtherExpensesMember" xml:lang="en-US">Interest and Other Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_InterestAndOtherExpensesMember" xlink:to="lab_caps_InterestAndOtherExpensesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Stock Repurchased During Period, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xml:lang="en-US">Equity Method Investment, Description of Principal Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="lab_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BeneficialOwnershipPercentage" xlink:label="loc_caps_BeneficialOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_BeneficialOwnershipPercentage" xml:lang="en-US">Beneficial Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_BeneficialOwnershipPercentage" xlink:to="lab_caps_BeneficialOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_BeneficialOwnershipPercentage" xml:lang="en-US">Represents the beneficial ownership percentage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredDebtCurrent" xml:lang="en-US">Secured Debt, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtCurrent" xlink:to="lab_us-gaap_SecuredDebtCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_UABResearchFoundationExpense" xlink:label="loc_caps_UABResearchFoundationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_UABResearchFoundationExpense" xml:lang="en-US">UAB Research Foundation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_UABResearchFoundationExpense" xlink:to="lab_caps_UABResearchFoundationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_UABResearchFoundationExpense" xml:lang="en-US">Amount paid to the UAB Research Foundation, as required by the UAB Research Foundation Exclusive License Agreement.</label>
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdvisoryFees" xlink:label="loc_caps_AdvisoryFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_caps_AdvisoryFees" xml:lang="en-US">Advisory Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_caps_AdvisoryFees" xlink:to="lab_caps_AdvisoryFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_caps_AdvisoryFees" xml:lang="en-US">Amount paid as advisory fees.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyMember" xml:lang="en-US">Royalty [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>caps-20190331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DataTracks Rainbow Version 3.0 - www.datatracks.com - on 11-May-2019 [12:09:07] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#DocumentAndEntityInformation" roleURI="http://www.capstonethx.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedStatementOfOperations" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#OverviewOfBusiness" roleURI="http://www.capstonethx.com/role/OverviewOfBusiness" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#AustralianRefundableResearchDevelopmentCredit" roleURI="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#SaleOfCommonStockAndIssuanceOfsecuredDebt" roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#LipimetixDevelopmentIncLicenseAgreement" roleURI="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#OverviewOfBusinessPolicies" roleURI="http://www.capstonethx.com/role/OverviewOfBusinessPolicies" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#SaleOfCommonStockAndIssuanceOfsecuredDebtTables" roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#OverviewOfBusinessDetailsTextual" roleURI="http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual" roleURI="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#AustralianRefundableResearchDevelopmentCreditDetailsTextual" roleURI="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#SaleOfCommonStockAndIssuanceOfsecuredDebtDetails" roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual" roleURI="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual" />
<roleRef xlink:type="simple" xlink:href="caps-20190331.xsd#LipimetixDevelopmentIncLicenseAgreementDetailsTextual" roleURI="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual" />
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_DocumentAndEntityInformationAbstract" xlink:label="loc_caps_DocumentAndEntityInformationAbstract_187665" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentType_187411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_187659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityEmergingGrowthCompany_187659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_187661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntitySmallBusiness_187661" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="loc_us-gaap_StatementTable_33" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34" xlink:to="loc_us-gaap_ClassOfStockDomain_43" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33" xlink:to="loc_us-gaap_StatementLineItems_35" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_AssetsAbstract_36" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_36" xlink:to="loc_us-gaap_AssetsCurrentAbstract_37" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_420335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_420335" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_OtherAssetsCurrent_45" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_AssetsCurrent_46" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_37" xlink:to="loc_us-gaap_Assets_49" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_AccountsPayableCurrent_50" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_51" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39" xlink:to="loc_us-gaap_LiabilitiesCurrent_52" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_SecuredLongTermDebt_54" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" xlink:to="loc_us-gaap_StockholdersEquityAbstract_42" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_CommonStockValue_56" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42" xlink:to="loc_us-gaap_StockholdersEquity_59" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" xlink:to="loc_us-gaap_MinorityInterest_60" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_41" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_62" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BalanceSheetParentheticalAbstract" xlink:label="loc_caps_BalanceSheetParentheticalAbstract_159" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_BalanceSheetParentheticalAbstract_159" xlink:to="loc_us-gaap_StatementTable_160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_160" xlink:to="loc_us-gaap_StatementClassOfStockAxis_161" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161" xlink:to="loc_us-gaap_ClassOfStockDomain_163" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_160" xlink:to="loc_us-gaap_StatementLineItems_162" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_164" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_165" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_318" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_318" xlink:to="loc_us-gaap_StatementTable_319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_320" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_320" xlink:to="loc_us-gaap_ClassOfStockDomain_324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_319" xlink:to="loc_us-gaap_StatementLineItems_321" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_361657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_Revenues_361657" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_OperatingExpensesAbstract_322" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SublicenseTransactionCosts" xlink:label="loc_caps_SublicenseTransactionCosts_361668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_caps_SublicenseTransactionCosts_361668" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_325" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_326" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_322" xlink:to="loc_us-gaap_OperatingExpenses_327" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_361674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_OperatingIncomeLoss_361674" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_328" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_329" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_330" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_ProfitLoss_331" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_332" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_NetIncomeLoss_333" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_323" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_323" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_334" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_321" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_335" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_568" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_568" xlink:to="loc_us-gaap_StatementTable_569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_569" xlink:to="loc_dei_LegalEntityAxis_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_570" xlink:to="loc_dei_EntityDomain_579" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_569" xlink:to="loc_us-gaap_StatementClassOfStockAxis_571" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_571" xlink:to="loc_us-gaap_ClassOfStockDomain_572" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_569" xlink:to="loc_us-gaap_StatementLineItems_573" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_ProfitLoss_582" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" xlink:to="loc_us-gaap_AdjustmentForAmortization_583" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" xlink:to="loc_us-gaap_OtherNoncashExpense_584" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_575" xlink:to="loc_us-gaap_ShareBasedCompensation_585" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_586" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_587" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_576" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_588" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_574" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_589" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_577" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_577" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_590" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_420391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_420391" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_578" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_596" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_597" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_573" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_598" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/OverviewOfBusiness">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_609" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_609" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_610" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_20" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_21" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_14" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_RefundableResearchAndDevelopmentCreditTextBlock" xlink:label="loc_caps_RefundableResearchAndDevelopmentCreditTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_14" xlink:to="loc_caps_RefundableResearchAndDevelopmentCreditTextBlock_15" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_26" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock" xlink:label="loc_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_26" xlink:to="loc_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock_27" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_361707" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_420556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_361707" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_420556" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/OverviewOfBusinessPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_64" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_DescriptionOfBusinessPolicyTextBlock" xlink:label="loc_caps_DescriptionOfBusinessPolicyTextBlock_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_caps_DescriptionOfBusinessPolicyTextBlock_65" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_CompanyHistoryPolicyTextBlock" xlink:label="loc_caps_CompanyHistoryPolicyTextBlock_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_caps_CompanyHistoryPolicyTextBlock_66" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BasisOfPresentationAndManagementPlanPolicyTextBlock" xlink:label="loc_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock_67" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_UseOfEstimates_68" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_79" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy" xlink:label="loc_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy_78" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_70" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountsPayablePolicyPolicyTextBlock" xlink:label="loc_caps_AccountsPayablePolicyPolicyTextBlock_365592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_caps_AccountsPayablePolicyPolicyTextBlock_365592" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_420684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_420684" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_361816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_361816" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_80" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_94" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ScheduleOfJointVenturePaymentsTableTextBlock" xlink:label="loc_caps_ScheduleOfJointVenturePaymentsTableTextBlock_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94" xlink:to="loc_caps_ScheduleOfJointVenturePaymentsTableTextBlock_95" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_97" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_97" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_98" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_100" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountingPoliciesTable" xlink:label="loc_caps_AccountingPoliciesTable_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_100" xlink:to="loc_caps_AccountingPoliciesTable_101" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_srt_RangeAxis_102" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_102" xlink:to="loc_srt_RangeMember_103" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_104" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_105" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_106" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_106" xlink:to="loc_us-gaap_EquityComponentDomain_107" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_107" xlink:to="loc_us-gaap_CommonStockMember_120" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_423157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_107" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_423157" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_423164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_107" xlink:to="loc_us-gaap_RetainedEarningsMember_423164" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_dei_LegalEntityAxis_108" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_108" xlink:to="loc_dei_EntityDomain_109" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BrookstoneMember" xlink:label="loc_caps_BrookstoneMember_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_109" xlink:to="loc_caps_BrookstoneMember_121" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember_420341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_109" xlink:to="loc_caps_LipimetixMember_420341" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_CreditFacilityAxis_110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_110" xlink:to="loc_us-gaap_CreditFacilityDomain_111" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_112" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_112" xlink:to="loc_us-gaap_ClassOfStockDomain_113" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1PreferredStockMember" xlink:label="loc_caps_SeriesB1PreferredStockMember_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_caps_SeriesB1PreferredStockMember_123" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_caps_SeriesB2PreferredStockMember_124" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_363062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_srt_ProductOrServiceAxis_363062" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_363065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_363062" xlink:to="loc_srt_ProductsAndServicesDomain_363065" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_420429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_420429" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_420431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_420429" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_420431" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_423239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_423238" xlink:to="loc_us-gaap_TypeOfAdoptionMember_423239" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_423267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_423267" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_423268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_423267" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_423268" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_423270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_423268" xlink:to="loc_us-gaap_OtherAssetsMember_423270" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountingPoliciesLineItems" xlink:label="loc_caps_AccountingPoliciesLineItems_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesTable_101" xlink:to="loc_caps_AccountingPoliciesLineItems_116" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_128" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_130" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_137" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xlink:label="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_138" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_139" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromRelatedPartyDebtNet" xlink:label="loc_caps_ProceedsFromRelatedPartyDebtNet_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_ProceedsFromRelatedPartyDebtNet_140" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_141" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_142" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_362814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_362814" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_362835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_362835" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ReimbursementOfRevenue" xlink:label="loc_caps_ReimbursementOfRevenue_362839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_ReimbursementOfRevenue_362839" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_420340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_420340" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xlink:label="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_420435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_420435" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AmortisationOfFinancingCostOfWarrants" xlink:label="loc_caps_AmortisationOfFinancingCostOfWarrants_423154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AmortisationOfFinancingCostOfWarrants_423154" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_423158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_NetIncomeLoss_423158" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_423232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_423232" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_423255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_423255" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AccountsPayableCorporationAgreement" xlink:label="loc_caps_AccountsPayableCorporationAgreement_424851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AccountsPayableCorporationAgreement_424851" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdditionalFundForOperations" xlink:label="loc_caps_AdditionalFundForOperations_424852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AccountingPoliciesLineItems_116" xlink:to="loc_caps_AdditionalFundForOperations_424852" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_346" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_346" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" xlink:to="loc_dei_LegalEntityAxis_348" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_348" xlink:to="loc_dei_EntityDomain_349" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_349" xlink:to="loc_caps_LipimetixMember_351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_347" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_350" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_352" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_353" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_350" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_354" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_356" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_356" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_dei_LegalEntityAxis_358" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_358" xlink:to="loc_dei_EntityDomain_359" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixMember" xlink:label="loc_caps_LipimetixMember_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_359" xlink:to="loc_caps_LipimetixMember_380" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_VotingCommonOwnershipUnitsMember" xlink:label="loc_caps_VotingCommonOwnershipUnitsMember_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_359" xlink:to="loc_caps_VotingCommonOwnershipUnitsMember_381" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_NonVotingPreferredOwnershipUnitsMember" xlink:label="loc_caps_NonVotingPreferredOwnershipUnitsMember_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_359" xlink:to="loc_caps_NonVotingPreferredOwnershipUnitsMember_382" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementAxis" xlink:label="loc_caps_AgreementAxis_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_caps_AgreementAxis_360" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AgreementDomain" xlink:label="loc_caps_AgreementDomain_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AgreementAxis_360" xlink:to="loc_caps_AgreementDomain_361" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ExclusiveLicenseAgreementMember" xlink:label="loc_caps_ExclusiveLicenseAgreementMember_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_AgreementDomain_361" xlink:to="loc_caps_ExclusiveLicenseAgreementMember_383" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_srt_RangeAxis_362" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_362" xlink:to="loc_srt_RangeMember_363" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_363" xlink:to="loc_srt_MaximumMember_384" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_363" xlink:to="loc_srt_MinimumMember_385" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_364" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_364" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_386" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_365" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_365" xlink:to="loc_us-gaap_EquityComponentDomain_366" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_366" xlink:to="loc_us-gaap_PreferredStockMember_388" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_366" xlink:to="loc_us-gaap_NoncontrollingInterestMember_389" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_CreditFacilityAxis_367" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_367" xlink:to="loc_us-gaap_CreditFacilityDomain_368" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_368" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_390" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_StatementClassOfStockAxis_369" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_369" xlink:to="loc_us-gaap_ClassOfStockDomain_370" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1PreferredStockMember" xlink:label="loc_caps_SeriesB1PreferredStockMember_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_caps_SeriesB1PreferredStockMember_391" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_caps_SeriesB2PreferredStockMember_392" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB1AndB2PreferredStockMember" xlink:label="loc_caps_SeriesB1AndB2PreferredStockMember_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_caps_SeriesB1AndB2PreferredStockMember_394" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_370" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_395" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_TypeOfArrangementAxis_371" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_371" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_372" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_373" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_373" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_397" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_StatementScenarioAxis_374" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_374" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_398" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_srt_OwnershipAxis_375" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_375" xlink:to="loc_srt_OwnershipDomain_376" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipAsConvertedMember" xlink:label="loc_caps_OwnershipAsConvertedMember_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_376" xlink:to="loc_caps_OwnershipAsConvertedMember_399" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember" xlink:label="loc_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_376" xlink:to="loc_caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember_400" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureMember" xlink:label="loc_caps_JointVentureMember_424779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_376" xlink:to="loc_caps_JointVentureMember_424779" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_TitleOfIndividualAxis_377" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_377" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_378" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_357" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_379" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_402" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsInVotingCommonOwnershipUnits" xlink:label="loc_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits_403" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits" xlink:label="loc_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits_404" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure" xlink:label="loc_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure_405" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OwnershipPercentageCoventure" xlink:label="loc_caps_OwnershipPercentageCoventure_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_OwnershipPercentageCoventure_406" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_PercentageOfRoyaltyPayment" xlink:label="loc_caps_PercentageOfRoyaltyPayment_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_PercentageOfRoyaltyPayment_407" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity" xlink:label="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity_409" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureOperatingExpensesInterCompanyTransactions" xlink:label="loc_caps_JointVentureOperatingExpensesInterCompanyTransactions_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureOperatingExpensesInterCompanyTransactions_410" use="optional" order="50" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureOperatingExpensesAllocatedToCompany" xlink:label="loc_caps_JointVentureOperatingExpensesAllocatedToCompany_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureOperatingExpensesAllocatedToCompany_411" use="optional" order="51" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AnnualMaintenancePayments" xlink:label="loc_caps_AnnualMaintenancePayments_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_AnnualMaintenancePayments_412" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_MilestonePayments" xlink:label="loc_caps_MilestonePayments_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_MilestonePayments_413" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_RoyaltyExpense_414" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_PercentageOfNonRoyaltyIncome" xlink:label="loc_caps_PercentageOfNonRoyaltyIncome_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_PercentageOfNonRoyaltyIncome_415" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_416" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_LineOfCredit_417" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_418" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_419" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_420" use="optional" order="60" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_421" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_JointVentureMethodInvestmentOwnershipPercentage" xlink:label="loc_caps_JointVentureMethodInvestmentOwnershipPercentage_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_JointVentureMethodInvestmentOwnershipPercentage_422" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts" xlink:label="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts_423" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_424" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_425" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_426" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_427" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_428" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ManagementFees" xlink:label="loc_caps_ManagementFees_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_ManagementFees_430" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManagementFeeExpense" xlink:label="loc_us-gaap_ManagementFeeExpense_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ManagementFeeExpense_432" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions" xlink:label="loc_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions_433" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_434" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_435" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_436" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_437" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_438" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_440" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_442" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_443" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_444" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_445" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_379" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_447" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_300" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ScheduleOfResearchAndDevelopmentTable" xlink:label="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_300" xlink:to="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_us-gaap_StatementClassOfStockAxis_302" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_302" xlink:to="loc_us-gaap_ClassOfStockDomain_303" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_LipimetixAustraliaPtyLtdMember" xlink:label="loc_caps_LipimetixAustraliaPtyLtdMember_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_303" xlink:to="loc_caps_LipimetixAustraliaPtyLtdMember_309" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_srt_RangeAxis_304" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_304" xlink:to="loc_srt_RangeMember_305" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_305" xlink:to="loc_srt_MinimumMember_311" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_306" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_306" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_312" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_307" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_307" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_313" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ResearchAndDevelopmentDisclosureLineItems" xlink:label="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ScheduleOfResearchAndDevelopmentTable_301" xlink:to="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_314" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_315" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_caps_ResearchAndDevelopmentDisclosureLineItems_308" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_316" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_465" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_465" xlink:to="loc_us-gaap_StatementTable_466" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_us-gaap_StatementClassOfStockAxis_467" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_467" xlink:to="loc_us-gaap_ClassOfStockDomain_469" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_us-gaap_StatementLineItems_468" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_470" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_471" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_472" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_473" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SecuredLongTermDebtGross" xlink:label="loc_caps_SecuredLongTermDebtGross_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_caps_SecuredLongTermDebtGross_474" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_475" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468" xlink:to="loc_us-gaap_SecuredLongTermDebt_476" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_478" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_478" xlink:to="loc_us-gaap_StatementTable_479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_StatementClassOfStockAxis_480" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_480" xlink:to="loc_us-gaap_ClassOfStockDomain_481" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SeriesB2PreferredStockMember" xlink:label="loc_caps_SeriesB2PreferredStockMember_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_481" xlink:to="loc_caps_SeriesB2PreferredStockMember_495" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_482" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_482" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_483" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_CreditFacilityAxis_484" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_484" xlink:to="loc_us-gaap_CreditFacilityDomain_485" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_485" xlink:to="loc_us-gaap_SecuredDebtMember_497" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_486" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_486" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_487" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_InterestAndOtherExpensesMember" xlink:label="loc_caps_InterestAndOtherExpensesMember_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_487" xlink:to="loc_caps_InterestAndOtherExpensesMember_498" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_srt_OwnershipAxis_488" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_488" xlink:to="loc_srt_OwnershipDomain_489" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BrookstoneMember" xlink:label="loc_caps_BrookstoneMember_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_489" xlink:to="loc_caps_BrookstoneMember_499" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_srt_RangeAxis_490" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_490" xlink:to="loc_srt_RangeMember_491" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_491" xlink:to="loc_srt_MinimumMember_500" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_492" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_492" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_493" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_493" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_501" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_479" xlink:to="loc_us-gaap_StatementLineItems_494" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_502" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_InterestExpenseDebt_503" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_504" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_505" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_506" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_507" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_508" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_ProceedsFromRelatedPartyDebtNet" xlink:label="loc_caps_ProceedsFromRelatedPartyDebtNet_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_caps_ProceedsFromRelatedPartyDebtNet_509" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_510" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_511" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_SecuredLongTermDebt_512" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_513" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_514" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_516" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_BeneficialOwnershipPercentage" xlink:label="loc_caps_BeneficialOwnershipPercentage_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_caps_BeneficialOwnershipPercentage_517" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_518" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_519" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_520" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_362456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_362456" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent_362959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_SecuredDebtCurrent_362959" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_362961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_362961" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_423843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_423843" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_423844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_AdjustmentForAmortization_423844" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_423846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_423846" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_423865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_CommonStockValue_423865" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdditionalFundForOperations" xlink:label="loc_caps_AdditionalFundForOperations_423886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_caps_AdditionalFundForOperations_423886" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424160" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_424259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_424259" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_424264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_494" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_424264" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_361733" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_361735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_361733" xlink:to="loc_us-gaap_StatementTable_361735" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_361736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_361735" xlink:to="loc_us-gaap_StatementClassOfStockAxis_361736" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_361737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_361736" xlink:to="loc_us-gaap_ClassOfStockDomain_361737" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_361765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_361735" xlink:to="loc_srt_ProductOrServiceAxis_361765" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_361766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_361765" xlink:to="loc_srt_ProductsAndServicesDomain_361766" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_361767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_361766" xlink:to="loc_us-gaap_RoyaltyMember_361767" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_361768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_361766" xlink:to="loc_us-gaap_LicenseMember_361768" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_361738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_361735" xlink:to="loc_us-gaap_StatementLineItems_361738" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_361740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_Revenues_361740" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_SublicenseTransactionCosts" xlink:label="loc_caps_SublicenseTransactionCosts_361743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_caps_SublicenseTransactionCosts_361743" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_361746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_361746" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_UABResearchFoundationExpense" xlink:label="loc_caps_UABResearchFoundationExpense_361750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_caps_UABResearchFoundationExpense_361750" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="caps-20190331.xsd#caps_AdvisoryFees" xlink:label="loc_caps_AdvisoryFees_361754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_caps_AdvisoryFees_361754" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_361757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_361738" xlink:to="loc_us-gaap_LegalFees_361757" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759156480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Capstone Therapeutics Corp.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000887151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAPS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,385,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759476848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 1,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent license rights, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">732<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Secured debt and accrued interest, net of unamortized issuance costs</a></td>
<td class="nump">2,584<span></span>
</td>
<td class="nump">2,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Capstone Therapeutics Corp. Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">190,487<span></span>
</td>
<td class="nump">190,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(192,609)<span></span>
</td>
<td class="num">(191,754)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Capstone Therapeutics Corp. stockholders' equity (deficit)</a></td>
<td class="num">(2,095)<span></span>
</td>
<td class="num">(1,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="num">(2,095)<span></span>
</td>
<td class="num">(1,244)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749116528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,385,411<span></span>
</td>
<td class="nump">54,385,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759074672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">SUBLICENSE REVENUE</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_SublicenseTransactionCosts', window );">Sublicense transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) after operating expenses</a></td>
<td class="num">(789)<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income (expense), net</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from operations before taxes</a></td>
<td class="num">(852)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET INCOME (LOSS)</a></td>
<td class="num">(855)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net Income (Loss) attributable to the noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders</a></td>
<td class="num">$ (855)<span></span>
</td>
<td class="num">$ (587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per Share Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted shares outstanding</a></td>
<td class="nump">54,385<span></span>
</td>
<td class="nump">54,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_SublicenseTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of sublicense transaction costs recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_SublicenseTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758912256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (855)<span></span>
</td>
<td class="num">$ (587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock based interest expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in other operating items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows used in operating activities</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows provided by investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Secured Debt funding</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows provided by financing activities</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH, BEGINNING OF PERIOD</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH, END OF PERIOD</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752179248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OVERVIEW OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Business Description and Accounting Policies [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-left: 0.5in; text-indent: -0.5in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note A. OVERVIEW OF BUSINESS</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.03in; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of the Business</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Capstone Therapeutics Corp. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the &#8220;JV&#8221;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV&#8217;s development activities.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Current Peptide Drug Candidates.</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Apo E Mimetic Peptide Molecule &#8211; AEM-28 and its analogs</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Company History</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our &#8220;Bone Device Business.&#8221; In November 2003, we sold our Bone Device Business.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In these notes, references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, the &#8220;Company&#8221;, &#8220;Capstone Therapeutics&#8221;, &#8220;Capstone&#8221;, and &#8220;OrthoLogic&#8221; refer to Capstone Therapeutics Corp. References to our joint venture or &#8220;JV&#8221;, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation, Going Concern, and Management&#8217;s Plans. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company&#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity&#8217;s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information presented as of December 31, 2018 is derived from audited financial statements.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management&#8217;s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our significant estimates include accounting for stock-based compensation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and Other Contingencies</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Joint Venture Accounting. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash.</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash consists of balances held in commercial bank accounts.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Payable. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable includes officer compensation of </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company&#8217;s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity.</div> &#160;&#160;&#160;&#160;During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU 606&#8221;) No. 2014-09 &#8220;Revenue from Contracts from Customers&#8221;. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i)&#160;identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Upfront License Fees</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.&#160;&#160;For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;In February 2016 the FASB issued ASU 2016-02 </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases (Topic 842) </div> and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cooperation Agreement.</div> &#160;In May 2018 the Company&#8217;s joint venture (&#8220;JV&#8221;) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (&#8220;ANJI&#8221;) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the &#8220;Sub-License&#8221;) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&#8217;s AEM-28 and analogs intellectual property in the Territory of the People&#8217;s Republic of China, Taiwan and Hong Kong (the &#8220;Territory&#8221;). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses &#8211; Research &amp; Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities &#8211; Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $52,000, respectively, and has been shown net. In the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 the Company charged costs totaling $401,000 to research and development expense related to its activities under the Cooperation Agreement.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company&#8217;s financial statements at March 31, 2019 or December 31, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629867168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (&#8220;JV&#8221;), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now Series A Preferred Stock), which have preferential distribution rights. On March 31, 2016, the Company converted 1,500,000 shares of its preferred stock into 120,000 shares of common stock, increasing its common stock ownership from 60% to 64%. On August 11, 2017, the remaining $3,500,000 (3,500,000 shares) of Series A preferred stock became convertible, at the Company&#8217;s option, into common stock, at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next LipimetiX Development, Inc. financing, exceeding $1,000,000 on independently set valuation and terms. On August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock for $1,000,000 (LipimetiX Development, Inc. incurred $15,000 in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown as a reduction of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company&#8217;s ownership in the JV to 62.2%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting its Series A Preferred Stock to common stock, the Company&#8217;s ownership would change to 69.75%. The JV 2016 Equity Incentive Plan has 83,480 shares of the JV&#8217;s common stock available to grant, of which, at December 31, 2018, options to purchase JV common stock shares totaling 81,479 have been granted and are fully vested. All options were granted with an exercise price of $1.07, vested 50% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised, and the Series B-1 Preferred Stock Warrants were exercised, the Company&#8217;s fully diluted ownership (on an as-converted basis) would be approximately 65.11%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase 14,126 shares of the LipimetiX Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $10.70 per share, subject to adjustment and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date of grant. If exercised, this option would reduce the Company&#8217;s fully diluted ownership (on an as-converted basis including assumed exercise of other options and warrants) to approximately 64.31%.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (&#8220;Benu&#8221;) and UABRF to commercialize UABRF&#8217;s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (&#8220;UABRF&#8221;) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock), representing a 40% ownership interest in the JV at formation, and $378,000 in cash (for certain initial patent-related costs and legal expenses).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1 Preferred Stock offering, raising funds of $1,012,000 ($946,000 net of issuance costs of approximately $66,000). Individual accredited investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV&#8217;s common stock at the election of the holders and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with a ten-year term.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock for $1,000,000.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Series B (B-1 and B-2) Preferred Stock is a participating preferred stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in future distributions on an equal &#8220;as-converted&#8221; share basis with common stock holders. The Series B Preferred Stock has &#8220;as-converted&#8221; voting rights and other terms standard to a security of this nature.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Exclusive License Agreement assigned by LipimetiX, LLC to the JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non-Royalty Income received.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (&#8220;JDC&#8221;) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an &#8220;as -converted&#8221; basis) stockholders.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were entered into effective June 1, 2016. However, no Management or Accounting Services fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time. In August 2017 the Accounting Services Agreement monthly fee was increased to $20,000 and will thereafter be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31, 2019, accounting fees of $400,000 were earned but unpaid. In August 2017, a Management Fee of $300,000 was approved by the joint venture&#8217;s Board of Directors with $150,000 paid and charged to expense in the third quarter of 2017 and $150,000 paid and expensed in the first quarter of 2018. In the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 a Management Fee of $50,000 was charged to expense and paid in the second quarter of 2019..</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The joint venture formation was as follows ($000&#8217;s):</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.50in;width: 50%;"><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 77.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Patent license rights</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 20.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,045</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(667</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash paid at formation</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">378</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Patent license rights were recorded at their estimated fair value and were amortized on a straight-line basis over the key patent life of eighty months.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. In the Company&#8217;s consolidated financial statements, joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were being allocated to the Series A preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 of losses were allocated to the Series B-1 Preferred Stock ownership interests. As of December 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture, with the loan due December 31, 2016. The due date of the revolving loan was extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June 30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company&#8217;s option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance. At March 31, 2019, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $140,000, was $1,740,000.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The joint venture incurred net operating income (expenses), prior to the elimination of intercompany transactions, of ($684,000) in 2019 and ($10,282,000) for the period from August 3, 2012 (inception) to March 31, 2019, of which ($684,000), and ($8,670,000), respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2019, losses totaling $667,000 have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would the joint venture&#8217;s ability to continue operations. If the joint venture does not continue as a going concern, at March 31, 2019, the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the common stock noncontrolling interests.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752185232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_RefundableResearchAndDevelopmentCreditTextBlock', window );">Refundable Research And Development Credit [Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note C </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-transform: uppercase; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Australian Refundable Research &amp; Development Credit</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In March 2014, LipimetiX Development LLC, (Now LipimetiX Development, Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits claims for a refundable research and development tax credit. At December 31, 2018, expected refundable research and development tax credit of AUD$4,000, is included in Other current assets in the Condensed Consolidated Balance Sheets. &#160;The expected refundable research and development tax credits for the three-month periods ended March 31, 2019 and 2018 were AUD$0 and AUD$4,000, respectively.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_RefundableResearchAndDevelopmentCreditTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Refundable Research &amp; Development Credit during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_RefundableResearchAndDevelopmentCreditTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639318096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock', window );">Issuance Of Common Stock And Secured Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 12pt;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note D </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-transform: uppercase; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement (the &#8220;Agreement&#8221;) with BP Peptides, LLC (&#8220;Brookstone"). The net proceeds have been used to fund our operations, infuse new capital into our joint venture, LipimetiX Development, Inc. ("JV") (As described in Note B above, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes totaling $1,000,000, plus $79,000 in accrued interest.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Agreement, Brookstone funded an aggregate of $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes and transaction costs, of which $1,012,500 was for the purchase of 13,500,000 newly issued shares of our Common Stock, and $2,427,500 was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased 5,041,197 shares of the Company&#8217;s Common Stock directly from Biotechnology Value Fund affiliated entities, resulting in ownership of 18,541,197 shares of the Company&#8217;s Common Stock, representing approximately 34.1% of outstanding shares of the Company&#8217;s Common Stock at March 31, 2019.</div></div><div style="background: none; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First Amendment to Securities Purchase, Loan and Security Agreement (the &#8220;Amendment&#8221;) with Brookstone. Interest on the Secured Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt&#8217;s maturity, October 15, 2020. In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to 6,321,930 shares of the Company&#8217;s Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement, converted into shares at $0.75. At March 31, 2019, 2,926,302 shares are fully vested and exercisable.</div></div><div style="background: none; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 12pt;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Warrants was determined to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $4,000 and $2,000 in 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018, respectively, and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000. Any additional amounts advanced will be added to the current Loan and subject to the same terms and conditions. At Brookstone&#8217;s sole discretion, the Maximum Amount may be increased to an amount not to exceed $700,000. The Company borrowed $50,000 in March 2019 against the Maximum Amount of $500,000.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs of $287,000 have been deferred and will be written off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. Additional transaction costs of $12,000 were incurred with the Amendment and will be written off over the period of the date of the Amendment, January 30, 2018, to October 15, 2020. At March 31, 2019 transaction costs of $157,000 has been amortized, and $23,000 in the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2019 and December 31, 2018, unamortized transaction costs of $142,000 and $165,000, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. Interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2019 and December 31, 2018, accrued interest of $249,000 and $213,000, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt of $36,000 in 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Secured Debt activity is as follows (000&#8217;s):</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 70%;margin-left: auto;margin-right: auto;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Secured Debt</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,477</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,427</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,178</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,128</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">157</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">134</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,335</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,262</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">249</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">213</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,584</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,475</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The secured loan bears interest at 6% per annum, with interest payable quarterly (now due at loan maturity) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. </div><div style="background: rgb(255, 255, 255); font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially owns over 20% of the Company&#8217;s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company&#8217;s outstanding common stock.</div></div><div style="background: none; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 18, 2017, the Company and Computershare Trust Company, N.A., as Rights Agent (the &#8220;Rights Agent&#8221;) entered into Tax Benefit Preservation Plan Agreement (the &#8220;Plan&#8221;), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017.&#160;&#160;The Plan is intended to act as a deterrent to any person (together with all affiliates and associates of such person) acquiring &#8220;beneficial ownership&#8221; (as defined in the Plan) of 4.99% or more of the outstanding shares of Common Stock without the approval of the Board (an &#8220;Acquiring Person&#8221;), in an effort to protect against a possible limitation on the Company&#8217;s ability to use its net operating loss carryforwards.&#160;&#160;The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share acquisition described above, and Brookstone&#8217;s acquisition of 5,041,197 shares of the Company&#8217;s Common Stock from Biotechnology Value Fund affiliated entities, making Brookstone an Exempt Person in respect of such transactions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_IssuanceOfCommonStockAndSecuredDebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752172704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note E LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the &#8220;Sub-License&#8221;) with Anji Pharmaceuticals Inc. (&#8220;ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&#8217;s AEM-28 and analogs intellectual property in the Territory of the People&#8217;s Republic of China, Taiwan and Hong Kong (the &#8220;Territory&#8221;). The Sub-License calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. The JV recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction costs related to the revenue totaled $254,000 and consisted of a $100,000 payment to the UAB Research Foundation, as required by the UAB Research Foundation Exclusive License Agreement, a $100,000 advisory fee and $54,000 in legal fees. As described in Note B above, at March 31, 2019, JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue recorded for the $2,000,000 payment reduced the amount of JV net losses previously allocated to the Company.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A copy of the UAB Research Foundation Exclusive License Agreement was attached as Exhibit 10.7 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with Securities and Exchange Commission (&#8216;SEC&#8221;) on August 10, 2012. A copy of the First Amendment and Consent to Assignment of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 30, 2015.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759524240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OVERVIEW OF BUSINESS (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_DescriptionOfBusinessPolicyTextBlock', window );">Description Of Business [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of the Business</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Capstone Therapeutics Corp. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the &#8220;JV&#8221;), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV&#8217;s development activities.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Current Peptide Drug Candidates.</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Apo E Mimetic Peptide Molecule &#8211; AEM-28 and its analogs</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_CompanyHistoryPolicyTextBlock', window );">Company History [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Company History</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our &#8220;Bone Device Business.&#8221; In November 2003, we sold our Bone Device Business.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In these notes, references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, the &#8220;Company&#8221;, &#8220;Capstone Therapeutics&#8221;, &#8220;Capstone&#8221;, and &#8220;OrthoLogic&#8221; refer to Capstone Therapeutics Corp. References to our joint venture or &#8220;JV&#8221;, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock', window );">Basis Of Presentation and Management Plan [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation, Going Concern, and Management&#8217;s Plans. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company&#8217;s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase <div style="display:inline;">93,458</div> shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity&#8217;s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information presented as of December 31, 2018 is derived from audited financial statements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management&#8217;s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our significant estimates include accounting for stock-based compensation.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and Other Contingencies</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy', window );">Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Joint Venture Accounting. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.&#8217;s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash.</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash consists of balances held in commercial bank accounts.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountsPayablePolicyPolicyTextBlock', window );">Accounts Payable Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Payable. </div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable includes officer compensation of </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company&#8217;s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stockholders' Equity, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity.</div> &#160;&#160;&#160;&#160;During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.</div></div><div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU 606&#8221;) No. 2014-09 &#8220;Revenue from Contracts from Customers&#8221;. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i)&#160;identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Upfront License Fees</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.&#160;&#160;For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;In February 2016 the FASB issued ASU 2016-02 </div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases (Topic 842) </div> and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cooperation Agreement.</div> &#160;In May 2018 the Company&#8217;s joint venture (&#8220;JV&#8221;) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (&#8220;ANJI&#8221;) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the &#8220;Sub-License&#8221;) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV&#8217;s AEM-28 and analogs intellectual property in the Territory of the People&#8217;s Republic of China, Taiwan and Hong Kong (the &#8220;Territory&#8221;). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses &#8211; Research &amp; Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities &#8211; Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $<div style="display:inline;">52,000</div>, respectively, and has been shown net. In the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 the Company charged costs totaling $<div style="display:inline;">401,000</div>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; to research and development expense related to its activities under the Cooperation Agreement.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company&#8217;s financial statements at March 31, 2019 or December 31, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AccountsPayablePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy for payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AccountsPayablePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_BasisOfPresentationAndManagementPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation and management plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_BasisOfPresentationAndManagementPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_CompanyHistoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for company history.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_CompanyHistoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest in an unincorporated joint venture or partnership that is included in the enterprise's financial statements using the proportionate consolidation method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 323<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6474809&amp;loc=d3e63930-109455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestInUnincorporatedJointVenturesOrPartnershipsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21459-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752162352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ScheduleOfJointVenturePaymentsTableTextBlock', window );">Schedule Of Joint Venture Payments [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The joint venture formation was as follows ($000&#8217;s):</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.50in;width: 50%;"><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 77.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Patent license rights</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 20.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,045</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(667</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash paid at formation</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">378</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ScheduleOfJointVenturePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of payments in formation of joint venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ScheduleOfJointVenturePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6610641392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt [Table Text Block]</a></td>
<td class="text"><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Secured Debt activity is as follows (000&#8217;s):</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 70%;margin-left: auto;margin-right: auto;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Secured Debt</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,477</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,427</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,178</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,128</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">157</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">134</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,335</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,262</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">249</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">213</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,584</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,475</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763806480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OVERVIEW OF BUSINESS (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>Jul. 14, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Aug. 25, 2016</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 03, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ReimbursementOfRevenue', window );">Reimbursement of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (855,000)<span></span>
</td>
<td class="num">$ (587,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountsPayableCorporationAgreement', window );">Accounts Payable Corporation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AdditionalFundForOperations', window );">Additional fund for operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB1PreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts', window );">Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity', window );">Joint Venture Losses Recognition Criteria Common Ownership Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember', window );">Series B2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts', window );">Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity', window );">Joint Venture Losses Recognition Criteria Common Ownership Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=caps_BrookstoneMember', window );">Brookstone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ProceedsFromRelatedPartyDebtNet', window );">Proceeds From Related Party Debt, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,074,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=caps_LipimetixMember', window );">Lipimetix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity', window );">Joint Venture Losses Recognition Criteria Common Ownership Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AmortisationOfFinancingCostOfWarrants', window );">Amortisation Of Financing Cost Of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AccountsPayableCorporationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable with Corporation Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AccountsPayableCorporationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AdditionalFundForOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Funding for Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AdditionalFundForOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AmortisationOfFinancingCostOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortisation Of Financing Cost Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AmortisationOfFinancingCostOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the common ownership equity value, upon which the company records joint venture losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent that cash inflow for issuance of preferred stock before adjusted stock offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ProceedsFromRelatedPartyDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds from related party debt after adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ProceedsFromRelatedPartyDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ReimbursementOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for expenses incured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ReimbursementOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=caps_BrookstoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=caps_BrookstoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=caps_LipimetixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=caps_LipimetixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758901456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) - Lipimetix [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2012</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Patent license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,045,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(667,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Cash paid at formation</a></td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=caps_LipimetixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=caps_LipimetixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6769240368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">77 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>Jul. 14, 2017</div></th>
<th class="th"><div>Aug. 03, 2012</div></th>
<th class="th"><div>Oct. 27, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Aug. 25, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits', window );">Joint Venture Investments In Voting Common Ownership Units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits', window );">Joint Venture Investments In Non Voting Preferred Ownership Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureOperatingExpensesInterCompanyTransactions', window );">Joint Venture, Operating Expenses, Inter Company Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,282,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureOperatingExpensesAllocatedToCompany', window );">Joint Venture, Operating Expenses Allocated To Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_PercentageOfNonRoyaltyIncome', window );">Percentage Of Non Royalty Income</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="num">(3,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ManagementFees', window );">Management Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions', window );">Operating Expenses Net Of Elimination Of Intercompany Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock, Amount Converted</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Stock, Amount Issued</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,480<span></span>
</td>
<td class="nump">83,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=caps_OwnershipAsConvertedMember', window );">Ownership As Converted [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember', window );">Ownership As Converted Including Options And Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=caps_JointVentureMember', window );">Joint Venture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB1PreferredStockMember', window );">Series B1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity', window );">Joint Venture Losses Recognition Criteria, Common Ownership Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts', window );">Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ManagementFees', window );">Management Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management Fee Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember', window );">Series B2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity', window );">Joint Venture Losses Recognition Criteria, Common Ownership Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts', window );">Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB1AndB2PreferredStockMember', window );">Series B1 And B2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 667,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureMethodInvestmentOwnershipPercentage', window );">Joint Venture Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AgreementAxis=caps_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_PercentageOfRoyaltyPayment', window );">Percentage Of Royalty Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AnnualMaintenancePayments', window );">Annual Maintenance Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AgreementAxis=caps_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AgreementAxis=caps_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_MilestonePayments', window );">Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=caps_LipimetixMember', window );">Lipimetix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure', window );">Joint Venture Investments Common Ownership Units, Co-venture (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_OwnershipPercentageCoventure', window );">Ownership Percentage Co-venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=caps_VotingCommonOwnershipUnitsMember', window );">Voting Common Ownership Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=caps_NonVotingPreferredOwnershipUnitsMember', window );">Non Voting Preferred Ownership Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AnnualMaintenancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the value of annual maintenance payments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AnnualMaintenancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share represents joint venture investments common ownership units of co-venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureInvestmentsCommonOwnershipUnitsCoventure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share represents joint venture investments in non voting preferred ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureInvestmentsInNonVotingPreferredOwnershipUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureInvestmentsInVotingCommonOwnershipUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share represents joint venture investments in voting common ownership units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureInvestmentsInVotingCommonOwnershipUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the common ownership equity value, upon which the company records joint venture losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureLossesRecognitionCriteriaCommonOwnershipEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage represents joint venture method investment ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureOperatingExpensesAllocatedToCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the operating expenses incurred by joint venture allocated to the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureOperatingExpensesAllocatedToCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_JointVentureOperatingExpensesInterCompanyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the operating expenses incurred by joint venture, in relation to inter company transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_JointVentureOperatingExpensesInterCompanyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the monthly management fees for services rendered during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the value of milestone payments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents operating expenses net of elimination of intercompany transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_OperatingExpensesNetOfEliminationOfIntercompanyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_OwnershipPercentageCoventure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage of co- venture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_OwnershipPercentageCoventure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_PercentageOfNonRoyaltyIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage of non royalty income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_PercentageOfNonRoyaltyIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_PercentageOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_PercentageOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent that cash inflow for issuance of preferred stock before adjusted stock offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ProceedsFromIssunanceOfPreferredStockBeforeAdjustedStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=caps_OwnershipAsConvertedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=caps_OwnershipAsConvertedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=caps_OwnershipAsConvertedIncludingOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=caps_JointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=caps_JointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB1AndB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_SeriesB1AndB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AgreementAxis=caps_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AgreementAxis=caps_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=caps_LipimetixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=caps_LipimetixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=caps_VotingCommonOwnershipUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=caps_VotingCommonOwnershipUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=caps_NonVotingPreferredOwnershipUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=caps_NonVotingPreferredOwnershipUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762030640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ResearchAndDevelopmentDisclosureLineItems', window );"><strong>Research And Development Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_LipimetixAustraliaPtyLtdMember', window );">Lipimetix Australia Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ResearchAndDevelopmentDisclosureLineItems', window );"><strong>Research And Development Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_LipimetixAustraliaPtyLtdMember', window );">Lipimetix Australia Pty Ltd [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ResearchAndDevelopmentDisclosureLineItems', window );"><strong>Research And Development Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ResearchAndDevelopmentDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ResearchAndDevelopmentDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_LipimetixAustraliaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_LipimetixAustraliaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6908247120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured Debt</a></td>
<td class="nump">$ 2,477<span></span>
</td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Transaction costs</a></td>
<td class="num">(299)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">2,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Amortization</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_SecuredLongTermDebtGross', window );">Secured Long term Debt Gross</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Secured Long-term Debt, Noncurrent</a></td>
<td class="nump">$ 2,584<span></span>
</td>
<td class="nump">$ 2,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_SecuredLongTermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of secured long term debt before adjusting accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_SecuredLongTermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762331152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>Jul. 14, 2017</div></th>
<th class="th"><div>Dec. 11, 2015</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Apr. 18, 2017</div></th>
<th class="th"><div>Aug. 25, 2016</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Secured Long-term Debt, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,475,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt Instrument, Increase (Decrease), Net</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AdditionalFundForOperations', window );">Additional fund for operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Derivative, Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible Notes Payable, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=caps_BrookstoneMember', window );">Brookstone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_ProceedsFromRelatedPartyDebtNet', window );">Proceeds From Related Party Debt, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock Repurchased During Period, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock Repurchased During Period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Secured Long-term Debt, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,427,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Equity Method Investment, Description of Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Brookstone beneficially owns over 20% of the Company&#8217;s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company&#8217;s outstanding common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,041,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,041,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,541,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,321,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AdditionalFundForOperations', window );">Additional fund for operations</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=caps_BrookstoneMember', window );">Brookstone [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,926,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=caps_BrookstoneMember', window );">Brookstone [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_BeneficialOwnershipPercentage', window );">Beneficial Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=caps_InterestAndOtherExpensesMember', window );">Interest and Other Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Secured Debt, Current</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember', window );">Series B2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock Issued During Period, Value, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AdditionalFundForOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Funding for Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AdditionalFundForOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the beneficial ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_ProceedsFromRelatedPartyDebtNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds from related party debt after adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_ProceedsFromRelatedPartyDebtNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=caps_BrookstoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=caps_BrookstoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=caps_InterestAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=caps_InterestAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caps_SeriesB2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6751426432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_SublicenseTransactionCosts', window );">Sublicense Transaction Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_SublicenseTransactionCosts', window );">Sublicense Transaction Costs</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_UABResearchFoundationExpense', window );">UAB Research Foundation Expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_caps_AdvisoryFees', window );">Advisory Fees</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_AdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid as advisory fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_AdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_SublicenseTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of sublicense transaction costs recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_SublicenseTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caps_UABResearchFoundationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to the UAB Research Foundation, as required by the UAB Research Foundation Exclusive License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caps_UABResearchFoundationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caps_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>31
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW=[]8^.KH&K@UUVH+U!+ P04    " !*8*U.F5R<(Q &  "<)P
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MH:\L 1>QA@524"!UZ!M+P$6@$%98@0HKEX\L"0""88DU*+%V^9$E 4 6G-Z
M$AN7;UL-0!:\1B%<3J$;P;8;PBP8CA:*%KD1;,\!#%XP'8&5NT?8C6#;#F$6
M?$=P^:+(C6 [#V$6K$=PE2.WB+%E_G'$) ;3#K^".%HG,5KXX2&XX)%;SSBU
M,_KOFD=PT2.WIK'SH0$86R68-8J&\IOIJ<(KV+TU#7VV.O7M/3:-Y@]\:/I?
M";]5K?#.3*IV99K*E3%)U5;")Y5OJ<X9TZ2F5ZF'*S7F0[,=)I)UXT$BF$XS
M^6]02P,$%     @ 2F"M3H.XK-/S @  A P  !@   !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6R-EUUOFS 4AO\*XK[%7WQ52:0UT[1)FU1UVG;M)DZ""C@#
M)^G^_8PAB/@<NMT$[+SO\7,,>N,L+KIY;0]*F>"M*NMV&1Z,.3Y$4;LYJ$JV
M]_JH:OO-3C>5-';8[*/VV"BY=::JC!@A253)H@Y7"S?WU*P6^F3*HE9/3=">
MJDHV?QY5J2_+D(;7B>=B?S#=1+1:'.5>?5?FQ_&IL:-HK+(M*E6WA:Z#1NV6
MX0?ZL&:D,SC%ST)=VLE]T+7RHO5K-_BR78:D(U*EVIBNA+27LUJKLNPJ68[?
M0]%P7+,S3N^OU3^YYFTS+[)5:UW^*K;FL RS,-BJG3R5YEE?/JNAH3@,ANZ_
MJK,JK;PCL6ML=-FZSV!S:HVNABH6I9)O_;6HW?4RU+_:< ,;#&PT4/&N@0\&
M[AFBGLRU^E$:N5HT^A(T_=,ZRNZEH _<;N:FFW1[Y[ZSW;9V]KQB^2(Z=W4&
MR6,O85/)K6(-%9R,DLBN/T(P%((Y/Y_Z*>[GJ)\[OYCZ/<3'7I(X2>TDE.1^
M'XB(BQD2@9((2,(]DEX23Q?QMWP--7F*8\0H1@PQA(<1(QB,>AR(2/ ,)TE0
MD@22Q!Y) A8A'@94\!R'2%&(%$(D'D3Z/]N!B$0Z\V RE"2#;_J,/T?].>PD
M\SK) 63"_0V%&B9BG(,2/#<() '!0>!^$9 =B&B&9";!*" 1Q">A8)'4CX@U
M(F(BF6'!@XPRR$)]%@:7B3/APR JD<X](SP6*0=OFV S%? XHS#/A)]G%(85
M2_UNWM7<DN")1F&D"3_2*!)7.1$9H)G1\1DB/-DHC#;A1QN%R75'<Y80/_!Q
M(4UC,<.$!QV%22?\I*,PQ>X8R6.?")%1)N9X\+BC&>1)?9[LG_G_KN26 X]-
M"G-3^+E)82BB^X+(YO>%X>G)8'H*/ST'S<UI!/XD82KXFQ1-CH/=^?R;;/9%
MW08OVMB3I3O_[;0VRE8D][:U@_U+, Y*M3/=;6KOF_Y<W ^,/@YG_FC\X['Z
M"U!+ P04    " !*8*U.:^#(X=@!  "Y!   &    'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;(U4VXZ;,!#]%>0/B,UMLXH J:&J6JF5HJW:/CLP!+0VIK83
MMG]?7UB6D*A='K!G?,Z9,\8X&X5\5BV #EXXZU6.6JV''<:J:H%3M1$#]&:E
M$9)3;4)YPFJ00&M'X@Q'A#Q@3KL>%9G+'621B;-F70\'&:@SYU3^V0,38XY"
M])IXZDZMM@E<9 ,]P7?0/X:#-!&>5>J.0Z\ZT0<2FAQ]"'=E8O$.\+.#42WF
M@>WD*,2S#;[4.2+6$#"HM%6@9KA "8Q9(6/C]Z2)YI*6N)R_JG]RO9M>CE1!
M*=BOKM9MCAY14$-#STP_B?$S3/VD*)B:_PH78 9NG9@:E6#*O8/JK+3@DXJQ
MPNF+'[O>C:-?>=A.M/N$:")$,R%,_DF()T*\(F#OS+7ZD6I:9%*,@?0?:Z#V
M3(2[V&QF99-N[]R:Z5:9[*5(288O5F>"[#TD6D"B:T1YBXC?1+"I/YN([IJ(
M'#]9F@A7)CQDZR"]@Y -(21=.?DO[,I-?-=-?.MFU?#>0])%F3 E_ED9>@_R
MRE-RUU-RZRE>>4IN*J5)_)@FX6HKRW< O2.\.$3VI_Y&Y:GK57 4VIQ'=VH:
M(3084;(Q>JVY1^: 0:/M=&OFTO]-/M!BF"X*/-]6Q5]02P,$%     @ 2F"M
M3A-E#(OI @  JPL  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6R%EF]O
MFS 0QK\*XOT*YG^J)%)AFC9IDZI.VUZ[B9.@ LYL)^F^_6Q#*?$=Z9N S7-W
MOW/(DUM>N'B1!\:4]]HVG5SY!Z6.]T$@-P?64GG'CZS33W9<M%3II=@'\B@8
MW=J@M@FB,,R"EM:=OU[:O4>Q7O*3:NJ./0I/GMJ6BG\E:_AEY1/_;>.IWA^4
MV0C6RR/=LY],_3H^"KT*QBS;NF6=K'GG";9;^0_DOB*%";"*WS6[R,F]9UIY
MYOS%++YM5WYHB%C#-LJDH/IR9A5K&I-)<_P=DOIC31,XO7_+_L4VKYMYII)5
MO/E3;]5AY1>^MV4[>FK4$[]\94-#J>\-W7]G9]9HN2'1-3:\D?;3VYRDXNV0
M1:.T]+6_UIV]7H;\;V%X0#0$1&. KGTK(!X"XO> Q#;?D]E6/U-%UTO!+Y[H
MOZTC-2\%N8_U86[,ICT[^TQW*_7N>9TFR^!L\@R2LI=$$PD9%8%./E:(L IE
M!,*CZP(55*0I7B%&>XAM?#*-SYP>>DEF)9V5A [$+<450X(R)#8\GC+D>'R*
MQJ>PA\+IH9>D-WJXI;ABR%"&##(L'(8,5""%PUE!310M<(X<Y<@!1^9T6N:@
M1A82AP-JXG#FS2U0C@)R.#7* M3("^?,*JA)XYGO98%R+""'\Q,J%Z#&)PB"
MB&9)2(C;10A98M<O0EC'%56H:(YEQKH(9 '>16"9(G4-"%.EBSD:U.8>2 1I
M4I<F@G7 P4!-/ ."NR&!=IBY=CAHG&-)711$E18SMD9P7R0)I,E=FN1#9[LI
MN>; _95 @\U<@QTTV0>G@JCF3P5W6I*!OXMLQB()[I$$FF3NFN2@*::DX5T(
MWGY<-F.5!/=* LTR=\V2($Z8Q 4XX(]D/4\P&7%:)O9V&I3>AI\Z9::)R>XX
M<3Y$9D1R]DLSB=K1Z3U-/\;^H&)?=])[YDH/8'9,VG&NF*8,[S3?04_.XZ)A
M.V5N<WTO^O&Q7RA^'$;C8)S/U_\!4$L#!!0    ( $I@K4Z\^LY!" ,  &0,
M   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL?5==;YLP%/TKB/<6;+Y,
ME41J,DV;M$E5IV[/;N(DJ("9<9+NW\\82HGO)2\!FW/O/<<VAYO%1:JW]BB$
M]MZKLFZ7_E'KYB$(VNU15+R]EXVHS9.]5!779J@.0=LHP7<VJ"H#&H9I4/&B
M]E<+._>D5@MYTF51BR?EM:>JXNK?6I3RLO2)_S'Q7!R.NIL(5HN&'\0OH5^:
M)V5&P9AE5U2B;@M9>TKLE_XC>=A0&V 1OPMQ:2?W7B?E5<JW;O!]M_3#CI$H
MQ59W*;BYG,5&E&67R?#X.R3UQYI=X/3^(_M7*]Z(>>6MV,CR3['3QZ7/?&\G
M]OQ4ZF=Y^28&08GO#>I_B+,H#;QC8FIL9=G:7V][:K6LABR&2L7?^VM1V^NE
M?Y)%0Q@>0(< .@:8VK<"HB$@^@R(K?B>F97ZA6N^6BAY\52_6PWO#@5YB,QB
M;KM)NW;VF5';FMGS*J.+X-SE&2#K'D(G$#(B I-\K$"Q"FL*PIT"&XA($KQ"
MA&J(;'PTU1#A\3$:']OX>!H?.VO00U(+J2WDCDU(]CH04,(RG$F",DF@DIF5
M2-'X%"I)'24]))F0C')'QTW(%8L,99%!%IG#(@,E$I?%3<@5"X:R8) %<U@P
M4,+9]PU$4)Q#CG+(X7[.:" A_GJ&0$44N>]G"$C>N4<3P9!PALF,41#(Q%W/
M 7-U<AB@ D'I#!/44!X)A4QREPD%1=QW>H-@9HR-X+Y#(D"$A2Z1"&X.S=VS
MCJ'B;&Z#<!<C,3AL;$X/[CXD@7K QR !3$-7S"W(-0_<Q4@*E<P8.L$=B$ +
M8JZE$\1@@!2(F9."FQ"!+N2^$&L"3082@9@Y(K@3D1P2<3\- ^;ZK,;@K"*H
MV;-*<5NCT-:8^XF@B&5%,7'88"@Z]]&DN+51:&W,M;8!DUX9: XZ&8ABH4LF
MF/1FE5 'V\:VWE:>:MVU09/9L55^I%UOY\RO30O=-[R?:?K^^R=7AZ)NO5>I
M3>=H^[N]E%H8CN&]6:NC:?G'02GVNKO-S+WJ^]Y^H&4S]/3!^,=B]1]02P,$
M%     @ 2F"M3C59MTFU 0  S@,  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6QM4V%OW" ,_2N('U 2[MI=3TFD7J=JDS;IU&G=9RYQ$E2(,R"7[M\/
M2)I%7;X -N_9S\9D(YI7VP(X\J959W/:.M<?&;-E"UK8&^RA\S<U&BV<-TW#
M;&] 5)&D%>-)<L>TD!TMLN@[FR+#P2G9P=D0.V@MS)\3*!QSFM)WQ[-L6A<<
MK,AZT< /<#_[L_$66Z)44D-G)7;$0)W3A_1XV@=\!+Q(&.WJ3$(E%\378'RM
M<IH$0:"@="&"\-L5'D&I$,C+^#W'I$O*0%R?WZ,_Q=I]+1=AX1'5+UFY-J<'
M2BJHQ:#<,XY?8*[GEI*Y^&]P!>7A08G/4:*R<27E8!WJ.8J7HL7;M,LN[N-T
M<WN8:=L$/A/X0CC$/&Q*%)5_%DX4F<&1F*GWO0A/G!ZY[TT9G+$5\<Z+M]Y[
M+0[W&;N&.#/D-$'X"I(N".:#+QGX5H83_X_.M^F[38&[2-^MZ/?)-G^_R=]'
M_G[-3S\4N 'Y*)&M^JG!-'&2+"EQZ.(4K[S+L#[P^![_X-.D?Q>FD9TE%W3^
M56/O:T0'7DERX\>G]9]K,134+AP_^;.91FPR'/;S[V'+%R[^ E!+ P04
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M/]AB"&A<.'[Q9S.-V60XW<\_B"S?N/P#4$L#!!0    ( $I@K4Z:J XXM@$
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M:K+]*,#"PF.8F<+3!#] "2(1EAX%S=2>SAQ4BDB$U4=!,^6GZ&G=4X9(A!L
M!<WL (H?:YHB$N$>0$$SFX#BQY\B9SL-MP$*"O<!F=RI-:BK[R8Z*N2M\:UL
MLCIVK#WS=_)_>-_NOG-UK1H=G:2Q-[N_?R]2&K"Q)$_VGBAMAQTG B[&#==V
MK/HVTT^,;(<62L8^GO\#4$L#!!0    ( $I@K4XXR[H]L0$  -$#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;&U3VXZ;,!#]%<L?L$X,VTL$2)M=
M5:W42M%6W3X[,("U-D-M$[9_7]L02E->\,QPSIF+Q]F(YM6V (Z\:=79G+;.
M]0?&;-F"%O8.>^C\GQJ-%LZ[IF&V-R"J2-**\=WN'=-"=K3(8NQDB@P'IV0'
M)T/LH+4POX^@<,SIGEX#S[)I70BP(NM% ]_!_>A/QGML4:FDALY*[(B!.J</
M^\,Q#?@(>)$PVI5-0B=GQ-?@?*ERN@L%@8+2!07ACPL\@E)!R)?Q:]:D2\I
M7-M7]4^Q=]_+65AX1/535J[-Z0=**JC%H-PSCI]A[N>>DKGYKW !Y>&A$I^C
M1&7CEY2#=:AG%5^*%F_3*;MXCK/^E;9-X#.!WQ#8E"A6_B2<*#*#(S'3['L1
MKGA_X'XV90C&4<1_OGCKHY=BG_",78+0C#E.&+[&+ CFU9<4?"O%D?]'Y]OT
M9+/")-*3%?UCNLU/-_EIY*?_=)C<=+B%N4W"5B/58)JX3):4.'1QD5?195\?
M>+R2O_!IV;\)T\C.DC,Z?[%Q_#6B U_*[LYO4.O?U^(HJ%TPWWO;3%LV.0[[
M^0&QY147?P!02P,$%     @ 2F"M3F6"6""W 0  T@,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL=5/M;ML@%'T5Q ,4QTG:*+(M-:VJ3=JDJ-.V
MW\2^ME&!ZP&.N[<?8-?U.N\/<"_GG/O!)1O0O-@6P)%7);7-:>M<=V3,EBTH
M;F^P ^UO:C2*.V^:AMG. *\B24F6)LDM4UQH6F31=S9%AKV30L/9$-LKQ<WO
M$T@<<KJA;XYGT;0N.%B1=;R!;^"^=V?C+3:K5$*!M@(U,5#G]'YS/.T"/@)^
M"!CLXDQ")1?$EV!\KG*:A(1 0NF" O?;%1Y RB#DT_@U:=(Y9" NSV_J3[%V
M7\N%6WA ^5-4KLWI@9(*:MY+]XS#)YCJV5,R%?\%KB ]/&3B8Y0H;5Q)V5N'
M:E+QJ2C^.NY"QWT8;_:'B;9.2"=".A,.,0X; \7,'[GC169P(&;L?<?#$V^.
MJ>]-&9RQ%?'.)V^]]UILMON,78/0A#F-F'2)F1',J\\ATK40I_0?>KI.WZYF
MN(WT[3)Z\A^!W:K +@KL_BKQ]D.):YB[#T'8HJ<*3!.GR9(2>QTG>>&=!_8^
MC6_R#A^G_2LWC="67-#YEXW]KQ$=^%22&S]"K?]@LR&A=N%XY\]F'+/1<-A-
M/XC-W[CX U!+ P04    " !*8*U.^ -2>S<$  "1%@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6R56-ENHT@4_17$^S34"D2VI8YC)Y%FI*A;,_U,
M['*,FL4#).[Y^P%<L4S5*3?.0UA\[E;<<VJ9':OZ9[-7JO5^%7G9S/U]VQ[N
M@J#9[%61-E^J@RJ[7W957:1M]UB_!<VA5NEV,"KR@(:A#(HT*_W%;'CW4B]F
MU7N;9Z5ZJ;WFO2C2^K][E5?'N4_\SQ??LK=]V[\(%K-#^J:^J_;OPTO=/05G
M+]NL4&635:57J]W<_TKNGKGL#0;$/YDZ-A?W7E_*:U7][!^>MW,_[#-2N=JT
MO8NTNWRHI<KSWE.7Q[_:J7^.V1M>WG]Z7P_%=\6\IHU:5OF/;-ONYW[L>UNU
M2]_S]EMU?%*Z(.%[NOH_U8?*.WB?21=C4^7-\-_;O#=M56@O72I%^NMTS<KA
M>M3^/\VP =4&]&Q ^%4#I@W85 .N#?A4 Z$-Q%0#J0WD5(-(&T13#6)M$$\U
M2+1!8A@$I^\W-,1#VJ:+65T=O?K4TX>TIPZY2[J6V_0OAPX;?NMZHNG>?BP(
MBV?!1^](8^Y/&#K")&/,$F!X.,8\( P98U8(0\>8M8TQ$(\V0H@QY,F&,"/?
M9Y0+.V.";ES/@TOAX-+! 1LYX-@!@P[8X("/'!B%K$\8.6#* 2/#X<^HYO>X
M44(<)L1!0M)(Z(01%X'$E3@"QA$@3F3$$58<1P@)0T@0PNC\M;1"$!%;0_LD
MK:$E3#@KCF Z$4C'(-DZLM+A(7'&B6&<V(XCC'K6L5U/QV:K[-C^T-2930*S
M24 VAB2L$8;B("3$(A<"%\Q4E="J^H]8"*OL1P04<>2LG#B4EX"DN)D4L<:8
MQNY(6(8(!9%,&=&@47,1Z0Z%!8L Q1*F0&C05(4@6(H(T"(1.5Q@E2%BND 3
MK"($R(@P9838.G+M*V*!($ A1.)P@;E/XAOJQ80E@(VF,J\TZ)(A"7?W$L6L
MI8"UTB#C2H-&$AT2MPQ13$8*R"C-M0FUR2BO5.58$P R2FI&LLEX=0 Q&2D@
MHW0M8##)*)_>,123C$Z9RS5H<L=@,E) 1KMCP*1^M6,P'2F@HS3D^UZ#1C,I
M6IP]3 6N)@#'V6,EH& 9((69O3W!)XR;ZO8P#;;Z+6R<-Y8?"N3'Y.F2VO)#
MK\S/#,L/0_)C$I79:X%K?<NP^C"D/M+A LL*NV6OX=AL(+DPB+ID]MS-.'?W
M'\.ZPL#D+6,S%K>_8QAQ=RPL0 P(D'1,G P+"Y,WC"[6"X:F;W.IBT"1JUK,
M; :8'1&'"TPREDROEF/R\ GD67.;/*[-*.8-![R)'%L#CGG#;^ -Q[SA@#>1
MN;O@-F_L'=4CMS?I[HF).[;H@%J1JR+,&'[#NIACQG"T+K8&Q=XXHQW7$\#!
M#5=P<>K5'];^E=9O6=EXKU7;5L5PS+6KJE9U/L,O78U[E6[/#[G:M?UMU-W7
MIT/2TT-;'?0!<' ^A5[\#U!+ P04    " !*8*U.1M=#=-4!  "I!   &0
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MH^)4VJ=7G:3B;%+141AY=V/7VW&<]"^T=4(X$<*9$,3_)$03(;HA8)?,MOI
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M!KF3!J32G%0ZTS24F8 /#4"E.:AT9N@R2R(+ @%.:<XIG3G0!P"0]N/34@W
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M>&"L(P>'\W&RBP]E_8$#NCB!+M[2@7.ZT'-3-_21PHL1PO[P ;"<!"QZQG0
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MARH'"?@M"04A0Y]3BR*P, F8,DF[%2W1)&[*H6T\ 5,FP93L)9[$36E"Y&^
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M8YCCC\3]D3"BV/=GP,1C0[&6T"$$)U5,>A3C'L7(&'O)7L4@=!5%I*$$-Y0
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M3%)5! /X[BDO&BNXR;/=:#)1\ Z\$?/;]9<>BBA.LJ=@M)J/\[2QU/[=J L
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MOX1". >WN!RED7S'R!$:VT7X#M!. $IERJ>)"E41)4BLR+!7 <*R$"@R'3U
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MOH R@J-M'9IE;A_65KR#ZV@Q]DI!/37!&,")C:@, U]+-522J6W(6_4W)E^
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MK=(%F8WD(+>S";\WV6Q9[LZ!QHV6*2@VCJ(IEUPV1J1M])PMJEKTN0Z@1PU
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MKXTRH/B(US-@!K;971:T#2S[:0[M=IDXZ@@?D;;*-^O;*@>[00FT6.IG4+C
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M>'+N>R+#!/T7ZN#AG#EC7O\9B!5)DBBIO<<C^B=,>[L0)]![Q@&@05JL>%^
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M(=EFBN54;O_)=V59_?'_ E!+ P04    " !*8*U.-\?Y[3T"  """@  #0
M 'AL+W-T>6QE<RYX;6S55MMJVT 0_95E74H")9+LVB6-)&@#@4(; O%#W\):
M&DD+>U%7*]?.UW<ONM@NO;EIB?W@G3FS<^;L!<W&C=XRN*\ --IP)IH$5UK7
M;X.@R2K@I+F0-0@3*:3B1!M7E4%3*R!Y8Y,X"Z9AN @XH0*GL6CY#=<-RF0K
M=()G X1\_K7,(<$/9R^_M%)?O4!^G+R:3,*'\ZM#_,P%SC'R'!_R!$>+USCX
M?=*+T/Q^R.RB!_3S/Z3_&?D!]<)2!]T6I7$AQ?Y.6<#4)AS0FK $7Q-&5XK:
MK()PRK8>GEH@DTPJI,T1&6V119I''XZ\9T^OX^%42.5J^PK^?]5-/PCTGA5(
M&1L$3K$'TK@F6H,2-\9QDQWX70AU]G);&X6E(MMH.L=C@AM,D954.:BA3(1[
M*(T9%%:.HF5E1RWKP :UEMP8.26E%,1IZ#,ZP]!FP-B]O=J?BSWN38'\''LD
M(49616^:57?F>&JAD[S+YKEW:<.C>%%-UU*_;\URA//MW8$[!07=.']3# (,
M.ZEKMGW':"DX^,7\LF!T9,$T)GT=5$E%'PV?O2J9 4!AM :E:;:+?%6D7L)&
M]]=I4QRK>7J"FI]ZGTL0H C;%6WN_G/>Y?^L>/;F[R6[K\JAX"?4:!O5"8B<
MGX+(Q?,7.;O\QQJ#KNOLM+:]QC:@:-52IJGHU%8TS\'KL2^+!-_:1PW;:R]C
M?S/TFJS,@W"/W^3F4)"6Z3N[1!=,\&A_M,*CQ3!K.5 D>+0_04Y;?ND*CJ_.
M]!M02P,$%     @ 2F"M3GR\^["D @  A@X   \   !X;"]W;W)K8F]O:RYX
M;6S%EUUOVR 4AO\*\M4F376<)NF'FDJ.358VQXYL)]O=1&S2H-H0 6FV_OIA
M1UFQ-*'=>+GBZP#/.0=XQ<.1BY<-YR_@9UTQ.75V2NWO75<6.U)C><7WA.F1
M+1<U5KHIGEVY%P27<D>(JBMW.!A,W!I3YCP^G-=:"M=L<$4*13G3G4W'FI*C
M?!]OF@!K@U>2X\W4&3@ 'Q2?TTH1$6)%/@M^V%/V/'4\!VRID"IK]FXM:\IH
M3=](V;;DCA^?N*!OG"E<987@5=7.:@;:27H'^:=G382B1<=0X4V*->O4F0ST
M@J]4T@VMJ/HU==IZ11SMA6NXT<;A7)Z">"_^)8Q\NZ4%"7EQJ E3IS@*4C6[
M,[FC>^D AFLR=<XF +,20*8T#4#LM)2V;7S16Z/RY)?2$7N'!>*>Z@&!2J\!
M[P\R2.(0QAD,@:YE281"/]>-F1_Y<0"! 3FT0 XO"/EC:$!>6R"O+P*9Y;I8
MP-B '%D@1Q>$[$1R;($<]PN9K&&Z1O ;2.9@MLI0#+/,()M8R";]DGU)4)R#
M-8SS50K!/$E!"-<P2I8ZP3E(#,@;"^1-OY#^*LM3/T)^#%(X7\6A/XN@KF;0
M3X,G\TK?6B!O^X7,?,VD\QLDBT42ZP.8!%^!'X< 9=G*-V_+G07RKE_(""W1
M N;HNYGF3P#%P16(4&"^X /;$S[X__<%?%CRBA:4R(\FIE5I>I8:Z^7IO#V>
M36N\GL7&>C*[F#:U\7J6F[\G/20*TTJ"W,2TZ8W7L^#8DWYM8MH4Q^M9<NR8
M(Q/3)C]>S_IC?=J[9],F0%[/"F2_0IVDVR3(NZ0&=9-N$R'ODBK42?K0ID+#
M5H7<\[^G)%O*2!GK+:3NU]^I8BE 4YQ>X-&X<7I[J*I ]R4LXKC]J31KG+^
MC[\!4$L#!!0    ( $I@K4Z?]L-7-0$  &$-   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'.]UTMN@S 0@.&K(!\@9IR$)%7(*IMLVU[ @N&A $:V
MJR:WK\NF1$H\7:#9@)#1S+_Z$,=W[+1OS>":=G3)K>\&EXO&^_%-2E<TV&NW
M,B,.X:0RMM<^/-I:CKJXZAJE2M-,VOD,<3K.9R:7,A?V4H)(/K6MT>="WCKY
M;>S5-8C>R>D&J[ @O'(?\3_K356U!9Y-\=7CX)]4_"T0\GF0B@<I]J!U/&C-
M'K2)!VW8@[;QH"U[4!8/RMB#=O&@'7O0/AZT9P\ZQ(,.[$&0$C*F_$D4UOQ:
M \$U\'L-!-C +S809 ._V4"@#?QJ \$V\+L-!-S +S<0= ._W4#@#?QZ*T)O
MQ:^WFNGM&FVQ_/"V'6JW=,G#\)<U,[B=OW>X?,8T]>7^F=(^;$$Y71?_@DU3
M?R/DPQ_5Z0=02P,$%     @ 2F"M3O^+>AIH 0  >@X  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULS9?;3@(Q$(9?A>RM84M1\1#@1KU5$GV!VLZR#3VE+0AO
M[^P")I(UP0#)W&RWG>D_7[N3/]GQQR9 ZJVM<6E2U#F'1\:2K,&*5/H #B.5
MCU9DG,8Y"T(NQ!S8<# 8,>E=!I?[N=$HIN-GJ,32Y-[3=KV1GA0B!*.ER-H[
MMG+J0+2_$RPCF#8GU3JD*TPH>B]K5$FX-BDPF@IV1(7#C<T<][VM($:MX%]H
MOJJT!.7ETN*6,H4(0J4:(%M3IEI$4.\Y:C??\<Y$S*_"HC!;&_8KH;P<1]X8
MZ 9H(^>LG+$MH*M4&]@^^4D%]]T@?81^B!B-67<<#Y%F&$VL23SG$:%I'07J
MJ.(H?;D/^^7CHGWONO"?8&+M<-JMGX]C2(3CF@C'#1&.6R(<(R(<=T0X[HEP
M/!#AX ,J(%0<E5.Q5$[%4SD54^547)53L55.Q5<Y%6/E5)QU>$%G;<?2"NW^
M(OGT?K&OS]I?SNDW4$L! A0#%     @ 2F"M3A\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ 2F"M3B?HAPZ"
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    " !*8*U..WTLY>X    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    " !*8*U.F5R<(Q &  "<)P  $P
M            @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M $I@K4Y?)GA$;P(  -D(   8              "  ?<(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !*8*U.@[BLT_,"  "$#   &
M            @ &<"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ 2F"M3FO@R.'8 0  N00  !@              ( !Q0X  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $I@K4X390R+Z0(  *L+
M   8              "  =,0  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !*8*U.O/K.00@#  !D#   &               @ 'R$P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 2F"M3C59MTFU
M 0  S@,  !@              ( !,!<  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( $I@K4X=L4E$L0$  ,X#   8              "
M 1L9  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !*8*U.
MQ0M3#;<!  #/ P  &               @ $"&P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ 2F"M3H,XBS6V 0  T@,  !@
M     ( ![QP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M $I@K4Z:J XXM@$  -(#   9              "  =L>  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ 2F"M3LW8(%8X @  TP<  !D
M             ( !R"   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !*8*U..,NZ/;$!  #1 P  &0              @ $W(P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $I@K4YE@E@@MP$
M -(#   9              "  1\E  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ 2F"M3O@#4GLW!   D18  !D              ( !
M#2<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !*8*U.
M1M=#=-4!  "I!   &0              @ %[*P  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( $I@K4[4%)\\Z@8  *(K   9
M      "  8<M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ 2F"M3@4ZEUU' @  :P<  !D              ( !J#0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !*8*U.?)KR7RD"  #.!@
M&0              @ $F-P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( $I@K4XYZ*O1Y00  -T9   9              "  88Y  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 2F"M3FU\:PU@
M @  ' @  !D              ( !HCX  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !*8*U.>BL+G]=/  !W( $ %
M@ $Y00  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " !*8*U.-\?Y
M[3T"  """@  #0              @ %"D0  >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( $I@K4Y\O/NPI (  (8.   /              "  :J3  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " !*8*U.G_;#5S4!  !A#0  &@
M        @ %[E@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " !*8*U._XMZ&F@!  !Z#@  $P              @ 'HEP  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     '0 = +T'  "!F0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>81</ContextCount>
  <ElementCount>157</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Disclosure - OVERVIEW OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/OverviewOfBusiness</Role>
      <ShortName>OVERVIEW OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs</Role>
      <ShortName>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit</Role>
      <ShortName>AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt</Role>
      <ShortName>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement</Role>
      <ShortName>LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - OVERVIEW OF BUSINESS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/OverviewOfBusinessPolicies</Role>
      <ShortName>OVERVIEW OF BUSINESS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables</Role>
      <ShortName>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables</Role>
      <ShortName>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - OVERVIEW OF BUSINESS (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual</Role>
      <ShortName>OVERVIEW OF BUSINESS (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/OverviewOfBusinessPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails</Role>
      <ShortName>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual</Role>
      <ShortName>JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual</Role>
      <ShortName>AUSTRALIAN REFUNDABLE RESEARCH &amp; DEVELOPMENT CREDIT (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails</Role>
      <ShortName>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual</Role>
      <ShortName>SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="caps-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual</Role>
      <ShortName>LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement</ParentRole>
      <Position>20</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>caps-20190331.xml</File>
    <File>caps-20190331.xsd</File>
    <File>caps-20190331_cal.xml</File>
    <File>caps-20190331_def.xml</File>
    <File>caps-20190331_lab.xml</File>
    <File>caps-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>36
<FILENAME>0001171843-19-003295-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-19-003295-xbrl.zip
M4$L#!!0    ( $I@K4Y*S:E^NY$  'UF!0 1    8V%P<RTR,#$Y,#,S,2YX
M;6SLO6MSV\:R*/I]5^W_@*OM[$A5%,VG2-E)3E&RG*4LV]*R9*]][ZU;+A 8
MDHA!@,%#$G/K_/?3W3,##!Y\4Q8IS:J51"2!F>Z>GNZ>GG[\\K\>QJYQQX+0
M\;U?#^K5VH'!/,NW'6_XZT$<#8Z[!__KM__\CU_^K^/CWYG' C-BMM&?&N_,
MR+P-3.M[:'PV':_OWQM?^2A&LUHSCHW[^_NJ#0]%]%#5\L?P)?Q:KQ]_-*?'
MC5K]U/A_ZXTWM=,WM<[_9_S_O8__^_@89WKH!Z[S!O]M &Q>^,8R)^&O!Z,H
MFKQY_1J'Q2\BWV/1Z ''?8UCU9K-^H%XP76\[YD7<+"J'PSAR5KS-?[<-T,F
M'\=?;2=Y07WXY#7_,7FT,/1]DYZMGYZ>OJ9?DT=#I^Q!&+3^^G\^?KBQ1FQL
M'CM>&)F>E8'%F0-[_GDG]%N->F?>&_P)^8+-)@&S<!5GOG/ZV@RLP'?9Z_1A
M^;KEQUX43+/$"IE5'?IWK\6/N!Z=XUK].%T1*PX"8*M9[XE?2UZTF5/^#OR
MCW>SC[,':U3^//Y2\H+CW;$P*G^%_X8O-;,O>:9CA>7OT$\E>(2.5?X"_("/
MUW./1Y-@QO/P2PD><7@\-,U)\L[ #/NTGN*'DE<>W#E<\S\?%%:.HV .L\"O
M"=A!5(0 OE1GQRV.^^1-2#O@,QL8M&_>1-,)^_4@=,83%]F;OAL%;/#K >[W
M8[G)JP\A<./K5%)8OA>QA\AP@*.O:_5O\']\]M:O-;\U^=\'Z=/,BYQHFGYV
M;/QFX+# ((!8!E-)]?/+?Q[\5H/_=;N=>KO^R^O\RSC@Z_(9)BQP?#O]#!LX
MB$!\LM\0-*1*+1DP_4T!V%8>;@()TXEL^>CK_%2O,[290:Q>>.7M*)&XG(M*
ML):_;(1UO2&P[NXJUMWC>F.;6"<;HZMLC-W"/K,QNJMLC.YC;(RVE"0[1:3L
MQF@K)-J816!3<(S;MS[\7>=_[Q3V&19IXQ99ED7HX?J66:3[#;82#-[8*2(I
M+ +TP;VQ/2G2%2S2 "FRF]AG6(3COR2+Y(BU,8L@@1J"6#NJ<$J(U5A6Y&;T
MTU:(103J$&=QX=/976)U5N$L>GB+P@?V'2?6B:+,3W:76">HGY<EULEC*//N
MMT9[]XBD2.H39)%&>ZM6+F#=W,%]I&!-&V.+5FZ]EDH1^+O1V3WL<U*D7EM!
MBL##C<[VI(AR)-@'_;3BD6#+^JFEG)].OC5KNT^LUBKGIY/C9FW[^HE[8>KM
MW3M'Y;TPR^LG>KC>WAJQ,OZ(W9)5&4F]77]$QO>T6_LHXX79KN^IW#WY[8,S
M<<8L<AX^LG&?!39S/K"AZ5X0H+T')_PQ]!'<SX9CYB48V##EP\1U+"?BT!DV
MP.KQ^R* ]$T!5'37OLFA],OKTK$4PBG3[ITC==&R]N(P"DS7,:^CZ8?(YKC'
M(3KF;R*8&1$_=\TPO!K<1+[U?9>77%PHO)D#>)8!2I%_D?QP"8\$+(QZGGT5
MC5AP\3 !JK)0Y8=+S_+'+"'N!]\R(Z#[/G#$7-"))^83X$7RQ%G@^]_I-IMC
M&P;1U;T'_QTYDUU>=(#S30Y06N(\/B]R46]@%!:>-:X#-F!!P&P2CB]"[,]#
M_27S0OWE\D(IZB^2%SXX%NJ[1-)?![X=6]%5 )2Z@]]V>=%1X)?#*]DA@]V+
M7-_/_M1TH^DS7=\,=B]R?7NV[:!):[K7IF-?>N?FQ(E,MU287_P5 [+G_G@"
MMI 7A;N\]@6!7@Z\?&PN&5XD8WQFD>EXS+XP \_QAN%+XXAR_%\D*]#!MA>&
M+,IPP9GI8MSNS8BQO3K4SX9;/E% ^'DO>S9H$LQ[*P;+]AWK1^IRG\-W3O3>
MM!QWQUVX<AG+($ZD0![)QUCB1P[YU#Z7/5F=/WS'B[X"/,!RSV-]BACM]PI]
M9G>^>P=Z/BLSGJ_\FXOP?J^E=D_],/?4CUM4?9^\V^L#QZBQ[\W>:<_XI%A
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M$T)^MI4@:6RL/):$I$BQ)$7HV@^H2'@4!4X_CM#\O?7++W.+\&^L:9;AN'5
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M!P455R ;WY3G9A!,!WYP;P9V;XR1:D5,-[JC+L X9^JLB^ .#C0D]2^]WF!
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M*F(%DKP#T)N@COZ*S0 01&JAC.: Y <9F8"4$9H#%DU!ISAC1 M F1 [$<H
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M(]F32X&"OD1US$=X:TQ9E"K.,3-#L,O&@GBF._V;SH]Y3ITZS+5I%P#QPHA
M#YVAY^ X*&*$BI_X/FX6VXR _F#JF'<^7AK*C8=M",'D$=L+7TK8E(P;/"@#
MY-_!.I"P[ZIZUD<FK;+7<$^E,7F).DUD0<;'DJ;E*:>**#V<@/1%]PILMDG
MCI,Q$C4U0G>0>8?W<# >[%.4+?R0HXZ(8@TI@6.A><"/%.G;?%-'. 0_X#@B
M"\Q.A$B%:Q$XI,0HB5"5"&U(YK>TU>5) D6KSZ,U<;RQB41$H8QHN\Z &8=P
MH'+%^<9 <:?8'E^J-U7CFC^,(]\&)AR)0&085P@.D_+Z2(L-+3:>C=@03@EI
M@\BJCR98*NQAXG(=.X#%"TP'34@P0.&,#68$=Y(*GR?]@&[*?F3"-C&3]K?T
M*AG]/EUN.YAO-4,:D?]Y(C:W5LYZESW[76;[L"A"'88Q:AF'W'ABSX"FC$8.
M:%P /+.!E/T%2H[1P:5\4R5>Q[$YI8L9O$ 9Q-3"+7\\44^]W"#X<M.K*-="
MRCG_SSAP0CBNB%2/09G3$AV(!4&@CI=>% GW@-[S>L\_JSTO-GHEV=*I&ZQ"
M%WJ>'69V-A8%)G<-WAS0C1_NG50K&G3S<><$49Q^#X^/?9NYQOT(3%KXVW,B
MKKC)-P3Z&@3+A#\H3M/CI'$#6LKI74>]\S:<)4KTYM2;\[ELSBW$/(F,,N-:
MW/^]"^*A<0X[SK%!)\_?+GN^=4#.1(SH#1.BDX"(9.SSCEJ#'Y;;A7I'KK4"
M^:6E2"-ZNNQE?B/_4=S(RQWY4=[()]JM_G;&[?PSWJS[O"NUGMMP5\'&<)V)
M#P>RB('I=\&#!ANGIP9 Z8$M:3GHYN6_DF\6A\!M83CCB1]$)F@XO(-#PU$=
M"7::"9+1"<=5HS#)(>U'BE!$;Q"<-/'Z#71F9B;?LN(@E/$??AR19=KW[6E5
MA-C ^YC?PCW$>,N*#W@^Q=&E "P.PS!Z _0$FW@IY8J++#^,)GA1BT,?PM#X
MQ3'^?B0NC%S?M!$"H/9WL)7M' 6XORK$BF61C$DB^%W?Q]NL@)ECB0>/'0GG
M0FD$CC7*3@ CXMT>WH31W?L$K/I06O"N<\>""N:QH--<WJN[:+HGSQ L5>-"
MWH_"VH9C<SZQR/6'O#YAQ/  5_C=&, Y "?'1<A%_G!Z]F/'M>-)?BTX4BRD
MLPN=1ESSKY@E$%*\#ODIA%SF_-E5V5,&6N'= I$3QTG$.+]W0*!--_3+7PW3
M=P_)WX\!5/C4B#V8G@]CT],HQB;\5L&8C/P0_B%6.)+WN;!+R;UIV+"/)1N;
M'B!,ZT)G,W4GA'$ A&/B7$;P3:@ZH5PN#I-<6Z/OR.MT'+Z"[P'Y*-H"F,=E
M9D WHC)B"D<8L0E^"U.Y PP<H*E]7$[X\O ?-]>_'RF\<W@SA46%GX[K1QE&
MJL[0BQ1@EHEW@Z]*KF\ =8Q-]0/^@XA6$'?2(1,\,V0>T#K/XWW&<0,&I3 !
M$0@"G%J1M^627@'#>UZ68;$(.R6@J,*;GM&].:U(/UO ^E,>K87O6V9@._Z=
M&8))@"&XP-;H'4,9E9-W8V:-3$](%MZ#08WQ* 3V]7*A<.BRHS/VG_"29<8A
M15OGY@=IC9==%70).!,,*7?Y;IC*GW@T-&)1_(WCB&O,QQ\!_8 5HPB$505$
M%Q>WKC/N"SD5!?YW5C6P4!.>Z.6MN")%.7O.EO[Y6&VDC1V[\(>'%_(@2/L@
M"4,8TH6UCX'9L':'T4A^.>) \X\4N0+<PKT32!%W:MS%+@8H8%0"[J6\G!%(
MHA2913-8C:LXR(:&BG!J(VE*;(AD5"/I0:S< GJX'4+!O#W7[)L@,6&;GSD8
MZST<F6-#YO<::8(O%XQ&/T"E(:1#(G-RD:(ANGY$!N<LGM(VJ+9!GXL-NL[9
M6MZ0_,-!I3+=_>.9W@9Z&\RGX'7@X G&-S[Y=U0OP&C4:DU*;!!J%>-# :@8
MC6VL3<.C+3%HC8SW *PFA_KH@LDM<[[P @_C^>P[DT)7E;PED2^%_GP,J./)
M8/#EV!<!IAA/2=?X V,<HUGBA]\98 9:M8\)261&.5B&H\(59*JL#3:>@%H%
M2P=U7\ !3@8DBV."668!F*=.P)6RS-]"DH32N.6:$&"C&8%[[V&>$)9)A S1
M6,D$ ^>!?PL4 QV.YBG&VXI"<60T $1Q)FON# =^1\\G.:I5);<#,[J*2Q*"
M9**1RE_7,DC+H#V409=)7A4P.L]A3*IXP1&R'Z+%[W")XKHRI-CD;7?(1O4B
M,._A"('7CRB16, M99F1&(*AK&2D\O0JU>!%*Y<EEOB]'[CV/;H_2C,R*W@2
MYU9SA9O8KIODF2JI2E7C!H!G?\6P))AJBAN7#>"%*"SDG ;2>J?#2/9 D^95
M)@>"H<^C$]6T5!*:J40C;\8 QAT51&'5. 2:?Z3YDCRV@,$C'L^C4'(\*3(D
M :"<TA14J>2)WC%*%%5R0RE!+!FTDHY8/=)22TNM/95:[UD_B#'Q .3624YN
M6; SR"V7BBF3]P9.?G*5#DIX+/_[XO,#%TUPX+<9=RQC-G>:Q)+VWZ3I3*P$
MRVTR17RI0HL"KGURGI;M7$K7$)&0/&.[PO,X(^=XX/0#7_$0S,TRG^&\Z/U]
M>V$<\A_]X&@]D(AX&?&D9IW3CQEQ)=XJ'UX\(T':4:/IA?LTM'#ZX:GJQF&/
MSF16X/3YM1*5G3HS^F"*W!]MGFFN-]H.;C2]O=;;7F!FS\@7"-@$;7G\4F:W
MI@&1(1ORY^DN9FI035);Y-6.6>*,R-0E,"-^*H@C,!;^5A^7_DB8$ Q_BRXL
M\:82/L=N))PX7%'3:R8HS(@NEB;<;T-)O7A)-D ]2:<'):H3O1;<6X*7+I25
MR>'7>UGOY>>SE]$W^0%]EJ)L5IIQ;_NX:?O"O\;K2DD['#2>AWL0S^>E-;C@
M4']E13[Z[^JH@VLB^_">#/,QN3/P1A>#.'#CT6ATU5R "+;HO#I?/I[EX1!"
MT]1US26].Y_/[KST1*R&AWTY*MRKCKN33GN*0WW9ZG69GS*UZWC(D/+K@GIY
MI5MRT<.9WU$<*,^D^UZ]""",%XF SQFR^(5@@VS)ODP5J4HZPYQ:5,8A95]C
M/,3LDE8Z"5F+GN<C>M:)$#CCMX\84TJ' ).[ZGXG0P*+(;# X_O^8Y+K)/<B
M93E=NR9>'/SP?;3-_#+3$A4_*4N;-SK&5,Y0=L@*^1U!GS$/"36A0Q!Y1V5(
MG3S9W#NNJV28XN%F2+2T)"WYA2V5*!]C#4X6BIB\3*5.Q0L;8D67@9G42E.]
ML"*@3 3S6CXVQL1G^KM]Q:KEFY9OJU,PE4 4BYCW%!2V8<#HLD%-G[;,B8.!
M&6;?Q\HK&$PN\L\L,^1>BWL_^,X#7?FC?=,UI9TRP/J(+$@=BZ6>0X,'J"12
M0*G&8& K@P!O</%^5848,4H+-D6N"+EE?.1Y:>DYJX^D,DPR099E&+(*_QE.
M*9S6-[#^!*,\VM#H3S%</W3Z+E:B&II#D=EJRI<<ZS584'A%JMSC('8B!5[4
M0@X<C(O'[R=QWZ40\X&H;#$ R/L1_H1K$4TQTC\6A>T&%-9+1"8W4-&7^X[[
M<C.$JN#I\8\80,9['6RL4^%(V<:K9J75JE5J>"=$ESD>BV1Q/-)QY$5Z<##9
M']Y_U:C4.BW^N#G@-6ZF'.J!F#%ILF=< [<[(39U(=!$54^5+!;UCH597C6Z
M'1R5(^6$5HS-1?(.Z@HO%""B"! +E1OHEOU5G8"#?^1U6@8A7NJ4;N^,4T"]
MW>7N.0)BCF6<813>)M(X.VX82:=(@WH*<>;*E1[@D>SW#'87Z39>(3L-9"X4
M+$E"T<G_YP!!,1+1H(@D',(#5#!L29HA\03Q>M6NB74\O!51^AA,+2H;(>5P
M4_AQA)$6- ]>Y1^C/. ,9^;8"0\8,M/T,[D'$83WH#:-[O$_\S6,;E(FQ56^
M>.!N#UY+CHJS<A<&AB/43XD+3RO*5VW^569%,U<98A(?,S" >#81$+Y7)KX6
M2POG%-_DEX;BUVG^SC)M+"6,"YX=@="7+ A2/^LVY30W ?H'[+AEB!;4R,IB
M'8[P$I/=.<GMJ1+D0K49(Y2H(O4(<QFBK#B2B0R9ZAL%VZAJ_,._9Y2/DV<[
M+M#[3,IT.[F8S1X;R3=L8D!<3FAB_ E?3?FB7!@5)GQ+%L_4-72T$?4,C2CN
MGS*PD4%2X$V:55P'Q9X9P^ZC2G"((5=>F& V3@]'ZME(!)]2H(-I_PD:C7_O
M,3";0@PWD7MN8#I!YJ2)\Z,T2L>5I><JXE*(M$*Z%V7&#@:)83Z7J*Z=FYF"
MU5 AR9-1@**33!+/1$'!E5OI# FP$N<)-=3C>3989TBB!6N:!,_=,:FBY9@\
M(XL]8%5115S)NJ6 ,1:5-:;,##@P<TG+7_5"WZ6R"+8*^CPW&U4) OIF+9^3
MVD^&?^^)8$7'=B@8>IXSC=H R[88BM6C'HP95EVA !LM,+7 ?#8"\UP$OSD>
MW8*ET?2^'Z&/GTQ\U\<JO:$0-R081$ ^QK26[>S$C80'+CH44E(J&73Y L/H
M;$I:X.%Y"T:;8%^9=/.EHAKM.]&UACHAF 73<I9-&_!>-12[-DQKC6*U:#+!
M[W$NUV&4MBH.W"KRF"J*V-"1&^PT<5D_-K\S(5!3"@HEP&P2J0"!RTR;(GUO
MZ?:D3 F5TC$$V%R;FX8F41->^#/V^*$L,>E+WY6%Y.BJAJ>Z1GYFZ5!V]CP/
M _)RQX9Z#<\-0JJC%#=X]=1WH!TH!Z+);S>[*#S+\#9)>!<>QW.Z#2Q])_-X
M)1W*,-A10?N"A*H6KT]P:?&%.[D9)C@M+!*UT]B3Y<=506(/SS $"UJB7"64
MZ YQ28!=6\FY0W<.&+\]!NPL4YZI14UJI:8=26ZPH6.24/Q6(AY/HJ0,1;("
MHH;# -/BA1F,TA+%'#D3PO1.HZ)>8'#SG?&^SJ&4N#.%=>:BAJ1V5;F70B\2
M#H*I,0E@0-,19;]2L@O.%#AX[TSCW8$5CRU^>"%-%3NAZ&QAQZ/?R?<PI*QJ
M]*0^Y/?\Z52H^/JFR(\9EU^7J7. EC7)%YPXH;%A<8*JJ%3(UV2*I01,*^OE
MEFU[8MZZR>21X_)H@"_9#KIB$R]<%EP9X3_17HZ=U2]:JZP=[ZK<IBA<GS@K
M4NF)5ER(+N]COGM1QH \HE74NT+OBF>S*]:QM3Z DN+UK:Y(29Z3KQRL#&S#
MOOL%)?1&T1MEHZ+3>!X/X_Z?9-CZ,-B0)^?A'2P,Q\THRS6=<?9N-"WJY7C"
MO$[-.KQZ7^ZB4;1Z 3LU3,I'E83YJ($ Z.R&@T)(5=3DS=O]B'DBEP* [_/B
M4#0R+W.%X0?D2')X_QL[<8YP ]Z@WI3"")X*?4KF,'J=&5%)T;=_QC9/'$GN
MZP#VOB_[TQ$$'# 9Q:'THB'G.0#,C7),%)V0AXD*=:G&^#31ZS;E>LZ_V( !
ML,T6^IL ;Q<&B2CU1%KV(AA"W%0J]$1#FG?J26B3-@P@ZM%Y#)9X(KD$O[14
M2:G<;1*4<016!JWA/(["2EAPT@ XAZ;CA5GK'X\;"F>JY(\]D;(;3;4!H^7R
MLY'+W!CAD3:R<5]R?R]VFFRZPWW&9IB5:'0S2"YGN8%!,#&'1 W%;/@!]]KJ
M;:.WS7/9-NO8_7]07,U7$5?32T[+>Q[J71J.E<\LQ\(UO*P6CS2E+K-./T9Q
M\^I$!N55E/LC3S:BY2&4O-B#N)]3WY:5-))N>KP(!2\'L4G 8%K'XQ%" <E#
MDD8C5HU/0F*J$'A)8>EYQ  +SN^[SI";>T)V<^H4@[Y$I%PA,X@*E&%I$JK:
MD_TY4Z,D$+7:,!H.H\UB+/(;,7Y[P%'(OBV:-I*3G3K$SQI^F@_:2%HF\OO3
MLL 2$2&2'9"JMR:7@C[5^58#/7AD9,D]YO(3BA5:.8K#^".+.ABU3,36\",&
M!YCJ5LOX30P(1>O[WF-!.'(F,NXW90,4(^[,Y]!"EX'/& A:4VM2Y==" 0BK
M.UO2'N!'*^+F'A)7\'(R669,>)Z';8H;V&:%PHE*I\*F]T2EPG0)C=-"%@T>
M!GJ2-OX68<JPD>H-"NL]?'7:(GE"D;W8O#/$"WN+<1OGB$=C)QNS7MB8N/;_
M-@/DZC3JFE<8$W,G,V#]GB4(5C9+NDK),I*L H SI.M6Y!2)S24.NH ]>[!X
MK"\=864</M<K":O^\35[E*6:PUBOVG?O>)@OQL(6ZPWG]A2>(F4IQ^+/7+A0
M(*P25Y:,A4LA#KT^"&;8#'B;9L>L<%E_,B-N_4R-6\<7;8J/EP%B&622@W?2
M?Q76@\>W$_\T9# [[R0_,:?9<W4\P=AS6;NI&.];*G3Z**Z]8W,P %G&:]IC
M34H\IGXH7\""@L3E#--VV3/6,_N:#.*=M7OD1R(%[0?:%DJ8MUA5?5FES?.7
M;9Z?F^'H.??&TAOB!6\(9&ZR@AV14I7DX(V8*V+\9!E1^,W[GN@=K1?T-G@V
MVV V!7<;[#7464_:C=?FE%\K[:V7*4%EPE&1$2<HR :.10V;T_@2E&Y[A=XZ
MJ_MJ;Q>SWN[2X1E/E*_JS3;_$&6/O:?T<R&2NR)O!)T[QK.]37[_*OB"3CIP
MJ'-X;&7NS$=MW:A"#KE5Q $OEX<M>X3+4UI9*OB9;P8VA9K#>9':CU6- H^6
MH(1]C!+6-8U7K3KW(R2OA*%O\<-C<G0^]Y,3M9*DFKHTZ5BL=;36T<]'1Z\A
M#LFI-H)?61 J6]6X(!=H9GL8I:D&)7^]BP-9BJ:>@XEJ&%BF>VRZSA"X)8QA
MCZHK%&+*$GQ5!FL89<#Y*Z9&82A.$L%'62N]U/,T,1W[&&UTX1.2:?OD2WK5
M2N5I@]^B9*4DNLN$&\@<^P!Y6A.'Q[Z$Y!@23L^0/*;\GA==6/*Q]TX SVV6
M6Y^O(2!*4CBRP-NYZJ9_G_CE;]+L'./)5P64"+6 P=J0#*P/C #*+$>WW4X7
MI,T+5\Q9$O3'47!+XA\D<OA #@'$KA[!M"C7HGS[HOPS9FS ]O@,2SCT2 )J
MIYS>'L]Q>UR*HKW43X/K6*GRTN@0U'Z>;6+T*3]W'$H#IU%[^[YW<Y9\K+\]
MDKJ[]/4O$[HT4]_OW7PQ3FHGF2$^^54"Z;AVJA8,E?N2$I\P9!T;"H7B8QS"
MTBBV%PQ419L@R97NW9SC1!5JE$MU84*Z\88=_G=Z)9;4&L/06M.PQ+"&W\>C
MFH@:\5W1L'M,=[]#'RM)8+X)"ZCUFJBRE%3<D3/*PV)RT2Y*GH=)*0C'EB>M
M0O4S7G6"U_N"4ZES)V_L>'0QSUI&G3T#G"3"=#)Q'5&?<.!C_V1>(/&.'8<1
MFQACWV840(<@!KSC@JC)!N]@V7;"ZXUQZ!RE&]!!YJ=(5=6PFTVB-.R9+^-;
M&,XYR@4.PR@R8GC!:&8^S",)1\ETE%5&XZ&VL"> 1:U(!0<V<VJ8*M !>&.P
ML>* R=)84;89#F9L6DR=3RXK/(17IO ()B?223NSVCC^W9&\0E4(6!A=VFPS
MD'U+-M_AW9%D;3F89$'B:^SI;H9'&?;B!2F1,:C44OGX.VH&KJW[[D=.Q$A@
MPH23@!V39#3V6266+ 3]_0:/;8Z5?^GMPB=6T+1:ZS[I(GV9@"H$,2.[8+UG
M\Y.Y=II&;XS+ 26[<%RR,2497VAYARTG6TN4$KX3:9\4,.0YXC.$J2&56IIN
M3PX*M:Z6FIY#ED0H1:TP3& G@Y;'7N@@]2M&+-8HZ8X&:Y3FE_-0(I?7GKHS
MW9B'$0IWA:"!?)5B_H+T^\A'QPQ_2W:G3,&5Q;'*;!]2"NK06%84-4_:.Y9K
M,M<U^RBC*(K2+GZ)UH'H4!^'/&2KSSPV<!22BSFJ90ZO]S"&^%U6'Q"1_=FE
MX\NVYE*)#C9AFL_$0T\Q\HG<(28/294FP+A/+%3.)%G[2+56%KV(R55"Y\+:
MW^%;SI@'J&(*TX2"K! 7^+:*FV']0;/X2P,0G61*!YXQ@.[3G0*W<G@)"G\8
M(%T&5 <VF/@A#S^6S(,/!:I9O@2[EZY\)HP;>3BIH2UL+F%Q<W#(1.'5* A,
M*N:&[ ;&UR M45<1]>.* RG4XY&VKBC QE%1C*>=,GE<-D@M'.T-^]&&1T)^
M-#6RQLC^&AZ+O6$6RDCE/'\-6]K';$1RB&O7F-XKVDA?VDC_@-<T>US<*F6L
M;.OA^@GW'_9NSA(7X,T7^N&XUMC_<)BM+;UQ>.M/',OHMAI'&;+POB!*KW;#
M'(OD 2#L,'9XF;"D,[$+&PT+OZ)UCL:Z(RK6*WXEM5M<*+RP:%/^87IRV7BC
M XI3X84-T1+S*0$]*8#K8#EQ\MSR?@-)S?;$184'$<_B/=CYN426 C#'/B8L
M!$/3$[>^U*- -2!=&DMICL*_R"1]R8PD"ADUPA'#? YL4L]+5>(PW]DT6\^3
MBI?C6)1DD!X'R"$*F"!_PG\8%3A#9-'*54KX8@X'B#*/7J=> DDXD*@&WU6=
M??G2PAA DURDFKS>9%)V&+-Y9#UA;I#+UIJ\_\+8M_EI)F!1X,N+6VZP@_'+
MEPDW1[*LF&1EVCX5A\LYL\6)Z$??5M,I#"'"U; =7A64)PRFF=J<^KC 6.*M
M)!,NS>BALP:EQ&4\VI5BH%.%,G 2-[O)<S&38RERFFCJ(+.H1!T<4;*MI[1+
MSW'CM/1%L(X"%'D?BFU\%D849&J3TF;[%R<F;,EB?=)_R18.@JY)$PF%%? 8
M3KE L/=8A!M=]2-3QCPF[=!2>+ZR! 5X$RAY3>IP9+S' MT[=2C2AIXV]'90
MVY>&3<Z* TOO8;LS_9RY1NG*Q6BFD^)1+@U>3:VDU&P.EJ@WVO/^=(SKD0E*
MTZ(B\]A1@[=:5"]I/_UQF9GB,&2,QTY=2._@%D3;D929:I,/K&E:WLN=!"$F
MH6;3_J7[.PWZ.L0Q%71NXOZQ>"J#%:<(X$JE=ZCM$3Y3$584SGWQ  B%J(J+
MTR01LU]Z9X!>R$@GO<=]+SKPX8]QF/@6TW6C!5;0E$VG9OBV.95N61 X$78O
M$N-=,W_BLLR80&79OLDX!W/$K!BWIG,O N3^@;;9/_%?>1(E8ZL$HLQ8*O@D
M,DL)/L_F3M!YW;,J:G<IE!(31J)B5O_R>ZK_S;5]4F5*3BJ\=_*"E9H0X66P
M T+%I%84QQ;L0ZH-BXV_1.TE\4U$9H<=Q$-U<D(MC*T17R0Y%6T=.[MOTNQG
M^I7 \"50:3$(L#ZR0$2\B"TO8I-TK9'L9G%OK1(-N1!B])8S3#]P%-L;WDT,
M6D^ZM %62KI.L.%5M.@W!_V<6(!G(8'R7<Y@ ML/"NNQ8""1,(S_DF3$CDE(
M!M'@S1GWJ1::S!WOA;+< R<9ELS@P1S\5?B[6^MFX]05:S])U:?A,=B17[.(
M:40A8J46UR($>*DBM/T2N_1"%CM.-E_];2H"Z$O\1RW646H?*J(3.. JK?J0
M7+?()BG2:I/IU^'(O_<(NPQ@O71/J:!]@N<^\)#/14"D5I]\>#E)/Z,S%S=A
M:;F)6;G[75D+*0:FRMFU/ 7!+!8KF)&UP>_&J$Q#78E5;I<&*^-/20)_0M:D
M%MV//$6IASAKA.=]6W ?(80+_*I5HQHN/"Y(,!R=C!56DT)'*:]%PCEEC@6T
MU@:_-OB?C<&_$T&/F==11AW7487)RW2T,%4EEG@-:]TCX]@X!T/'&4RERJ4:
M0+(**8ON47(ESY,TX)] 9<[S?6W@"3NMB HU<WQ@ZH"E6AU1 <"*/529RQMN
M@=SB%5/(_2&?+_>(((:+G4ZS#EOEW0H*"75^4-(;9MZ^C"@^HD^QE;\>U Z2
M2#3'CD9OZK7:3\"]^,PQ<*T?1V\&S@.SWQZ 7>FZ@LGI/?P\P=(P_',R?I#\
M92?SJW\&Z9\X#7[ZY74<'@]-<_+F3)2>?4<Q)T3.GF>G7'T--@*68[R%O7_F
M^M;WW_[S/WZ1+_-,IX\41G!)/4&1:E>RS- U"_ B$<U.Q_[UX#VRJ_VMW>P
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MJR<IV2#G<#1&07).]<X2KKD05=%R-.ETYW,W'V4V ?BP**3 9("U+2-"D3N
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MBIX YLW?%76.<NUAE!8#(,N5[@T(VCR2 =OB-E."RRB$R7(F/ Z$!P<E&V+
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MZQ;V?9*7F>24DZA)B2 [/V V>J(0'B9.D&",WL6OINO )!S*<]=TQDJ6*5/
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MB^R)Z?F'8^I6. D!)?E7?A=4:[5ZNC<R';]XC3Y,;$D)K=;;2R962/)?EL7
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MT$==$&19OLJBNGQ'&(X_M_P?<I6H$9X6R>,MMD6!P60&&%TEYBPREI;?*Y0
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M0+-XK[ULO9#CXWHC8;Q9PV=1?^^X+#B'KX=^4()XX49ZQLR?L*JH93$7B]R
MN*=A51IDYI$@W 8F2NF;Z;CON\7)"VIR%@?TKF_X7)D!<VM,FH#DW,W(!)/C
M2E$3A:E+G1)M.7U>P(8T8$[&MEM-6+EZEA/F )$%]V+,T+4^_#WP[Z-14@PI
M#^<:0G#.^%D0;@ 55];%*4Z]K$ $FRHS<V;8C$I-W,$7=Q12,>/FM%'KK%E
MIRRI0]^FKG.;>F%\N+R^_'AQ>_D_QKN+KQ<?KJX_7GRZK1B7G\ZK\-OYQ:>;
M"Z/W^^>+"_Q>WQOJ>\/G>&_8"T'FXZ&ASZ]T_#B0-VS&9S;Q@P@+ ;[W@['1
M/?ZG,0 EJ%3L(^<(/R+B<>OBP8+3S9 .-6,GI!+7/EY,3HV.O(@2GQO)9YCP
MCZ\S;BSYC63%8'3&MGFI;1.>Y?5L>DE5Z4.$1IZA&K6W((F/Q5/)M_6W1QSR
MGO>G@_>-P=BTR-C"2T:Z^CQ4ANA]^N/R@*K7AG%?5-"I@-JTX4"'5TZ K LZ
MX(Z5@),0Z$OO+(U+>(^;P.1%PZFT8LC2,O29 Z!2SD^6\L-,9=>%TRK>34X"
M+,9'31#H]5LX7SD1VC]BO&OF3]QL23]83<(#'SD?P9FX8MR:SKTH\/T//,S^
M$_^5)V4RMDI(7FI7H3(<K5U77%EZ,K\K*5*/5?MX$P*Z65.^-H'E*9X/&6,0
M4PDTO&2Y,=VT\&Z*'H)J8<8*;"'&C68Q6(@=(WC["#&,O$9^+2Z&\7U&>KEJ
MX.+RTNBB_B?5IE1O%\W4^X&E!.^QPCZM?91#O AC1/P1^BYOK$! BUK"G&[8
MGD&6,.;%TBT&IW:Y>"FI$DI1#PN /4[F"QE>H^/-= ![ U_%_03CIR6=>5L'
M>-%5ZR#*<:@4)G:(:+3IPI/3%D[(3DA=1W!M7M5S<(@Q9K(UP2D:$HCBS#.>
MG;=_*NK4IGWGA$C7 >,=B%X)>($0+AMB!4W&>(>(C"13 QA*JT["*F E;5$O
M,M,M GXJ5->GS9@6,)W7(R2I1_U9T#I9;7E/7;+$28^2$?57BOG^R (Y@<5S
M_#C$DJJS)M76B;9.GHUU B--$J6VAB3A132CR,30=Y1.%P\CI^]$ &>UD]LY
M&6WY+RY78:/EK"#T^.4KX(N*R6JCBH9J*BUA)B661_WD[<W%><9H\9,F/W4Q
M.$B[#&7>.P'\FC@':18,NQ$BNP=S##VI<O&%-4G6_&$D(RU[<5Z*^RVW/%']
MI2@+P-9$K#X/L17L80[Q'Z8'M)A*Q-HS9;*QN^%#"WT:212YO&Z^&BC.(0S>
M2&].2PH1%UTBRSK+'D=HUAOI=R_# _).QY.+=VYZ'RZ,J_?&^=7'CU>?C)O;
MJ_-_PA'AG7%Y<_.E]^D<?X2M_>7SQ3NP,?L;.X.T:O\QC@?>/:TCFY8EW[3D
M-VKA^9R/09GA.@:#P\33_P?9#TO\.IWC@DA^*3H@SJ[A@#X!R<<P(/C#><;O
MD%XG'XAC-AX )B(A2NE7$(?<^,<(3R)?6J ?NVL-T+V 2RM/,H08/I=KH3 O
M%OSPX(^O!T?&X?S#E9-V(2R0-99=",5Q1Q@@&9RP98>@L7':K+3:78-?2.#3
M<\#+:.FDPUHCWX.M>B3#SGE7 CR=EQ_U*[)+';8WE&',LAD<#.LC<^%9%/%7
MNTG4%><&V!_&J\ZI/*/FNYOI ]K^'M!^X/7+_DIV$)=H$"8FN>+644)E4&I1
M5TC#',(#0]$3\Q5L_Z2['\K*C*! I]0$/CU02QH0Y>A'Z8AX?7. CC#8O-2]
M9IG]2R%">7^9TIU,-$]MPT:^-],D@T16P8/U)OXLFJK>NU/JJ8I-P1+Y18J-
M!_&0-.(R!@!O-3K)T,*I1YY(\KR%W'BF[HD5ZK)Y944^YG3(;J#4_#6CSS+Q
M26Z8"E7;:%=JK7JE?MI1 )MYW%& %1%2, EU>3MS@&[6R -.&4X-BJTQWJ/Z
M4?IQ,KPC)5G*&Q#S,IM*5U>D6K?27@N>2MI%B3QO&69HMJKUGSC)TXOQ%?$M
M^ F7%==%.?7T ER+:RVN=\(0?\_Z 7E$ZLHU8,Y+TIUCCI?YN*CI[J8VNARM
MQ$9/9*GHD8Z-:45/-.'9,"A.&<6W[&O\EW2!<<,]!=9&@Y0W<E,NOY*&M[R#
M>7[HC)0:BXC>2HDBN/3XQ8TM[/]$4]&T@>EF22M4E)GT\@92*JI#M<;C"7X\
MJ30;]<IIL[:J-"5*FMBX&([Y3LAXPV/2\]5:IXW.0#XDI]>]@(<]3!R<)H=I
MFUOG/+63J^.$X :&P'+%+X%$VWLL[FXR>B+)[\Q>M:1C)>LBUY6B@GEGLO3\
M)7],KP452T<TD98,+$""45[5JIUV:=OD1N6T 92N-9*GL1U4[ KD1 MM04J<
M6:LFK9J6\V3NKW9"L3 PG<"X(V-3"!XAN$(2OC:#0<>.Q[TA?6:\:C6I';BQ
MZ&79&ETF3_%H?55PBNN*2D%9X51Y05R1^@&C=-'C>(QX8%R"$]+5N-+,,!$Q
M26" FEB7MAY.;NG3.WI^=XSBK9Y;OGSAL3 &\%5V"3%R$;XJHW28J8V1"RQ(
M$Z;S79FIY60V+3Q1E_B;3SGB$I\*GN<J"W+$D[0 G/QJLW[*+RT>\L?$<Z'B
M(I7%NWDG7[5%=OU<0Z[LZFYE2RYGHXD#>V(;%/NKDKF0]9(*Z\8$Z,$VB,>X
M!84M\$H<ZF%;8@O>=+3$HK#O\,[+3H6(;2N]1@7%$PS"N/\G[!GY>XCY BBU
M0AEUPR<(R3!(T<I85A10!&MN!2R-(<N!/C:GU.[5@X=,X1\VI1U$O5GA"Q[J
M8KSJ2!QOE>7J^T% T4Y  BEGDLHB( :&IN/!UBZ96R6;]G'NK66B#\AY$Z00
M44?AC-U\_VA;7CK@EI9BX1[D5L0\\D<FUH7K#!)K).OHBT9.$$V//;0;J(I)
MR!UO63^?8GLT:HMM#Q JJ0 K^#L)FSJW*2BHS>')QXI:R :6S$5-A'<(Y&SA
MU<T,4C2F*F765,D9:1;P;;D4(FTS,>BDK[4I)1D"\A164PJ;:B@M8P.%62.H
M8%_Q&CPRR;F,:/A4246@."T:,(NNK49J=-9/VL6R.!6%_3W<679&0:A^V(S/
MI"^J /DKU0JZS!_+R]PQ#K8@OR>/N1G1KIKC.JGPIO<%I^\LFN7O\K@D:)TJ
MMGF]64ZF&<N_!;*@]G9R'BHI56P<EJY53I[RT/##V'\W[0YM8V@;8U&@:QB/
MQV::P)&1"R)  3VWF8[P^]007D@7BXZ#>DNHE>.VT05>MD.O_91M"&_&D2^_
M$17KZ:OY;>%U0?U-"NK?CYR($;? 8). D2F^3:?[C^?F-8(JE]L!BQL^Z)Z:
MFA>?FA<!20#1PRK^,_A2MU*,RA7]_K:G68?1LL=(+?BTX-MOP:=Y4?/BKO"B
M5L):"2_%: 7'K99]6O;ML>Q;U)19>VMT^\/=D6J::9X?TRPVO30#:0;24D<S
MC68:S31:56D&VE\&TDRCF6;MIO*EYW,UU<NR&!L,WNX)=\FHDE:U]M,3L-I^
MN"@S*;LKBYF]9X[ZT_"&%D.:J5ZHP'GU$AFB]O@<H=Z<$9S[S"2-2JO3>8F,
MHM615D>:J313::;:9_6E;1QMXRQCXS2TC:/5T5YX_D21)QU.MM<BIU ,8C/Q
MHYE"BYRM6,#EC*0#HC5?:;[2IO1B?CELG,Y/5UO$*0A!HXUU5<2_D,'Y:@NK
M532%3+ZF022+I_GNB$[R:)X]"C\('D$$\VRB?I<6(]@9$;0??'&D[1NMA[0>
MVF4]I/E*\Y6V;[1]H^V;1[1OGF^,GU9..ZN<-"-I1M*,I'752[P3U[;M"M?@
M]<[\&A>:-[2FT9I&,Y)FI&?#2/NAFK3)HDV6&29+0YLL6M/H:+T]O;C<#S&C
M]E34%]E:VNR 7:LO'#5?:;[2EO.Z*JW>WC#C16LR+7$>4>)H1M*,I%67YBO-
M5[O,5\_+)&JVM";3$F=778G:4:VY2U^):D;2C+0OC+0?9H^^6]?F</G=>K/9
MUKRA-8W6-)J1-".]#$;:#]6D319MLI2;+(V3AN8-K6EVU8>G/<3/0?WT+"N(
MF6TXV!69A1MVZ] \H26.OJ?4?*7Y:O_XZGE9SZW-2MMH3:8EC@X)U(RT\XRD
M59?F*\U7VB1:PB2J-[4FTQ)G5]V)C^ZL;E3;FKN>$W=I1M*,].,9R?;COLL2
MRX@SPXNSC/;7#'J4^W;-%,_/7*ZTNYOET%!Y[%JK8C2:W:V7QR;(Z9\Z,=ON
M%+G6^D4;*IJ1GIZ1M$[2AHIFBI=@J+0ZF^4V:$-%ZY>\O^YU9(*@**&'Y3(S
MH%4;O37&YD-"503CH&R";;V\O948F\'0\13)]9!\EU T(R0LAN%QFF/FX_IS
M#L6?*\;/A-K/;_.HY5?@;8;\;PDCQ[.![/"QVJXYWIY(X]L1@SFL.&"VX?JF
M9_2!X\,DO-(P(^/D)V/" L/TO'A<,>Z=:)3^/#&GN.^,OV(S@*_<J7'H^?>&
M'3-\DP8<FU$<.-'T"$:P#2=,INM/#9-_@%_3(1W/,%W7\ >&'\.L8<BBL&KT
M0I@KB/#K"$#N#0/&QD#N"GT\]\<3TYO2#&>![W\/(V I@W8!#Q;U8:[/;.B$
M$6<ZXS-NY# =R!@&IA<!V=0!+)#])@!DLS$.C?],G.%PBCQM!.IPI)8!SCF\
MMZ@5U>XQ1\^8!/Z=$R*"0(4,X;/$):Y0"&>ZH0\$^BMV8$TS2P0/>_[8\<R(
M&=&];UA 5,>&3R'@ >MMV/"*%<&?$S]TB+;1"'AI9-XQ8$X&I ;),080;,Y#
MZJPAL!RL(/Q7^;;//#9P+%#RP)[^O1<:/NATHU'[27*3@(U+DVZCWGD+S\11
M&"%L,![.!W# <+#LR 0J$L0G$HE%.(1;1:']D]&/89NQ$&D,>VU-G*I+2L^B
M*'\*':?(V:<1LSNET<JNO+66RU'URC-ZD\!QC3H>&&KU3E%MX-\QC!N.S( 9
MMT$,JDC\7C$^57O5"N[)1&N@!#S$,>0&:]3>JC\F7]??'F5%Y:WY8)S1?HZ,
M:Y".++CC*N3:A1V<RM?\Z/BS.FK%0(%C(U2PY?/H]5ETCY(FCR9^5N$DK&P6
M6H'3)PAG"H_S. @0KL]LXJ,B]HSW<"XQNL?_- :."^^2#L"W;[A.=V"U<<J+
M!PMDTY!&'3LA:1,_69!3#G%58?SD+S1.B"H.MTA(7J(JMR($&^0L \(25/@M
MH B&2@AC'T;^D $H 0<*[0ES % ZI&=(E8>A;_&/0+TPMD;B73!3+%1;*",5
MZJ<2&.4OLHDS45;#."0R#H#C$B(BY$<X>JMZ>@IR.3#&/K"6D,^J+":>(T#.
MN52^(4V#L,-C]+@Y055LNO+U,]\,;)C54X'L)9!?$RY9=D'#RC/88(#+!_2"
M 2.&E!R"B8.F'FJKT$%SSG7&3L2YTI_-$68?*!J12H]#9C@1[F[@#""D29:4
M"^.!;@R"*<QY#P"',Y>9\.$P6B!&;=.S6,I12,H*M]"0XSW@*3:><,7JJXJ2
MW@!:3A Q^ E?YCN:5E4HXY3?S3XHTDK.;LPBJ;P'M&]7:JUZI7[:419MYHY1
M%W, 0L\X<Y#D(P_$VG!J?#5=L)/?Q\B.DCMM%!:T=RJ@_K[G[-$$<[' 2"^)
MK61CL$B]$'8( !S.5>QT8A;>D%\/:@=2?',?2KU6^PG$*CYS#.(4^/#-P'E@
M]ML#L(I=5TA?>@\_"^\)?BX+H5GV\/[+:\N<A&\NPS!&#K@:<!H2"7N>?<./
M#N]8/WKGA!;P%WR\!;5TYL(#O_WG?_P2A\=#TYR\N;%&S(Y=& $?OL7QD^<,
MQ_[UX#V2R/[6;G8:M4X'D #= P]\9H-?#ZYK]6_P?Y!+I[=^K?FMR?\^^$V?
M)A<=&,)X#,A,Y;80"V;@(J#8=N[HK!>B^![XKNO?A\9AK593]\W1FW4.\]K!
M\G3F*)<DTB E@9+UP@/<+NQKP$/^E=\#U5JM#A@*_VT'9(]X@+OFS3CRY3?"
M.4]?E0J;+"0ZD7Q-3_+]R(D8<0L,-@E #3C;/?+]>&XN(?(])TW?=^U-G-(+
M[R]T%++FQ:?F14 20/1^/6@<S.!+G481E2OZ_;UO78?1/IH!G"2:=3J;S\],
MU8)/"[Z=%WR:%S4O[@HO:B6LE?!2C/:.66S<9X'4P_.;K6K9IV7?;LN^1=F5
MVENCX_YV1ZIIIGE^3+/8]-(,I!E(2QW--)II---H5:49:'\92#.-9IH]KGZT
M5>Z2426M:NTGG;\[@U_44*W5Q<S>,T?]:7A#BR'-5"]4X+RH3D*2(6J/SQ'/
MKEI YR4RBE9'6AUIIM),I9EJG]67MG&TC;.,C=/0-HY61WOA^=-5]9^#7KI-
MDX1AS# *-Q,_FBFTR-'-731?:;[:/[YZ5J;T8>-TLT:*9879ME9;-&&/P@^"
M1Q#!/)NHWZ7%"'9&!.T'7QQI^T;K(:V'=ED/:;[2?*7M&VW?:/OF$>V;YQOC
MIY73SBHGS4B:D30C:5WU$N_$M6V[PC5XO3._QH7F#:UIM*;1C*09Z=DPTGZH
M)FVR:)-EALG2T":+UC0Z6F]/+R[W0\STQC[0ZV_B-'V1K:7-#MBU^L)1\Y7F
M*VTYKZO2ZNT-,UZT)M,2YQ$ECF8DS4A:=6F^TGRURWSUO$RB9DMK,BUQ=M65
MJ!W5FKOTE:AF),U(^\)(^V'VZ+MU;0Z7WZTWFVW-&UK3:$VC&4DSTLM@I/U0
M3=IDT29+N<G2.&EHWM":9E=]>-I#_!S43\^R@IC9AH-=D5FX8;<.S1-:XNA[
M2LU7FJ_VCZ^>E_7<VJRTC=9D6N+HD$#-2#O/2%IU:;[2?*5-HB5,HGI3:S(M
M<7;5G?CHSNI&M:VYZSEQEV8DS4@_GI%L/^Z[++&,.#.\.,MH?\V@1[EOUTSQ
M_,SE2KN[60X-E<>NM2I&H]G=>GEL@IS^J1.S[4Z1:ZU?M*&B&>GI&4GK)&VH
M:*9X"89*J[-9;H,V5+1^R?OK7D<F"(J$;_"#6.A?#VH'DCB</>JUVD\ "SYS
M###X<?1FX#PP^^V!83'7%2#3>_A9, 9^+O,.+@O7+Z_C\'AHFI,W-]:(V;'+
MK@;O6#^ZQ0=N@8AGKF]]_^T__^,7^=QG%C(SL$8]SW['[ICK3\;,BRX>)LP+
MF>'8OQZ\QS:V]K=VL].H=Q%<6$,8Z3,;_'IP7:M_@_\W:O736[_6_-;D?W_[
MX$R %R+GH1>'40!,;5Y'TP^1_9&-^RR(0YSZ)C(CAI.=NV887@UN(@"M]^"$
M!T8,^X7&_P)_?/MR\^[ @,5W@$%#I-!OM13/N?"OC6BCU5X*T<6@MFK ":O
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MKZ!2OBJIBJ)%ZF$JN4L5)=L;>VU+&]FYK?O%!8)#$38(8/$0S?SUUU_WS&
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M*AJF 6)YF632C.*0JS<V=*.Y'H.C[0X"!WE(4(B[!N="C]>(1GJCT^NVG/Z
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M2C(O[?2_5S(0@I%LDQ!D[OHIB;,K/;O/:K66%MY_G$2A,P+&,24G%>^@5G&
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M(4_5<81*<<?99WF=SM6C[TBP4AH D2[HE"RCZG#'_6?IU\+-P7,NH6HXBRL
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M3&";W;H)&LZ3(LZ;.1)LU@6PG=V;:H)#F*1(9246N,$UYUI%@-G9/9X.,H1
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MD-6=1PL/Q5/&_BRXK^(+G^[@>RHSC+@&+$:$;^4:&&%D,-QYG2 04WGD1^L
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MQ(^4P":Q_KK\QLMY6LOW'R"V9*S@E0"><T_K\9&BPH'01)CK:'%$4,QE@M(
MR+F7\C@Q* "$$1(C@^UWVD>6HHA;94P)"&&0PN]AISD:CVR%)K?!9DU8"*<D
M+\!VE_+OR%* SETRBJ!"""6P;:P</98A!E:/('J',%%- $IZNU6//BTP"&L4
MU@[>V^[9<Y'Z,R\3=#G5^)/5'1_UG(N0IAAX:C@(=R3A,G"!JP6@(7E598#K
M7+2T9NRMXD'HHPB@T3K\S)&MZ,56",( ((P0.&&LQOH:3:HH7]")E&'0)-4
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MA=S>LBV\(J> X+YDG[?\Y&7L/_X'4$L#!!0    ( $I@K4[$C^&.WS0  (?
M @ 5    8V%P<RTR,#$Y,#,S,5]L86(N>&ULU7U[;^-(DN?_!]QWR*LY[%8#
M<CVZ=^ZF>AX+6;9[=.NR?+:K>A>%08,B4S:[*5)-4BYK%_?=+Q\D13+?))69
M!=SM=%D1R<B,7T2^(B/^\J\OVP0\P[R(L_2OK]Z_>?<*P#3,HCA]_.NK?;DY
M^].K?_W;?_]O?_D?9V<_P13F00DCL#Z BZ ,'O(@_*T =T&<KK.OX#-M!?SP
MYATX U^_?GT3(:*2$+T)LRWZ(_KU_?NSC\'A[/MW[S^ +^^___'=AQ_?_>]_
M@/^:?_Q_9V?X2TF<_K8."@B09&GQUU=/9;G[\>U;W-[+.D_>9/GCV^_?O?OA
M;4WXBE+^^%+$'>JO/]2T[]_^^\?K^_ );H.S."W*( V/7+@9'M_[#Q\^O"6_
M(M(B_K$@_-=9&)1DK)1R 2$%_M=937:&_W3V_ONS']Z_>2FB5W@,\BR!=W #
MR.=_+ \[^-=71;S=)5AL\K>G'&[X,B1Y_A;SOTWA(]86;O\#;O_]_\+M_Z'Z
M\W6PALDK@"D_W2V%W?G0::MB>FM)QEN8QUETF0X3ML]M5^K[,LC+$7*W^6U)
M_I"503)(YC:G+6EOX+#Q/?)9&U?D&>&P<6UQ3BEMR4IJ/)B=44SP?U^C[W<D
M@R\E3",8U;)A3HGG) T3CTN:S,).8PEVO5G>[6<8[ HRF;S[@?K//^"__'*1
MA?LM3,MYBAQ &9>'9;K)\BUQW?-U@2>ELFZ(B$Z:_\6 ]]CKCI Y++)]'D*C
M'M-Q[$H3K$VD07,9XL1S-DS//MV_^EO-!H(T I01M#C!EYKW'W^AWV^Z,\^[
MPQ[D82T;^D]%?RJ*MV&&IMA=>=;IVB;/ML;C7(F2&0_)A J*J@^2+WBA*!W3
MP'TJ4*=(APH8OGG,GM]&,$8=>_\G_!_8;OYT]NY]M?+X _I3TXL'U"['0%@2
M"W; D4LXBOAW%X@6C5T-7-' G4R1<_2E"'_M*@D>!9KLT5A295^ROBZ;WP$F
M<*5,[OBUM<D=O)/;9;.H11LPE8'V:"U;:E]2H<E20N3[(KRK=&Z]W!'FF3%W
M>$\.@*NX"(/D/V"07Z&_% H(,-260<!**X0!)068%A!BUT 0C#0/"H)AM@0&
M"D1].'3HG0"B*[$*$I6#\ @4G!$7PX(SW"<#!EU WL''&"\:T_(FV(IF"3ZI
M)3@(Y.PCH5H/'^D )G2% =G@MM4O&]D3:WZ!4)<'R1)MNE_^#1ZDJF=HK>J>
ME52@_(H0$$J 2-VJ7S#"K/X%PWLR "SV>=Z9BN2+1#&Y)1A(Y.TCH2+M+!%<
M+Q=5P]T&A&JL3^P4KN($Y@OTO<<LE[N$'J55A]"74N ."!FHZ=SZ N[ LIZ
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M3(DPVQ$TV(M=H1XNLA3)M$=B58>>65J<0[0H@)3N(7B!Q>4+FCZS'.W+@OQ
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MO(U3,KVM-B1>,M1_G#NJ26M9+T;UFTEFP+[ZPM625QO0:A'_L]VF'Z]6)P!
M-RF%)]K7RUDQ*0JZ@?*<-V,IP@3R=["%"?3/N(V)42]63Q3(0:-4AD6ELKPN
MPSDX/=&*Z*CB=/P,XA2I1QG7(=*-<Z@-B!GJ,;H'F6',4(4P#V.&N"K1Q-:
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M8ZLN((S6K@TO"38Z%D#U8V=OJ+@^  VUYB20>J$LUL$C=A-*O1"6WFC'4L_
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M# 0%R.'O^Q@?6ZT/,EJD1&0<!4[_>AV'^--@_IA#\M;5^ 908"CSZ#DNLOR
M"[N*#*-+8\L0>I(Q0U[][*S0KG#X.K ^V=AIP5@UABW8(E@&]9!N$+FC*^9K
M^$BK#$N6#BT:BPN"MF1,"C'\F_.2S\S8]>=B9N L+AZS0Y#@<![%F\0>G<T%
M7T]"9BE'?_?BA2%W-)F5%V\H+5HRG;*4&N_1V;3HGH1LRF$ZZ?J@<>YH,O;-
M&4HJ\S4BI_]"_[$."OBW_P]02P,$%     @ 2F"M3D1R)(6K*P  2K<" !4
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ME$Y3%O+< IWEN U1W/L1 ]U,IM,DOL^3X ^0T&66S<3>,9YD(#GXG3/V:(/
M8LR&L[_B+P77;Q7!7,;!%0_$4AP]I:Q8?19S-QZQ]35\"YM&P%FSM?PQ2!?6
M](/0W9VO[,6O[FIE6*.T'KEU73MCN<^C[(&]Y3.KHX9^J"[HW7Q.NU:\Y<]V
M2 ;V%&_EUW?YK:V-O-&O[&JWL==M^Z%WC,6>J=J_L)OS1FU<-<<O4+VDH*IQ
M7MR1K@#$"CQHR>!^$BX BE]K>'\OK"Q)L/(SD;!K)*E.C.(OGFKPT:-8B4&^
M&"CR'UE4#.\9]_5Z1X<'!\.Y=(QF*N21@4 *.PMHT4]/R>OWD/'O,/LC\0\"
MQM&WO=[<RO*O\*?E7!Y@7,E\UYN(:0UZ/0EIHW1UBK#M+,:#?]Q@;-48-&_Q
M_:6XZ7\+GGFT)'N2)M.ZPIM/*-& F64PN>1%#"$4,DE#EO[R%?X# )RP%%;C
M52D2%$ Q^T)N6V=L!-,/!82+R']"*%MI4\+<=Y<S.1HY:?O=)&TA@5N6\@2$
M$)[YN6Z]K;0M8.]_@H4G1R4GL]]M,B]X%OC1_X83U@7\)=/0N=:ZA.[PJM3A
MDE,Z<('24D?-2:VT+^'W/PNM,F1R8H?=)+84P1U[X@)YG-_X4VS?E34M0/</
MW*53"4K.Y$&7F3P%4< M]Q*N V__D[TKJ5QK6\(^=)U+#)6<S,-NDGDZ2].5
M;X?Z2(0U+\ /'=YMM<#DK!YUD]52 A<\8NDI@'A*4O4"76E90CYRETL5)CF-
MQ]VD\2'U1>S+_?OT,8D0 E?:")C#P9Z[U,G1(&:!O6ZR-O\Z?%@5[Y]!;MEX
MEHM@'P%/_;%4="PEXOZ7TP0B0GI'C4$EL/,I2Y\ Q-_2Y$?^##!?_%B]\TI[
M% (<'KM.LQH;PF]'[48EHONI'T4? 2\*7E=:EI)RV&:DPH3PV,AD]'W="[$E
MSX1!O)Z56BVT:N)GCP6\6?;MR?=?2M5B49XM_K*N8_,_>Y50M0L>PSPXW/V3
MC&O<&3;=O?Z^[7)I$5<1C&""H&CH]8GN%-8"75TT"C24/HX6>3R-_"P;3TJW
MZ1N7[8;:/EY_T!%V/^C1\"B%0.D!:4YI%=)9,O5YK.!RL[$WZ,H2E7(CYQ.!
M0>G]:'%MPM>17<(_&BW*96.O/^P(D<:K<77NE(Z.YNR-L@S.&P;?^-6&'I51
M7$.&G#G)W%OR8KRR]#')V!4E>7,CHC&':^T]*INX@AT5C;+IM^3)H&53O+&
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MJ3S!]9$!L29GM'9_R!MTYQM06[':EPBBDXZ9V&K= !44#(@_*UL@VE2C5F2
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M1G+JJ)K#9(A#7'6"PB_[<BR4E38V="U+\XJ>P;^MZQC\R;OSXR>&U 98^>\
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M%RO$<,7]Q\(=K;IOU1VS$.K0H0]Z>X@1-2)[1+IN5IB70Q-4+.N(8Q]T?5>
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M<',M,C Q.3 S,S$N>&UL4$L! A0#%     @ 2F"M3JW:YJF2"P  \V,  !$
M             ( !ZI$  &-A<',M,C Q.3 S,S$N>'-D4$L! A0#%     @
M2F"M3GNZQU(H!P  RDT  !4              ( !JYT  &-A<',M,C Q.3 S
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( $I@K4XSU[E-62@  -%< @ 5
M      "  0:E  !C87!S+3(P,3DP,S,Q7V1E9BYX;6Q02P$"% ,4    " !*
M8*U.Q(_ACM\T  "'P ( %0              @ &2S0  8V%P<RTR,#$Y,#,S
M,5]L86(N>&UL4$L! A0#%     @ 2F"M3D1R)(6K*P  2K<" !4
M     ( !I (! &-A<',M,C Q.3 S,S%?<')E+GAM;%!+!08     !@ & (H!
(  ""+@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
